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What are atopic disorders?
In this thesis the word ‘atopic’ refers to a predisposition toward developing a certain 
allergic hypersensitivity, which can result in the clinical diagnosis of atopic eczema 
(also called atopic dermatitis), asthma, or allergic rhinitis (also called allergic 
rhinoconjunctivitis, including hay fever). Although closely related to atopic disorders, 
food allergies are beyond the scope of this thesis.
Aetiology
Since atopic disorders have a complex aetiology, involving both genetic and 
environmental contributions, these children show a wide range of phenotypes. Some 
children only have one atopic disorder with mild symptoms, whereas others have 
all three atopic disorders with severe symptoms and everything in between. Atopic 
disorders can be associated with functional impairment in terms of activity limitation 
and reduced quality of life as compared to children who have no atopic disorder.
Various environmental contributions have been proposed that could influence the 
development of atopic disorders, including pet ownership (1), traffic pollution (2, 
3), household tobacco smoking (4), and diet (5). Even geo-climatic factors seem to 
correlate with the prevalence rates of atopic disorders (6). Based on twin studies, 
there is evidence that atopic disorders are (for a large part) genetically determined 
(7). Multiple genes (mainly genes involved in the T-helper 2 innate immune reaction) 
are associated with atopic disorders (8). Several other genes are specifically related 
to asthma (8) or related to atopic eczema (9).
Over time, some atopic patients develop all three atopic disorders, i.e. atopic 
eczema, asthma and allergic rhinitis. In the triad of events that include these three 
disorders, eczema is often the first disorder to evolve. A biologically plausible 
pathway to explain this cascade was proposed by Burgess et al. (10). As a 
result of a defective skin barrier in children with atopic eczema, an epicutaneous 
sensitisation to an allergen can take place resulting in T-helper type 2 memory cells; 
these cells can migrate to nasal and bronchial lymphoid tissue. When the airways 
become exposed to the same allergen, this might cause asthma and/or allergic 
rhinitis symptoms to evolve as a result of an exaggerated IgE-mediated immune 
response. In practice, the number of patients completing this classic ‘atopic march’ 
seems to vary considerably (11, 12). For example, some patients with asthma 
subsequently develop eczema (13). Furthermore, it has been shown that the atopic 
march can occur at any age (14), not just in childhood. It has been estimated that 
approximately one-third of patients with atopic eczema develop asthma (15, 16). 
Despite there being a clear temporal association and plausible biological mechanisms 
12  Chapter 1
to explain the atopic march, at this moment there is no definitive proof for such an 
association (17).
Epidemiology
Atopic disorders represent an important health problem in paediatric patients 
and create a serious burden on primary care resources as a result of frequent 
visits to the general practitioner (GP) (18). Acute upper airway infections (9.5%), 
middle ear infections (6.3%), warts (4.9%), asthma (4.3%), and atopic eczema 
(3.8%) represent the five most prevalent paediatric diseases diagnosed in Dutch 
general practice (19); in this list, allergic rhinitis (2.4%) is on the 12th place. 
Also internationally the concern about these atopic disorders is demonstrated by 
the enormous participation in the International Study of Asthma and Allergies in 
Childhood (ISAAC) (6, 20). The ISAAC study showed globally one year prevalence 
rates in the open population for eczema, asthma and rhinoconjunctivitis in the 13-14 
year-old age group of 7.3%, 14.1% and 14.6%, respectively. In the 6-7 year-old age 
group, the one year prevalence rates in the open population for eczema, asthma and 
rhinoconjunctivitis was 7.9%, 11.7% and 8.5%, respectively (6). In the Netherlands, 
the prevalence rates obtained in a study conducted in the open population and based 
on ISAAC questionnaires, demonstrated one-year prevalence rates for symptoms of 
eczema, asthma and rhinoconjunctivitis of 13.5%, 12.3% and 28.3%, respectively 
(21).
Natural course of atopic disorders
In Germany, Illy et al. studied the natural course of atopic eczema in a cohort of 
1,314 children from the general population, until age 7 years (22). The prevalence 
increased to 21.5% at 2 years of age, but 43.2% were in complete remission by the 
age of 3 years.
Regarding asthma, Jenkins et al. screened 7-year-olds for this condition (23). The 
study was repeated 25 years later in a random sample (n=750); a quarter of those 
who had asthma as a child, reported asthma in adulthood. According to Sears, about 
half to two-thirds of the children with asthma will recover (24). An explanation for 
this observed recovery could be that viral infections are the main cause of wheeze 
before the age of 6 rather than allergic asthma. This is supported by data from a 
Dutch primary care study, which showed that for those children diagnosed with 
asthma between the age of 0-4 years, ≥ 60% were no longer known as such by 
the GP after 2 years and, after 10 years, 80% no longer carried this diagnosis 
(25). However, a different study, but based on the same Dutch primary care study, 
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demonstrated that when the same children were screened for asthma at a later age 
(10-23 years) 45% still had asthma (26), suggesting evidence for underdiagnosis.
Finally, regarding allergic rhinitis, a prospective study on the course of allergic 
rhinitis in 738 individuals (with an average follow-up of 23 years) showed that in 
a majority of the adult patients the symptoms of allergic rhinitis reduce over the 
years (27). Another prospective study (n=257) on various forms of allergic rhinitis 
(confirmed by the presence of specific IgE to pollen, pets or dust mites), looked 
at the percentage of patients with complete remission of symptoms in a period of 
8 years (28). This latter study found complete remission of symptoms in 12% of 
patients with pollen allergy, in 19% of patients with an allergy to pets, and in 38% of 
patients with house dust allergy.
In conclusion, an atopic disorder cannot be simply considered to be a chronic 
disorder in all initially affected patients.
Background of this thesis
Although atopic disorders in children represent an important health problem, 
epidemiological data from a general practice setting are scarce. Therefore, in the first 
part of this thesis, two systematic literature searches were conducted to examine 
available epidemiological data and compare two epidemiological sources (i.e. open 
population versus general practice). The knowledge obtained from these reviews 
was then used to acquire more reliable prevalence rates from an extensive and 
representative general practice database. In the second part of this thesis, different 
characteristics of atopic children in general practice were examined, focusing on 
comorbidity, medication use, and healthcare utilisation.
1. Different sources of epidemiological data
Epidemiological data are widely used to support GPs in their daily practice, e.g. as 
a guide to the management of patients in whom disease has already developed, 
and in creating strategies to prevent illness. Epidemiological data are also used by 
researchers to develop and prioritise research questions, and by policymakers to 
plan healthcare services and the workforce.
Two epidemiological sources are examined in more detail: i) epidemiological data 
obtained from the open population using health surveys, and ii) albeit with limited 
availability, epidemiological data obtained from general practice databases. Both 
sources provide valuable epidemiological data and are discussed further on.
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Observed differences between the two epidemiological sources could in part be 
explained by the operational definitions used. The diagnosis of the three atopic 
disorders is not straightforward. Not all skin itching is atopic eczema, not all 
wheezing is asthma, and not all sniffing is allergic rhinitis. Therefore, diagnoses may 
differ between those based on the patient’s own assessment and those based on 
the physician’s assessment. Diagnoses may even differ between physicians and a 
patient over time (e.g. a simple itch may become atopic eczema, and a wheeze may 
become asthma). This can result in a wide variation of prevalence rates. Remarkably, 
these two sources have not yet been systematically compared. Learning more about 
potential differences may help policy-makers to optimise their strategies and help 
GPs to become more aware about the healthcare demands of atopic patients and the 
possible misclassification of allergic conditions in children. Furthermore, insight into 
differences in prevalence rates provides valuable knowledge for researchers that can 
be used to acquire more reliable prevalence rates from general practice databases.
1.a. Open population data
Although survey data provide useful information on the prevalence of self-reported 
symptoms of allergic disorders and the derived diagnosis (29), the accuracy of 
data obtained from surveys depends on various items, including the accuracy and 
knowledge of the responders, and the definitions used by the researcher (30). 
Another potential limitation is that questionnaires ask about symptoms, i.e. these 
symptoms could also be attributable to other diseases; a concern that is shared 
by others (31, 32). The International Study of Asthma and Allergies in Childhood 
(ISAAC) is the largest worldwide collaborative research project ever undertaken 
to investigate atopic eczema, asthma, and allergic rhinitis in the open population 
using a standardized questionnaire (33-35). The study involves more than 100 
countries and nearly 2 million children. Nowadays, ISAAC provides most of the 
available survey data on atopic disorders in the open population regarding children. 
Results from the ISAAC studies are widely available and relatively easy to identify in 
online medical literature databases (36). Remarkably, non-ISAAC research groups 
(i.e. non-official ISAAC studies) have also published data using validated ISAAC 
questionnaires; however, the official ISAAC reviews do not include these latter data 
in their analyses. To what extent these data can be used as a valid alternative for the 
general practice setting is not known.
1.b. General practice data
In many countries, primary care professionals (e.g., family doctors/GPs) diagnose 
and treat atopic children. In the Netherlands, GPs are the gatekeeper of the 
healthcare system, are freely accessible, and use uniform coding systems for 
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recording the diagnosis, prescriptions and type of declared encounters. In principle, 
all non-institutionalised residents in the Netherlands are registered in a general 
practice, even if they do not visit the GP. Therefore, the electronic health records 
stored in primary care databases in the Netherlands contain valid information about 
the epidemiological denominator, making it an important source of epidemiological 
data (37). Furthermore, epidemiological data from primary care databases might be 
more specific (the prevalence is based on the assessment of a physician) and provide 
a better reflection of the true burden of disease in a general practice setting (38), as 
compared to data from the open population (29).
Unfortunately, the number of publications on the epidemiological study of atopic 
disorders in general practice databases is scarce and such studies are difficult to 
identify in online medical literature databases. The problem of identifying relevant 
publications lies in the complexity of identifying studies in a ‘general practice 
setting’ since the area of general practice is broad and difficult to define, mainly 
due to the different terminologies used. For example, the terms ‘family medicine’, 
‘general practice’ and ‘primary care’ (amongst others), can be used to describe 
basically the same research setting. Developing an electronic search filter that could 
reliably identify studies conducted in a general practice setting from various online 
medical literature databases, would be an efficient way to address this problem. 
Unfortunately, all search filters that have been reported in the last couple of years 
lack adequate sensitivity (39-42). A well-validated search filter for general medicine 
with good sensitivity and specificity will support the development of systematic 
reviews and meta-analysis regarding general practice topics, such as developing a 
systematic review on epidemiological data of atopic disorders in children.
1.c. Retrieving valid prevalence rates from a general practice database
For the correct use of general practice databases, two problems need to be 
addressed for which the knowledge derived from the systematic reviews can become 
useful. First, how to address the expected variation between general practice 
databases? Part of this variation might be explained by the fact that GPs often work 
with a ‘probability diagnosis’ which inevitably creates a risk of misclassification, 
resulting in either over- or underestimation. Other possible explanations could be 
variation in the clinical knowledge and/or skills of the GP, and coding difficulties 
(i.e. when coding diseases in electronic health records). Second, some studies in a 
general practice setting have presented life-time cumulative prevalences for atopic 
disorders in children (43-46). The question arises as to what extent these life-time 
cumulative prevalences provide relevant information compared with annual point 
prevalences, knowing that these disorders are not always chronic and/or can have an 
intermittent course. Therefore, it would be valuable to determine a reliable strategy 
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(and thereby an epidemiological definition) for the analysis of raw data derived from 
general practice databases, addressing both aspects, to be able to calculate valid 
prevalence rates.
2. Characteristics of atopic disorders in general practice
Recently, the registration of diagnoses in Dutch general practice has been promoted 
by financial incentives, and both quality and quantity has much improved. Therefore, 
new research in large databases using recent data may provide valuable new 
insights into the epidemiology of atopic disorders, especially when using clear 
epidemiological definitions for atopic disorders. General practice databases contain 
a wealth of information. Not only can prevalence rates be derived more reliably 
from these databases, also valuable data on comorbidity and prescribed medications 
are available. To our knowledge, no study has investigated the complete range 
of potential comorbidities in atopic children in a general practice setting, nor the 
complete range of potentially prescribed medication. Healthcare utilisation can also 
be reliably examined using these databases.
2.a. Atopic disorders and comorbidity
Comorbidities are important for clinicians treating atopic patients, as they may be a 
marker of patients at risk of poor outcomes. Also, they may point to specific effective 
treatment options, and are important to researchers as possible confounding factors 
in clinical trials. Associations have been shown between atopic disorders and other 
diseases in children, but in different clinical settings (e.g. birth cohorts, hospitals, 
or paediatric clinics). Proven interrelations exist with (amongst others) diabetes 
(47-49), ADHD (50-52), autism (53-55), and obesity (56-58). According to other 
studies, the presence of some comorbidities may even influence the course of atopic 
disorders (59-63).
The following are highly relevant research questions regarding comorbidity: i) Are 
atopic children at increased risk for specific non-atopic symptoms or diseases that 
GPs should be aware of to reduce the risk of underdiagnosing relevant comorbidity? 
and ii) Are children with one atopic disorder at risk of being underdiagnosed for 
having another atopic disorder?
2.b. Atopic disorders and medication
Evidence-based medicine guidelines support Dutch GPs in the decision-making 
process when prescribing medication (64-66). According to these guidelines, the 
cornerstone for the treatment of atopic eczema in children are emollients and 
corticosteroid creams, prescribed in a stepwise approach (64). When anti-asthmatic 
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inhalation medication is needed, a GP will start with a short-acting beta agonist, 
followed by inhaled corticosteroids when indicated (65). For allergic rhinitis, 
treatment will depend on the severity of symptoms. Intermittent symptoms are 
often treated with local or oral antihistamines on demand, while moderate to severe 
symptoms will be treated with corticosteroid nasal sprays (66). How often these 
atopic-related prescriptions are also given to children that are not labelled/diagnosed 
with a specific atopic disorder has not been extensively studied and could reflect 
underdiagnosis or insufficient coding. Furthermore, to what extent these atopic 
children have a higher risk to receive more non-atopic related prescriptions has not 
yet been examined in primary care.
Two relevant research questions regarding prescriptions are: i) Which medications 
are prescribed by GPs for atopic disorders? and ii) What kind of other medications do 
atopic children receive?
2.c. Atopic disorders and healthcare utilisation
Finally, how do these prevalence rates correlate to healthcare utilisation in primary 
care? Learning more about the magnitude of the burden posed by atopic disorders 
in children on general practice resources would be of interest. This information 
is important epidemiologically for the planning of healthcare services and the 
workforce. Most studies on healthcare utilisation are limited to asthmatic children 
(67-69). However, a recent study in Denmark (birth cohort) evaluated healthcare 
utilisation in children with atopic eczema, asthma and allergic rhinitis, using health 
surveys (70). The number of additional consultations per year for eczema, asthma 
and for allergic rhinitis are 1.8, 2.5 and 1.2, respectively. A relevant research 
question regarding healthcare utilisation is to quantify the current health burden 
posed by atopic eczema, asthma and allergic rhinitis on general practice resources 
based on physician-diagnosed disorders.
Aim and outl ine of this thesis
The first part of this thesis focuses on obtaining valid prevalence rates of atopic 
disorders in children. Chapter 2 presents the results of a systematic review 
(including a meta regression analysis) determining worldwide prevalence rates 
regarding children with atopic eczema, asthma, allergic rhinitis, and of having all 
three disorders, using data obtained from ISAAC questionnaires (including non-
official ISAAC studies) and examining interrelationships between these disorders. 
The aim of the study presented in Chapter 3 was to develop and validate objective 
search filters, applicable in frequently-used online medical literature databases, to 
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identify studies that are conducted in, or apply to, or refer to family medicine and 
general practice settings. The efficiency of this filter is then examined by deploying it 
in the systematic review presented in Chapter 4; this review compares self-reported 
prevalence rates in the open population (ISAAC studies) with clinician-diagnosed 
prevalence rates of the three atopic disorders in general practice settings. The 
knowledge obtained from these reviews is then used to acquire more reliable 
prevalence rates from the extensive and representative NIVEL Primary Care 
Database. In Chapter 5 four strategies are examined that can analyze raw data 
obtained from a general practice database in order to calculate valid prevalence 
rates.
In the second part of this thesis, different characteristics of atopic children in general 
practice are explored, focusing on comorbidity, medication use, and healthcare 
utilisation. First, in Chapter 6 a total of 404 different symptoms and diseases, and 
their possible association with atopic disorders, are examined. In Chapter 7 a total 
of 93 different medication groups were investigated for their possible association 
with atopic disorders. Then, in Chapter 8 a study is presented that aimed to 
quantify the current primary healthcare burden posed by atopic eczema, asthma 
and allergic rhinitis on general practice resources. In Chapter 9 the main results 
are discussed and recommendations are made for further research together with 
implications for clinical practice.
Finally, Chapter 10 summarises the main results of this thesis in English.
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Abstract
Purpose: To study the prevalence and interrelationship between atopic eczema, 
asthma and allergic rhinitis using data obtained from ISAAC questionnaires.
Method: The Medline, Pubmed Publisher, EMBASE, Google Scholar and the 
Cochrane Controlled Clinical Trials Register databases were systematically reviewed 
to evaluate epidemiological data of children with atopic disorders. To study these 
interrelationships, a new approach was used. Risk ratios were calculated, describing 
the risk of having two different atopic disorders when the child is known with one 
disorder.
Results: Included were 31 studies, covering a large number of surveyed children 
(n=1,430,329) in 102 countries. The calculated worldwide prevalence for atopic 
eczema, asthma and allergic rhinitis is 7.88% (95% CI: 7.88-7.89), 12.00% (95% 
CI: 11.99-12.00) and 12.66% (95% CI: 12.65-12.67), respectively. The observed 
prevalence [1.17% (95% CI: 1.17-1.17)] of having all three disorders is 9.8 times 
higher than could be expected by chance. For children with atopic eczema the 
calculated risk ratio of having the other two disorders is 4.24 (95% CI: 3.75-4.79), 
for children with asthma 5.41 (95% CI: 4.76-6.16), and for children with allergic 
rhinitis 6.20 (95% CI: 5.30-7.27). No studied confounders had a significant influence 
on these risk ratios.
Conclusions: Only a minority of children suffers from all three atopic disorders, 
however this co-occurrence is significantly higher than could be expected by chance 
and supports a close relationship of these disorders in children. The data of this 
meta-analysis supports the hypothesis that there could be a fourth distinct group of 
children with all three disorders. Researchers and clinicians might need to consider 
these children as a separate group with distinct characteristics regarding severity, 
causes, treatment or prognosis.
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Background
Atopic eczema, asthma and allergic rhinitis are common atopic disorders among 
children, making it an important public health problem worldwide. The prevalences 
of these three disorders show variability at regional and even at country level 
(1-4). Despite this variability, there seems to be a close relationship between 
these disorders. In a triad of events that include atopic eczema, asthma and 
allergic rhinitis, eczema is often the first disorder to evolve. A biologically plausible 
pathway to explain this cascade was proposed by Burgess et al (5). As a result of a 
defective skin barrier in children with atopic eczema, an epicutaneous sensitization 
to an allergen can take place resulting in T-helper type 2 memory cells; these cells 
can migrate to nasal and bronchial lymphoid tissue. When the airways become 
exposed to the same allergen, this might cause asthma and/or allergic rhinitis 
symptoms to evolve. However, in practice, the number of patients following this 
classic ‘atopic march’ seems to vary considerably (6, 7), only partially explaining the 
interrelationships.
The International Study of Asthma and Allergies in Childhood (ISAAC) was 
established in 1991 and formally closed in December 2012. The ISAAC study was 
divided into three phases. The purpose was to assess the worldwide prevalence of 
atopic eczema, asthma and allergic rhinitis in children in the open population and 
to obtain possible risk factors that could influence these three disorders using a 
standardized questionnaire (8-10). This makes ISAAC a reliable data source to use 
when studying the interrelationship of atopic disorders in children aged 6-7 and 
13-14 years. Although non-ISAAC research groups (i.e. non-official ISAAC studies) 
also published data using ISAAC questionnaires, the official ISAAC reviews do not 
include these latter data in their analyses.
The primary aim of this review is to calculate the worldwide prevalence in children of 
atopic eczema, asthma and allergic rhinitis, and of having all three disorders, using 
data obtained with ISAAC questionnaires and to examine interrelationships between 
these disorders using risk ratios. Risk ratios will describe the risk of having two 
different atopic disorders when the child is known with one disorder. A secondary aim 
is to analyze whether these risk ratios and prevalences are influenced by potential 
confounders such as study period, age, sex, continent, and use of the original 
English-language ISAAC questionnaire.
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Method
Search strategy
An extensive literature search was performed in Medline (OvidSP), Pubmed Publisher, 
EMBASE, Google Scholar and the Cochrane Controlled Clinical Trials Register. Two 
complementary search strategies were used for optimal article retrieval. The first 
strategy, focusing on the three atopic disorders, combined the following items: 
“Child” AND “Epidemiology” AND “Eczema” AND “Asthma” AND “Allergic rhinitis”. 
The second strategy, focusing on ISAAC studies, used additional items and different 
Boolean operators: “Child” AND “Epidemiology” AND (“Eczema” OR “Asthma” OR 
“Allergic rhinitis”) AND (“ISAAC” OR “International Study of Asthma and Allergies”).
The full search strategies can be found in Appendix 1. Since ISAAC started in 1991, 
only full-text articles published after 1991 were considered; there was no language 
restriction. The search was completed on February 2, 2015. A reference check was 
made on all articles finally included.
Study selection
Studies (n>100) with a cross-sectional or cohort design, including youngsters aged 
0-18 years, recruited in the open population (e.g. schools) were included. Studies 
using the ISAAC questionnaire, performed by both official and non-official ISAAC 
research groups, were included if the studies presented data on the prevalence of all 
three atopic disorders and their interrelationships.
One reviewer (EA) commenced the selection of studies, initially based on title and 
abstract. To check for any missed inclusions by the first reviewer, a random selection 
of 50% of the articles was independently checked by second reviewers (DP, JW, AB, 
NR, HM). This check showed that the first reviewer did not exclude any potentially 
relevant articles.
Of the abstracts selected, the full-text articles were retrieved. Two reviewers (EA 
and NR) independently performed the full-text selection using a standardized form 
based on the above-mentioned inclusion criteria. Studies were excluded if they only 
presented aggregated worldwide data, or when double inclusion of the data could not 
be ruled out. Disagreement was resolved in a consensus meeting or with the help of 
a third independent reviewer (DP). Authors of the studies were contacted regarding 
missing data.
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Quality assessment
To minimize the risk of information bias, the quality of the included studies was 
assessed by two independent reviewers (DP and AB). Disagreement was resolved in 
a consensus meeting.
ISAAC used the same standardized method in ISAAC phase 1 and 3. Methodological 
differences between these phases were studied (11) and it was concluded that 
the ISAAC methodology was replicated to a high degree by the majority of the 
study centers. This showed that the ISAAC protocol is robust and that working in 
accordance with this protocol implied substantial generalizability. Any important 
violations of this protocol were, therefore, identified in order to assess quality (Table 
1).
The present review includes only those articles that used the ISAAC questionnaires. 
This questionnaire has been translated into various languages by regional 
coordinators of ISAAC, using a consistent protocol that was evaluated by Ellwood et 
al. (12). Use of a validated questionnaire was also considered an important quality 
item and was part of the quality assessment (Table 1).
The above mentioned violations and the use of the original questionnaire or not 
could potentially influence the comparability of ISAAC and non-ISAAC studies. For 
this reason we performed a meta-regression analyses in order to evaluate if these 
violation would influence our outcomes (prevalence and RR).
Data extraction
Two reviewers (EA/JW and DP) independently extracted data from the included 
studies. A standardized digital form was used to record study design, participants, 
official ISAAC study or not, and outcome measures. In view of the outcome 
measures, the total number of participants and the number of participants with 
eczema (Ec), asthma (As), allergic rhinitis (AR) and of Ec+As, Ec+AR, As+AR 
and Ec+As+AR were extracted. These numbers were then entered in the Review 
Manager (RevMan) Computer program (Version 5.1. Copenhagen: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2011). This program provides risk 
ratios, 95% confidence intervals (CI) (using the Mantel-Haenszel test and random 
effects models) and the weight of every study. The extraction was limited to current 
symptoms (past 12 months) and data collected by written questionnaires. Study 
characteristics regarding gender, age, continent, validated (English) questionnaires, 
ISAAC/non-ISAAC study, number of participants, response rate, study period and 
ISAAC protocol violations were also collected. Data entry was additionally checked by 
two independent reviewers (AB, JW).
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Statistical analyses
In order to calculate the mean prevalences, the studies were weighted for their 
number of participants. Risk ratios (RR) calculated by RevMan describe the risk of 
having two different atopic disorders when a child is known with one disorder. For 
example, if the RR for asthma is four, this would mean that a child with asthma has 
a fourfold risk of reporting atopic eczema and allergic rhinitis in contrast to a child 
without asthma. Heterogeneity (I2) was assessed using a random effects model.
For the study characteristics of this meta-analysis, a mixed-effects model was used 
for natural logarithm of the calculated RR for atopic eczema, asthma and allergic 
rhinitis and for the prevalence of atopic eczema, asthma and allergic rhinitis and 
having all three disorders. Initial models for these seven responses contained all 
covariates of interest as fixed effects: percentage of males, age, continent, ISAAC/
non-ISAAC, number of participants, response rate, study period and the use of 
validated English questionnaires. The latter was chosen to explore the influence of 
using translations on the RR. Since not all studies provided data on the percentage 
of male participants and the response rate, and both variables did not have 
significant parameters in the complete case analysis, both variables were excluded 
from the models in order to be able to use all 57 studies for the meta regression. 
Some influential centers were removed from initial and final models using traditional 
measures: standardized residuals, DFFITS values, Cook’s distance and hat values. 
All calculations were conducted in R with the metafor package (Wolfgang Viechtbauer 
(2010)). A p value of 0.01 was considered the limit of significance because of 
multiple testing (Bonferroni correction).
Results
Identification and selection of the literature
The combined search strategies resulted in 5,178 original abstracts. No articles were 
excluded because of language barriers but the majority (n=3,607; 69.7%) did not 
meet the inclusion criteria, mainly because these articles did not present data on all 
three disorders or because ISAAC questionnaires were not used. We retrieved 1,571 
full-text articles for detailed evaluation. Of these, another 1,533 studies were not 
included, mainly because the studies did not use ISAAC questionnaires or because 
these articles did not present data on all three disorders. Finally 38 studies were 
initially included in this review for further analysis (2, 13-49) (Fig. 1).
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Description and final selection of studies
The ISAAC Phase 3 synthesis presented by Mallol et al. (30) covers a large number 
of surveyed children (n=1,184,821). Four of the included ISAAC studies (45-48) 
were excluded because it is assumed that the data from these studies were already 
included by Mallol et al. (30). The data presented by Song et al. (49) showed 
internal inconsistency and was therefore excluded. Furthermore, articles that only 
presented worldwide data (n=2) (44, 50) were not used for the final analysis.
Finally, data from 31 studies were used, covering a large number of surveyed 
children (n=1,430,329) in 102 different countries. Table 1 presents descriptive 
characteristics of the studies, including the results of the quality assessment. All 
officially acknowledged ISAAC studies, with the exception of one (38), used the same 
Figure 1. Flow diagram for selection of studies identif ied in the 
systematic review.
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definition for atopic eczema, asthma and allergic rhinitis. Non-ISAAC studies varied 
considerably in the definitions they used for the disorders.
Overall and regional difference in prevalence of atopic manifestations
The calculated worldwide prevalence for atopic eczema, asthma and allergic rhinitis 
for children in the open population is 7.88% (95% CI: 7.88-7.89), 12.00% (95% 
CI: 11.99-12.00) and 12.66% (95% CI: 12.65-12.67), respectively. Figure 2 shows 
the prevalence per continent. None of the continents significantly influenced the 
worldwide prevalence of any one of the atopic disorders, neither did percentage of 
males, ISAAC/non-ISAAC, number of participants and the use of validated English 
questionnaires. There were significant negative associations between age and 
prevalence of eczema and between study period and prevalence of asthma. The 
worldwide observed prevalence of having all three disorders is 1.17% (95% CI: 
1.17-1.17) and was not influenced by the above mentioned factors. If there would 
be no interrelationship at all between the three disorders, the expected worldwide 
prevalence of having all three disorders is only 0.12% (12.00%*7.89%*12.66%)). 
In the present review, the observed prevalence is 9.8 times higher than could be 
expected by chance, suggesting a close relationship between these disorders in 
children. It is remarkable that the prevalence of ‘all three expected’ is relatively 
consistent between the six continents (Fig. 2).
Figure 2. Prevalence (%) of the atopic disorders per continent.
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Interrelationship between the atopic manifestations
Calculated RR for children with atopic eczema, asthma and allergic rhinitis are 
presented in the Forest plots (Figs. 3-5). If possible, the Forest plots provide a 
subdivision per article by continent and age. The overall RR for patients having 
atopic eczema to also suffer from asthma and rhinitis is 4.24 (95% CI: 3.75-4.79). 
For patients with asthma the RR is 5.41 (95% CI:4.76-6.16) and for allergic rhinitis 
the RR is 6.20 (95% CI: 5.30-7.27). These risk ratios show a clear relationship of 
the three disorders. Additional analyses to examine whether RRs were influenced 
by covariates (percentage of males, age, continent, official ISAAC/non-ISAAC study, 
number of participants, response rate, study period and the use of validated English 
questionnaires) showed no significant effect on the calculated RR.
There is substantial heterogeneity (I2= 97-98%) between these studies. Subanalyses 
performed for different subgroups (percentage of males, age, continent, ISAAC/
non-ISAAC, number of participants, response rate, study period) showed no major 
change in heterogeneity.
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Figure 3. Forest plot of risk ratios for atopic eczema
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Figure 4. Forest plot of risk ratios for asthma
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Figure 5. Forest plot of risk ratios for al lergic rhinitis
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Discussion
A comprehensive literature search retrieved data from 102 different countries, 
making this one of the largest meta-analysis of atopic eczema, asthma and allergic 
rhinitis ever conducted. The calculated worldwide prevalence for atopic eczema, 
asthma and allergic rhinitis for children in the open population is 7.9%, 12.0% and 
12.7%, respectively. Overall this prevalence is higher than that presented earlier by 
Mallol et al (30). None of the individual continents had a significant influenced on the 
worldwide prevalence of one of the atopic disorders.
In this review, the observed prevalence of having all three disorders is 1.17% (95% 
CI: 1.17-1.17). This co-occurrence is substantially higher than could be expected 
by chance, based on the individual prevalence of each disorder (0.12%). This 
supports the hypothesis that there could be a fourth distinct group of children with 
all three disorders. A new and different way of looking at the interrelationships is 
by calculating RRs; the RRs presented in this review, describe the risk of having the 
other two atopic disorders when a child is known with one disorder. The RRs ranged 
from 4.24–6.20 and were not significantly influenced by any of the confounders 
investigated. Since all RR were > 1, this implies that the observed co-occurrence 
is not based on chance, but suggest a clear relationship between the disorders. 
Remarkably, the RR of atopic eczema is low compared with the other two disorders; 
this might be because we used prevalence data based on having complaints in the 
past 12 months and not on lifetime prevalences. On average, atopic eczema is seen 
in children at a younger age than those studied in this review, thereby resulting in 
a lower RR. This study also showed a significant decline in the prevalence of asthma 
when a child becomes older.
The wide variation in the prevalence of atopic disorders (1-4) has received 
considerable attention. Possible causes of these variations include (amongst others): 
genetics, use of paracetamol, use of antibiotics, breastfeeding, diet, body mass 
index, living in a rural area, and air pollution. However, none of these proposed 
factors fully explains this wide variation. Remarkably, when looking at the prevalence 
of having all three disorders, this wide variation does not occur to the same extent. 
In the present study, the limited degree of overlap between the three conditions 
(1.17%) was very similar to that reported by others (30, 50). Asher et al. (44) 
even showed that this overlap has been relatively consistent over a period of seven 
years; for 6-7 year olds this overlap increased from 0.8% to 1.0% and for the 13-14 
year olds the overlap increased from 1.1% to 1.3%. This consistency in prevalence 
also suggests that a fourth group of children with atopic disorders might exist. In 
addition to the three regularly described groups of children with atopic eczema, 
asthma or allergic rhinitis, there seems to be a fourth distinct group of children with 
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all three disorders, that may show distinct characteristics regarding severity, causes, 
treatment or prognosis.
We suggest to add another chapter to the already impressive ISAAC study, focusing 
on this potentially distinct fourth group of children with all three manifestations. Is 
this group distinctive due to severity of symptoms? Does this group have a different 
genotype? Does this group need a different pharmacological approach? Does this 
group have a different prognosis? Which factors influence this group?
This meta-analysis has some limitations. First, one reviewer selected the studies 
based on title and abstract. Despite a random check of 50% of the retrieved articles 
showing concordance, we assumed that no relevant articles were missed. However, 
the full-text selection was done by two independent reviewers. In our review there 
was no limitation for any language and (where possible) authors were contacted for 
missing data.
When conducting a large multicenter international cross-sectional study, there is 
always a risk of potential limitations. Clear examples include language problems, 
cultural differences, environmental aspects, different healthcare systems, etc. Either 
an overestimation or an underestimation might be found. Another concern is the 
possible overestimation of the prevalence of the three atopic disorders. Although the 
questionnaires asked about symptoms, the symptoms could well be attributable to 
other diseases; this concern is shared by others (28, 46, 48, 51). Furthermore, Cane 
et al. (52) showed that the conceptual understanding of ‘wheeze’ differs between 
reporting parents and epidemiology definitions. Finally, different research groups 
used different definitions for the atopic disorders; this could have influenced our 
results.
The high level of heterogeneity that we found suggests that the included studies 
differ significantly from each other. However, this can be explained by the large 
number of participants in each study. Because the studies have such large 
populations, the CIs will be very small. Even small differences will result in statistical 
heterogeneity, but not in clinical heterogeneity.
This meta analyses supports the hypothesis that these three atopic disorders are 
clearly related. A biological plausible pathway for these relationships can be found in 
the atopic march theory. However, the obtained data in this meta-analysis does not 
allow to quantify the effect of this atopic march theory. This is due to two limitations. 
The first limitation relates to the cross sectional methods used. We have no follow-up 
data available for an individual child. The second one is that we limited our data 
inclusion to symptoms within the previous year (year prevalence). Using year-
prevalences instead of life-time prevalences could result in an underestimation of 
the prevalences. Atopic dermatitis often goes into a clinical remission, but the atopic 
phenotype persists. The same applies to asthma. For example, when establishing the 
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prevalence at the age of e.g. 12 years, the child may answer no, but in fact might 
still have an atopic phenotype.
Conclusions
We studied the prevalence and interrelationships between atopic eczema, asthma 
and allergic rhinitis in children using data obtained from ISAAC questionnaires. The 
interrelationships were studied using risk ratios, adjusted for potential confounders. 
Our meta-analysis has shown that the prevalence of children with a co-occurrence 
of atopic eczema, asthma and allergic rhinitis was low, but significantly higher than 
could be expected by chance. The prevalence of having all three atopic disorders was 
remarkably consistent in all continents. This study supports the hypothesis that there 
might be a forth distinct group of children with all three disorders, in contrast to the 
traditional classification of children with atopic eczema or asthma or allergic rhinitis. 
Researchers and clinicians might need to consider this forth group as a separate 
group of children with their own characteristics.
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Appendix 1
Search string ONE contained the following specific terms:
For Embase
(asthma/exp OR wheezing/de OR (asthma* OR wheez* OR hyperresponsiv* OR 
hypersensit* OR (hyper NEXT/1 (responsiv* OR sensitiv*))):ab,ti) AND (eczema/
de OR ‘atopic dermatitis’/de OR (eczem* OR (atopic NEAR/3 dermatit*)):ab,ti) 
AND (rhinitis/exp OR conjunctivitis/exp OR (rhinitis* OR rhinoconjunctivit* OR 
conjunctivit* OR (Pollen NEAR/3 Allerg*) OR Pollinos* OR ((hay) NEXT/1 (fever*)) 
OR hayfever):ab,ti) AND (Epidemiology/exp OR ‘epidemiological data’/exp OR 
epidemiology:lnk OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* 
OR relat* OR correlat* OR (case NEAR/3 (control* OR comparison OR referent)) 
OR epidemiolog* OR cohort* OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* 
OR aetiol* OR (natural NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR 
course*):ab,ti) AND (child/exp OR newborn/exp OR adolescent/exp OR adolescence/
exp OR ‘child behavior’/de OR ‘child parent relation’/de OR (adolescen* OR infan* 
OR newborn* OR (new NEXT/1 born*) OR baby OR babies OR neonat* OR child* 
OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR 
(under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* 
OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR 
preschool* OR highschool*):ab,ti)
For Medline via OvidSP
(exp asthma/ OR (asthma* OR wheez* OR hyperresponsiv* OR hypersensit* 
OR (hyper ADJ (responsiv* OR sensitiv*))).ab,ti.) AND (exp Dermatitis, Atopic/ 
OR exp Eczema/ OR Eczem*.ab,ti. OR (atopic ADJ3 dermatit*).ab,ti.) AND (exp 
Rhinitis/ OR exp Conjunctivitis/ OR (rhinit* OR rhinoconjunctivit* OR conjunctivit* 
OR (Pollen ADJ3 Allerg*) OR Pollinos* OR hayfever* OR hay fever*).ab,ti.) AND 
(exp Epidemiologic Studies/ OR exp Epidemiologic Factors/ OR epidemiology.xs. 
OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR 
correlat* OR (case ADJ3 (control* OR comparison OR referent)) OR epidemiolog* OR 
cohort* OR risk* OR caus* OR odds ratio* OR etiol* OR aetiol* OR natural histor* 
OR predict* OR prognos* OR outcome* OR course*).ab,ti.) AND (exp child/ OR exp 
infant/ OR (infan* OR newborn* OR new born* OR baby OR babies OR neonat* OR 
perinat* OR postnat* OR child* OR kid? OR toddler* OR teen* OR boy? OR girl? OR 
minor? OR underag* OR (under ADJ2 ag?) OR juvenil* OR youth? OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatric* OR 
44  Chapter 2
peadiatric* OR school* OR preschool* OR highschool* OR suckling*).ab,ti. OR 
((adoles*.ab,ti. OR adolescent/) NOT exp adult/))
For PubMed publisher
(asthma[mh] OR (asthma*[tiab] OR wheez*[tiab] OR hyperresponsiv*[tiab] 
OR hypersensit*[tiab] OR hyper responsiv*[tiab] OR hyper sensitiv*[tiab])) 
AND (Dermatitis, Atopic[mh] OR Eczema[mh] OR Eczem*[tiab] OR (atopic AND 
dermatit*[tiab])) AND (Rhinitis[mh] OR Conjunctivitis[mh] OR (rhinit*[tiab] OR 
rhinoconjunctivit*[tiab] OR conjunctivit*[tiab] OR (Pollen AND Allerg*[tiab]) OR 
Pollinos*[tiab] OR hayfever*[tiab] OR hay fever*[tiab])) AND (Epidemiologic 
Studies[mh] OR Epidemiologic Factors[mh] OR epidemiology[sh] OR 
(prevalenc*[tiab] OR inciden*[tiab] OR trend*[tiab] OR associat*[tiab] OR 
comorbid*[tiab] OR relat*[tiab] OR correlat*[tiab] OR (case AND (control*[tiab] 
OR comparison OR referent)) OR epidemiolog*[tiab] OR cohort*[tiab] OR 
risk*[tiab] OR caus*[tiab] OR odds ratio*[tiab] OR etiol*[tiab] OR aetiol*[tiab] OR 
natural histor*[tiab] OR predict*[tiab] OR prognos*[tiab] OR outcome*[tiab] OR 
course*[tiab])) AND (child[mh] OR infant[mh] OR (infan*[tiab] OR newborn*[tiab] 
OR new born*[tiab] OR baby OR babies OR neonat*[tiab] OR perinat*[tiab] OR 
postnat*[tiab] OR child*[tiab] OR kid* OR toddler*[tiab] OR teen*[tiab] OR boy* 
OR girl* OR minor* OR underag*[tiab] OR under ag* OR juvenil*[tiab] OR youth* 
OR kindergar*[tiab] OR puber*[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] 
OR prepuberty*[tiab] OR pediatric*[tiab] OR peadiatric*[tiab] OR school*[tiab] OR 
preschool*[tiab] OR highschool*[tiab] OR suckling*[tiab]) OR ((adoles*[tiab] OR 
adolescent[mh]) NOT adult[mh])) AND publisher[sb]
For Cochrane
((asthma* OR wheez* OR hyperresponsiv* OR hypersensit* OR (hyper 
NEXT/1 (responsiv* OR sensitiv*))):ab,ti) AND ((eczem* OR (atopic NEAR/3 
dermatit*)):ab,ti) AND ((rhinitis* OR rhinoconjunctivit* OR conjunctivit* OR (Pollen 
NEAR/3 Allerg*) OR Pollinos* OR ((hay) NEXT/1 (fever*)) OR hayfever):ab,ti) AND 
((prevalenc* OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR 
correlat* OR (case NEAR/3 (control* OR comparison OR referent)) OR epidemiolog* 
OR cohort* OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* OR aetiol* OR 
(natural NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR course*):ab,ti) 
AND ((adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby OR 
babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR 
girl* OR minors OR underag* OR (under NEXT/1 ag*) OR juvenil* OR youth* OR 
kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* 
OR paediatric* OR school* OR preschool* OR highschool*):ab,ti)
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For Google scholar
asthma eczema rhinitis prevalence | incidence | epidemiology | cohort | risk | 
etiology | prognosis | outcome adolescents | infants | children | newborns “family | 
general | primary physician | practice | doctor | care”
Search string TWO contained the following specific terms:
For Embase
((asthma/exp OR wheezing/de OR (asthma* OR wheez* OR hyperresponsiv* OR 
hypersensit* OR (hyper NEXT/1 (responsiv* OR sensitiv*))):ab,ti) OR (eczema/
de OR ‘atopic dermatitis’/de OR (eczem* OR (atopic NEAR/3 dermatit*)):ab,ti) 
OR (rhinitis/exp OR conjunctivitis/exp OR (rhinitis* OR rhinoconjunctivit* OR 
conjunctivit* OR (Pollen NEAR/3 Allerg*) OR Pollinos* OR ((hay) NEXT/1 (fever*)) 
OR hayfever):ab,ti)) AND (Epidemiology/exp OR ‘epidemiological data’/exp OR 
epidemiology:lnk OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* 
OR relat* OR correlat* OR (case NEAR/3 (control* OR comparison OR referent)) 
OR epidemiolog* OR cohort* OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* 
OR aetiol* OR (natural NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR 
course*):ab,ti) AND (child/exp OR newborn/exp OR adolescent/exp OR adolescence/
exp OR ‘child behavior’/de OR ‘child parent relation’/de OR (adolescen* OR infan* 
OR newborn* OR (new NEXT/1 born*) OR baby OR babies OR neonat* OR child* 
OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR 
(under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* 
OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR 
preschool* OR highschool*):ab,ti) AND (Isaac OR ‘Asthma and Allergies in Childhood’ 
OR ‘Asthma and Allergy in Childhood’):de,ab,ti
For Medline via OvidSP
((exp asthma/ OR (asthma* OR wheez* OR hyperresponsiv* OR hypersensit* 
OR (hyper ADJ (responsiv* OR sensitiv*))).ab,ti.) OR (exp Dermatitis, Atopic/ 
OR exp Eczema/ OR Eczem*.ab,ti. OR (atopic ADJ3 dermatit*).ab,ti.) OR (exp 
Rhinitis/ OR exp Conjunctivitis/ OR (rhinit* OR rhinoconjunctivit* OR conjunctivit* 
OR (Pollen ADJ3 Allerg*) OR Pollinos* OR hayfever* OR hay fever*).ab,ti.)) AND 
(exp Epidemiologic Studies/ OR exp Epidemiologic Factors/ OR epidemiology.xs. 
OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR 
correlat* OR (case ADJ3 (control* OR comparison OR referent)) OR epidemiolog* OR 
cohort* OR risk* OR caus* OR odds ratio* OR etiol* OR aetiol* OR natural histor* 
OR predict* OR prognos* OR outcome* OR course*).ab,ti.) AND (exp child/ OR exp 
infant/ OR (infan* OR newborn* OR new born* OR baby OR babies OR neonat* OR 
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perinat* OR postnat* OR child* OR kid? OR toddler* OR teen* OR boy? OR girl? OR 
minor? OR underag* OR (under ADJ2 ag?) OR juvenil* OR youth? OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatric* OR 
peadiatric* OR school* OR preschool* OR highschool* OR suckling*).ab,ti. OR 
((adoles*.ab,ti. OR adolescent/) NOT exp adult/)) AND (Isaac OR “Asthma and 
Allergies in Childhood” OR “Asthma and Allergy in Childhood”).ab,ti.
For Pubmed publisher
((asthma[mh] OR (asthma*[tiab] OR wheez*[tiab] OR hyperresponsiv*[tiab] 
OR hypersensit*[tiab] OR (hyper responsiv*[tiab] OR hypersensitiv*[tiab])) 
OR (Dermatitis, Atopic[mh] OR Eczema[mh] OR Eczem*[tiab] OR (atopic AND 
dermatit*[tiab])) OR (Rhinitis[mh] OR Conjunctivitis[mh] OR (rhinit*[tiab] OR 
rhinoconjunctivit*[tiab] OR conjunctivit*[tiab] OR (Pollen AND Allerg*[tiab]) OR 
Pollinos*[tiab] OR hayfever*[tiab] OR hay fever*[tiab]))) AND (Epidemiologic 
Studies[mh] OR Epidemiologic Factors[mh] OR epidemiology[sh] OR 
(prevalenc*[tiab] OR inciden*[tiab] OR trend*[tiab] OR associat*[tiab] OR 
comorbid*[tiab] OR relat*[tiab] OR correlat*[tiab] OR (case AND (control*[tiab] 
OR comparison OR referent)) OR epidemiolog*[tiab] OR cohort*[tiab] OR 
risk*[tiab] OR caus*[tiab] OR odds ratio*[tiab] OR etiol*[tiab] OR aetiol*[tiab] OR 
natural histor*[tiab] OR predict*[tiab] OR prognos*[tiab] OR outcome*[tiab] OR 
course*[tiab])) AND (child[mh] OR infant[mh] OR (infan*[tiab] OR newborn*[tiab] 
OR new born*[tiab] OR baby OR babies OR neonat*[tiab] OR perinat*[tiab] OR 
postnat*[tiab] OR child*[tiab] OR kid* OR toddler*[tiab] OR teen*[tiab] OR boy* 
OR girl* OR minor* OR underag*[tiab] OR (under ag*) OR juvenil*[tiab] OR youth* 
OR kindergar*[tiab] OR puber*[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] 
OR prepuberty*[tiab] OR pediatric*[tiab] OR peadiatric*[tiab] OR school*[tiab] 
OR preschool*[tiab] OR highschool*[tiab] OR suckling*[tiab]) OR ((adoles*[tiab] 
OR adolescent[mh]) NOT adult[mh])) AND (Isaac OR “Asthma and Allergies in 
Childhood” OR “Asthma and Allergy in Childhood”) AND publisher[sb]
For Cochrane
(((asthma* OR wheez* OR hyperresponsiv* OR hypersensit* OR (hyper NEXT/1 
(responsiv* OR sensitiv*))):ab,ti) OR ((eczem* OR (atopic NEAR/3 dermatit*)):ab,ti) 
OR ((rhinitis* OR rhinoconjunctivit* OR conjunctivit* OR (Pollen NEAR/3 Allerg*) 
OR Pollinos* OR ((hay) NEXT/1 (fever*)) OR hayfever):ab,ti)) AND ((prevalenc* 
OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR correlat* OR 
(case NEAR/3 (control* OR comparison OR referent)) OR epidemiolog* OR cohort* 
OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* OR aetiol* OR (natural 
NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR course*):ab,ti) AND 
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((adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby OR babies 
OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR 
minors OR underag* OR (under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* OR 
paediatric* OR school* OR preschool* OR highschool*):ab,ti) AND (Isaac OR ‘Asthma 
and Allergies in Childhood’ OR ‘Asthma and Allergy in Childhood’):ab,ti
For Google scholar
Asthma | wheezing|hyperresponsive | hypersensitivity | eczema | “atopic dermatitis” 
| rhinitis | conjunctivitis | “Pollen Allergy | allergies” | Pollinos | “hay fever” | 
hayfever prevalence | incidence | comorbidity | comorbidities | epidemiology | 
epidemiological infants | children Isaac
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Abstract
Purpose: Physicians and researchers in the field of family medicine often need to 
find relevant articles in online medical databases. Because a search filter may help 
improve the efficiency of such searches, we aimed to develop and validate search 
filters to identify studies in the field of family medicine/general practice.
Method: To develop a search filter for family medicine, a precise definition was 
obtained which allows to classify articles as ‘relevant’ or ‘irrelevant’ to family 
medicine. This definition allowed to create a reference standard set of articles. Using 
specialized software, filter candidate terms and phrases were derived from this 
reference standard. Using these candidate terms and phrases, an optimal sensitive 
and an optimal specific filter were created. Finally, two filters were validated on two 
external validation sets.
Results: The sensitive filter has a sensitivity of 96.8% with an adequate specificity 
of 74.9%. The specific filter has a specificity of 97.4% with an adequate sensitivity of 
90.3%
Conclusions: Two well-validated search filters were developed for family medicine 
with good sensitivity and specificity. Both filters can be applied in daily practice 
by family physicians and researchers. The quality of these filters is good when 
compared with other search filters applied in different scientific fields.
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Background
Although many physicians use online medical databases to obtain biomedical 
information for clinical practice (1-3), the enormous volume and diversity of the 
available literature makes this a challenging process. Lack of time and skills, as well 
as a clear preference for asking an expert colleague or consulting a print source, are 
considered as barriers to the use of online databases (4, 5). A specific search filter 
might enhance the retrieval of relevant articles at the point of care by the physician. 
On the other hand, researchers in the field of family medicine completing a systematic 
review, will need a ‘sensitive’ search tool in order not to miss relevant articles.
Electronic search filters, both sensitive and specific, can be used to improve the 
overall efficiency of a literature search. Search filters are strings of keywords and/
or text words connected with Boolean operators (e.g. AND, OR, NOT). These 
topic-specific keywords can be found in the title or abstract of an article, or in the 
subject headings assigned to it. However, the indexing of these articles with subject 
headings is often inconsistent. The area of family medicine is particularly broad and 
difficult to define, mainly due to the different terminologies used. For example, the 
terms ‘family medicine’, ‘general practice’ and ‘primary care’ (amongst others), can 
be used to describe basically the same field.
Therefore, there is a need for a validated ‘family medicine’ search filter to support 
both family physicians and researchers. These filters should apply to the most 
frequently-used databases, e.g. PubMed, Ovid Medline, Embase and Cochrane.
To our knowledge, four filters have been developed for family medicine. Although 
the PHC Search Filter (6) can be considered specific, it was not designed to be 
comprehensive regarding what it retrieves. Jelercic et al. (7), Glanville et al. (8) and 
Gill et al. (9) also created search filters, but they also lack good sensitivity.
The present study was conducted to develop and validate objective search filters, 
applicable in frequently-used databases, to identify studies that are conducted in, or 
apply to, or refer to family medicine and general practice settings.
Method
Definition of family medicine
To develop an efficient and objective search filter, a clear definition of relevance 
to family medicine/general practice (FM/GP) is needed. WONCA Europe provides a 
consensus statement in which they define the discipline of FM/GP (10). Based on a 
short questionnaire that was sent to colleagues worldwide using the e-mail list of 
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the Cochrane Primary Healthcare Field, we learned that this definition was shared 
by many. However, the respondents indicated that two additional aspects should be 
taken into account. First, an inpatient hospital setting should explicitly be excluded. 
Second, one should be aware of the difference between ‘primary care’ and ‘FM/
GP’. Primary care was often regarded by the respondents as an umbrella term, that 
includes FM/GP, but could also include (amongst others) midwives, psychologists 
and physiotherapists. Based on an analysis of the submitted answers to the 
questionnaire, the WONCA definition was shortened as followed:
General practice/family medicine is the frontline of health care. It is a place where a 
patient can go without referral. This specifically trained physician can be consulted 
for acute and chronic health-related matters. Family medicine is considered to be 
out-of-hospital (together with the emergency department) care.
Relevance to general practice referred to any research article that explicitly indicated 
it was completed in a FM/GP setting as defined by WONCA, excluding inpatient 
hospital care and focusing specifically on FM/GP. Research articles that have ‘FM/
GP’ as their research domain were also considered relevant (e.g. research on the 
efficiency of GPs).
Development of reference standard
Using Scopus, a list of 160 journals (in order of relevance for family medicine) was 
compiled. Five journals with a high rating (top 20) and five journals with a low rating 
Table 1. Journal t it les randomly selected from Scopus.
Rank in 
Scopus
Journal title Hits on FM/GP*
in Scopus
Hits in 
2009 in 
PubMed
With an 
abstract
Included in 
the reference 
standard
2 British Journal of Family Medicine 5309 246 97 (39%) 63
3 Journal of Family Practice 3712 170 78 (46%) 44
5 American Family Physician 3404 260 104 (40%) 73
10 Canadian Family Physician 2669 264 89 (34%) 58
12 Family Practice 2288 119 112 (94%) 77
108 Age and Ageing 391 213 117 (55%) 79
121 Journal of Clinical Psychiatry 371 373 272 (73%) 188
128 Palliative Medicine 363 129 109 (84%) 73
144 Emergency Medicine Journal 305 367 217 (59%) 146
148 Intensive Care Medicine 280 415 303 (73%) 199
Total 2556 1498 1000
* FM: family medicine; GP: general practice
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were randomly taken from this list (Table 1). From the obtained list of journals, 
1000 articles published in the randomly selected year 2009, with abstracts and 
MeSH terms, were randomly selected. These articles were imported in EndNote X5 
and anonymized, showing only the titles, abstracts and keywords to the reviewers. 
Two independent reviewers (DP and FvdL) classified the articles as being relevant 
or irrelevant to family medicine using the shortened definition based on the WONCA 
definition. If the anonymized information was not sufficient for a classification, all 
bibliographic data or even the full text was provided. Articles that refer to family 
medicine were tagged ‘positives’. From this reference standard, two random sets 
were derived: a term identification set containing 1/3 of the reference standard and 
a development set containing 2/3 of the reference standard.
Generating a list of potentially useful terms
Using specialized software (PubReMiner (11) and AntConc (12)) candidate filter 
terms and phrases were derived in the term identification set from the bibliographic 
information of positive articles based on frequency of occurrence. Each retrieved 
term (MeSH term, text word or text phrase) was subsequently combined with various 
PubMed field codes ([mh]; [mh:noexp]; [mj]; [mj:noexp]; [sh]; [all fields]; [ad]; 
[tw]; [tiab]; [ti]). We included candidate filter terms for further analysis if that term 
retrieved at least 5% of the positive articles. Furthermore, the ratio between the 
percentage of positive articles containing the term and the percentage of negative 
articles containing the term had to be ≥ 1, and this ratio had to be significant 
(Chi-square test: p<0.05).
Creating and validating a sensitive and specific filter
With a list of candidate terms and phrases retrieved during the process described 
above, optimal search filters were created in the development set. The sensitive filter 
was created by sorting the search terms by accuracy. One by one, the items were 
meticulously added to the filter, whilst monitoring its performance. When an added 
term did not contribute to the overall accuracy of the filter, the item was excluded.
The specific filter, with a target specificity of at least 95%, was created by discarding 
all search terms that had a specificity of ≤ 95%. Search terms that scored a specificity 
of 100% formed the basis of the filter. The remaining search terms were then sorted 
by accuracy, and were added one by one to the existing filter. When an added term 
did not contribute to the overall accuracy of the filter, the item was excluded.
The obtained filters were then validated in different validation sets (see below), 
calculating sensitivity and specificity. Finally, all the false negatives from different 
validation sets, missed by the sensitive filter, were manually screened by two 
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independent reviewers (DP and AB) to identify unique extra terms that could be 
added to the sensitive filter in order to improve its performance. These terms were 
then tested on both development and validation sets and included if they improved 
the overall accuracy of the sensitive filter.
Development of validation sets
In addition to the reference standard, two external validation sets were created. 
The first was created during the screening process of a family medicine relevant 
systematic review on atopic disorders in children (review standard) (13). The search 
for this review was not limited to family medicine, but all the references found for 
this review were also scored by two independent reviewers (DP and E. van Alphen) 
to classify articles as being relevant or irrelevant to family medicine. Relevance 
to general practice referred to any research article that explicitly indicated it was 
completed in a FM/GP setting as defined for the reference standard.
The second validation set was created by sending an e-mail to the list of the 
Cochrane Primary Healthcare Field (questionnaire standard). In this e-mail the 
participant was asked to send a reference of an article that they considered to be 
relevant for ‘primary care’, in particular for family medicine. These 500 references 
are considered to be positives. The negatives were collected from a random sample 
of articles from PubMed that were manually reviewed by two independent reviewers 
(FvdL and D. Al Rashad), creating 1,000 negatives.
Results
Creating and validating the filters
A total of 126 terms and phrases were considered as candidate filter terms. The 
original sensitive filter that was constructed missed a total of 35 ‘positives’ in both 
the reference set and in the two validation sets. Manual evaluation of these 35 false 
negative references led to our decision to add three more terms to the sensitive 
filter to increase its performance, i.e. ‘GP’ ‘GPs’ and ‘general pract*’ were added; this 
substantially improved the filter.
Table 2 shows the strings of the sensitive and specific filters that were constructed 
using this methodology, including the translation for use in different search engines. 
Table 3 presents the results of a comparison between the performance of our 
filters and that of other published search filters (6-9). In the validation process 
the sensitive filter had an overall sensitivity of 96.8% (range 95.4-100%), with an 
adequate overall specificity of 74.9% (range 69.2-89.5%). For the specific filter 
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the overall specificity was 97.4% (range 94.8-99.3%), with an adequate overall 
sensitivity of 90.3% (83.9-96.0%). Both the sensitive and the specific filters perform 
better compared to other recently published filters on the same topic (6-9). In table 
4 the performance of our filters is compared to a combination of relevant Mesh terms 
(General Practice[Mesh] OR General Practitioners [Mesh] OR Physicians, Family 
[Mesh] OR physicians, primary care [mh]), i.e. a strategy used by many physicians 
in daily practice. Furthermore, the filter was tested against five search strategies 
used for general practice relevant Cochrane Reviews (14-18).
Discussion
Two well-validated search filters were created for family medicine, both with good 
sensitivity and specificity.
Our specific filter was developed to help family physicians find answers to clinical 
questions at the point of care when time is limited. The specific filter provides the 
physician with references that are relevant, but with a small risk of missing articles. 
If an answer to the question is not found using the specific filter, use of the sensitive 
filter could be the next step.
Our sensitive filter can also be used by researchers conducting a systematic review. 
The sensitive filter provides considerable efficiency. For example, we constructed a 
search string for a systematic review on atopic disorders in children through which 
3,972 publications were found. If our sensitive filter had been applied, the number 
Table 2. The fi lters translated for different interfaces.
Pubmed Ovid (Medline/
Embase)
Embase.com Cochrane
Sensitive 
filter
(“family”[all fields] OR 
physician*[all fields] 
OR practice*[tw] OR 
“primary care”[all 
fields] OR “Primary 
Health Care”[mh] 
OR primary[tw] OR 
general pract*[tiab] 
OR gp[tiab] OR 
gps[tiab])
(family.af. OR physician$.
af. OR practice$.mp. OR 
primary care.af. OR exp 
Primary Health Care/ OR 
primary.mp. OR general 
pract$.af. OR gp.tw. OR 
gps.tw.)
(family OR 
physician* OR 
practice*:de,it,lnk,ab,ti 
OR ‘primary care’ 
OR ‘Primary Health 
Care’/exp OR 
primary:de,it,lnk,ab,ti 
OR (general NEXT/1 
pract*) OR gp:ab,ti OR 
gps:ab,ti)
(“family” OR 
physician* OR 
practice*:ti,ab,kw,pt 
OR “primary care” 
OR [mh “Primary 
Health Care”] OR 
“primary”:ti,ab,kw,pt 
OR general pract*:ab,ti 
OR “gp”:ab,ti OR 
“gps”:ab,ti)
Specific 
filter
(“Primary Health 
Care”[mh] OR 
“primary care”[all 
fields] OR “Physicians, 
Family”[mh] OR 
general pract*[all 
fields] OR “family”[ad] 
OR family pract*[all 
fields] OR family 
physician*[tw])
(exp Primary Health 
Care/ OR primary care.
af. OR exp Physicians, 
Family/ OR general 
pract$.af. OR family.in. 
OR family pract$.af. OR 
family physician$.mp.)
(‘Primary Health Care’/
exp OR ‘primary care’ 
OR (general NEXT/1 
pract*) OR family:ad 
OR (family NEXT/1 
pract*) OR (family 
NEXT/1 physician*): 
de,it,Ink,ab,ti)
([mh “Primary Health 
Care”] OR “primary 
care” OR [mh 
“Physicians, Family”] 
OR general pract* OR 
family pract* OR family 
physician*:ti,ab,kw,pt)
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of relevant articles could have been limited to 1,478. In this example, no relevant 
articles were missed. Comparing our sensitive filter to the ‘common practice’ 
of search strategies used when conducting, for example, Cochrane systematic 
reviews, all tested literature searches showed a lack of good sensitivity (see online 
supplementary materials). Thus, it can be assumed that relevant references were 
missed in these reviews which might have been found when applying our sensitive 
search filter.
The present filters do not use the Boolean operators AND or NOT, but combined 
single search terms and phrases in an OR relationship. However, in our methodology, 
‘phrases’ were already separately identified as combination of words in an AND 
matter that could potentially discriminate between FM/GP-relevant or not. For 
example ‘primary health care’ was identified in this way. These three words are 
combined in an AND matter, but the quotes also demand it to be in this specific 
order. Using an objective method, the developed filters did not always end up 
with phrases that one would expect, like ‘family physician’. However, our objective 
method suggested the single words ‘family’ and ‘physician’ to be more distinctive. 
Finally, using NOT would imply a substantial risk of excluding relevant articles and 
was therefore rejected.
There are two important arguments for manually improving the sensitive filter. In 
order for this methodology to create a completely objective filter without manual 
improvement, it was estimated that about 30,000 articles had to be scored. Manually 
evaluating the false negatives overcomes the use of a relatively small ‘reference 
standard’. Furthermore, in order for AntConc to find phrases, the 126 candidate filter 
terms were used. Words like ‘general’ and ‘practice’ did not meet the requirements 
for inclusion in the list of candidate filter terms, because the words themselves are 
not specific enough.
Translating the search strategies developed for PubMed to the syntax of the other 
databases (Ovid, Embase and Cochrane), carries a small risk of losing some 
sensitivity and specificity. Ideally, one would use the candidate filter terms and start 
constructing the search filter using the different interfaces. Unfortunately, the other 
databases did not have an ‘application programming interface’ (a set of routines, 
protocols, and tools for building software applications) that allowed communication 
with the software programs that were used for the development of these search 
filters. Instead the filters were directly translated into the syntax of the other 
databases, without optimization for that specific database.
We noticed that, in many cases, the title and abstract did not disclose sufficient 
information to determine whether (or not) an article was relevant for family 
medicine. In many cases the setting and/or relevance to family medicine could only 
be determined by scrutinizing the full text; this omission will influence both the 
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sensitivity and specificity of search filters. We emphasize that mentioning the setting 
in the title or abstract will help to find all relevant literature available for family 
medicine.
Conclusions
Two useful filters were created for a search on articles related to family medicine. 
The sensitive filter has a sensitivity of 96.8% with an adequate specificity of 74.9%. 
The specific filter has a specificity of 97.4% with an adequate sensitivity of 90.3%.
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Abstract
Purpose: To examine whether significant differences exist between the self-reported 
prevalence of atopic disorders in the open population compared with physician 
diagnosed prevalence of atopic disorders in general practice.
Method: Medline (OvidSP), PubMed Publisher, EMBASE, Google Scholar and the 
Cochrane Controlled Clinical Trials Register databases were systematically reviewed 
for articles providing data on the prevalence of atopic eczema, asthma and allergic 
rhinitis in a GP setting. Studies were only included when they had a cross-sectional 
or cohort design and included more than 100 children (aged 0-18 years) in a general 
practice setting. All ISAAC studies (i.e. the open population) that geographically 
matched a study selected from the first search, were also included. A quality 
assessment was conducted. The primary outcome measures were prevalence of 
atopic eczema, asthma and allergic rhinitis in children aged 0-18 years.
Results: The overall quality of the included studies was good. The annual and 
lifetime prevalences of the atopic disorders varied greatly in both general practice 
and the open population. On average, the prevalence of atopic disorders was higher 
in the open population.
Conclusions: There are significant differences between the self-reported prevalence 
of atopic disorders in the open population compared with physician diagnosed 
prevalence of atopic disorders in general practice. Data obtained in the open 
population cannot simply be extrapolated to the general practice setting. This 
should be taken into account when considering a research topic or requirements for 
policy development. GPs should be aware of the possible misclassification of allergic 
disorders in their practice.
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Background
The atopic syndrome is a predisposition toward an exaggerated IgE-mediated 
immune response in reaction to an allergen. A patient with atopy typically 
presents with one or more of the following disorders: atopic eczema (atopic 
dermatitis), asthma or allergic rhinitis. In this article atopic disorders refer to 
allergic manifestations for which atopy is a prerequisite. Epidemiological data on 
atopic disorders in children can be obtained from various sources, each having its 
own advantages and limitations. This review examines data obtained from general 
practice and survey data obtained in the open population. Depending on the research 
topic or the requirements for policy development, reliable data from either the open 
population or general practice (or both) might be needed.
The International Study of Asthma and Allergies in Childhood (ISAAC) has yielded 
many publications related to the open population (1). Albeit such survey data 
provide useful information on the prevalence of self-reported symptoms of allergic 
disorders and the derived diagnosis (2), they also imply a risk of overestimation 
of the prevalence of atopic disorders. For example, a runny nose can be caused by 
allergic rhinitis or by a viral upper airway infection; distinguishing between these 
two causes may be difficult for a patient when completing a questionnaire. Although 
the prevalence based on a clinician-diagnosed disease might solve this problem, it 
will imply a risk of underestimation of the burden of disease. For example, patients 
might have a ‘threshold’ with regard to visiting a physician or might consider their 
complaints not serious enough to visit one. Because, epidemiological data on atopic 
conditions in children in a general practice are scarce, we performed a systematic 
review.
We expected to find a significant difference between the self-reported prevalence 
in the open population (ISAAC studies) and the clinician-diagnosed prevalence of 
a disorder in general practice. More insight into these differences may help policy-
makers to optimize their policies and help general practitioners (GPs) become more 
aware about the possible underdiagnosis of allergic conditions in children.
Method
Search strategy
Two separate search strategies were used to collect data on the two sources (i.e. 
general practice and open population). First, a comprehensive search for relevant 
studies in general practice was performed in Medline (OvidSP), PubMed Publisher, 
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EMBASE, Google Scholar and the Cochrane Controlled Clinical Trials Register 
databases. The search strategy (Appendix 1) combined the following items: ‘Child’ 
AND ‘Epidemiology’ AND ‘Eczema’ AND ‘Asthma’ AND ‘Allergic rhinitis’. All articles 
in these five databases were considered and reviewed; no language restriction 
was imposed and the search was completed in January 2015. All references of the 
included studies were examined in order to be as comprehensive as possible.
A second search, performed in the ISAAC database, was also conducted in 
January 2015. ISAAC provides its users with a database that holds citations on 
all publications which are part of the ISAAC collaboration (1), representing the 
open population. However, because of known regional differences (3), we looked 
for studies that geographically matched (i.e. the same country) the studies finally 
selected in the first search strategy.
Study selection
Based on title and abstract, two reviewers (DP and EvA) independently selected 
articles retrieved in the first search strategy. All studies that provided data on the 
prevalence of asthma, allergic rhinitis and atopic eczema were considered, so long as 
they had a cross-sectional or cohort design and included more than 100 children (0-
18 years) in a general practice setting. If the abstract was not conclusive regarding 
these items, the article was included for full-text assessment. Any disagreement was 
resolved in a consensus meeting. Finally, the full-text of the selected abstracts was 
independently reviewed by two reviewers (DP and JW). Studies were not included 
if they did not meet the above-mentioned inclusion criteria or if selection bias was 
present (e.g. data were retrieved from a specific cohort within a general practice 
setting).
The second search strategy focused on the ISAAC database (1). Two reviewers (DP 
and JW) independently checked this database for relevant articles. All studies were 
included that geographically matched (i.e. the same country) a study selected from 
the first search.
Quality assessment
The quality of the included studies was independently assessed by two reviewers 
(DP and AB). Any disagreement was resolved in a consensus meeting. Assessment 
of the quality of the finally included studies conducted in general practice, was 
done by scoring the following items: population size, description of participants 
(age and percentage males), study year, data sources (paper or digital patient 
files, structured interviews, etc.), selection bias (e.g. not using all patient files 
but a selection thereof) and whether or not the methods used are reproducible. 
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With regard to reproducibility, the emphasis was on the definitions used for atopic 
eczema, asthma and allergic rhinitis. ISAAC used a standardized method. Ellwood et 
al. showed that the ISAAC methodology could be replicated to a high standard by the 
majority of participating centers (4). This indicates that the ISAAC protocol is robust 
and working in accordance with this protocol implies high quality. Any important 
violations of this protocol were obtained for the quality assessment of the finally 
included studies.
Data extraction
All data extraction was independently performed by two reviewers (DP and AB). Data 
were collected on the number of children studied, study period, study design, and 
country. The outcome measures are the prevalences of atopic eczema, asthma, and 
allergic rhinitis in children aged 0-18 years.
Results
Selection and description of the literature
The search strategy regarding general practice yielded 4,274 unique articles. Most 
of these (n=4,242) did not meet the inclusion criteria, mainly because only 2.2% of 
these studies (n=95) were conducted in a general practice setting. Of the 34 articles 
retrieved for full-text evaluation, 28 were excluded because they did not meet the 
inclusion criteria.
Finally, six studies were included in the present review for further analysis with 
regard to general practice; one study was performed in the Netherlands (5) and 
five in the UK (6-10). These six studies were published between 1974 and 2009. 
In table 1 the results of the quality assessment are presented. There was no 
evidence of selection bias. Four of the six studies had an adequate description of the 
methodology, whereas two studies failed to describe the exact definitions used for 
the disorders examined. Two studies presented data on annual prevalence and four 
U.K. studies presented data on lifetime prevalence.
The ISAAC database contained 604 articles. Of these, seven eligible studies (11-17) 
were selected that could be geographically matched to the selected general practice 
studies. Of these, six were performed in the UK (11-16) and one in the Netherlands 
(17). All four UK studies were conducted between 1995 and 2002 (11-14). The study 
on Dutch adolescents was conducted in 2003 (17). Table 2 presents the results of 
the quality assessment of these studies.
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Atopic eczema
The annual and lifetime prevalences of the atopic disorders varied widely between 
the studies and the populations involved. The annual prevalence (Table 3) of atopic 
eczema ranged from 1.8%-9.5% in general practice and from 11.4%-24.2% in the 
open population, whereas the lifetime prevalences (Table 4) ranged from 7.2%-
36.5% in general practice and from 16.5%-27.1% in the open population.
Asthma
In general practice, the annual prevalence (Table 3) of asthma ranged from 3.0%-
6.5%, whereas in the open population it was as high as 12.3%-34.2%. The lifetime 
prevalence (Table 4) of asthma in general practice was 4.2%-22.9% compared with 
19.1%-35.6% in the open population.
Allergic rhinitis
In general practice the annual prevalence (Table 3) of allergic rhinitis ranged from 
0.4%-4.1% compared with 15.1%-37.8% in the open population; the lifetime 
Table 3. Studies presenting annual prevalence
Study Source Country No.
included
Time
period
Age
group
(years)
Eczema Asthma Allergic
rhinitis
Wijga et al. 2011 General Practice NL 79,272 2001 0-9 5.5% 5.3% 0.4%
10-17 1.8% 3.0% 0.4%
Ven et al. 2006 Open Population NL 9,713 2003 12-14 13.5% 12.3% 28.3%
Simpson et al. 
2002
General Practice UK 252,538* 1999 0-4
5-9
10-14
9.5%†
4.5%†
3.4%†
4.3%†
6.5%†
6.2%†
0.7%†
2.3%†
4.1%†
Austin et al. 1999 Open Population UK 27,507 1995 12-14 16.4% 33.3% 18.2%
Jeffs 2000 Open Population UK 3,772 1995-1996 12-14 22.7% 34.2% 37.8%
Anderson et al. 
2004
Open Population UK 15,083 1995 12-14 16.2% 33.9% 18.4%
Anderson et al. 
2004
Open Population UK 15,755 2002 12-14 11.4% 27.5% 15.1%
Austin 2005 Open Population UK 4,298 2002 12-15 12.0% 27.8% 15.3%
Shamssain et al. 
2007
Open Population UK 3,000
3,000
1995-1996 6-7
13-14
15.8%
17.0%
18.1%
19.9%
20.6%
29.6%
Shamssain et al. 
2007
Open Population UK 1,843
2,195
2001-2002 6-7
13-14
24.2%
19.0%
25.4%
22.2%
15.8%
32.2%
* Total study population
† Prevalences calculated based on the assumption of male/female ratio = 1.04:1.00
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prevalence (Table 4) ranged from 1.0%-11.4% in general practice and from 18.3%-
47.7% in the open population.
Differences between the Netherlands and the UK
In both the Netherlands and the UK, similar differences exist between the 
prevalences of the atopic disorders in the open population and the general practice 
population (Fig. 1). In general practice the annual prevalence of atopic eczema and 
asthma are very similar. There is a large difference in the prevalence of diagnosed 
allergic rhinitis: in the UK this diagnosis is registered more frequently (0.4% vs 
2.4%). On the other hand, in the open population there is a higher prevalence of 
allergic rhinitis in the Netherlands (28.3%) compared to that of the UK (19.3%). 
Finally, a substantial difference exists between the two countries in the annual 
prevalence of asthma in the open population (12.3% vs 30.3%). Unfortunately, the 
data were not sufficient to allow comparisons at the regional level.
Table 4. U.K. studies, l i fetime prevalence
Study Source No. 
included
Time 
period
Age 
group 
(years)
Eczema Asthma Allergic 
rhinitis
Blair 1974 General Practice 1,907 1970-1973 0-10 7.2% 6.3% 4.8%
Mortimer 1993 General Practice 1,077 < 1993 3-11 20.2% 19.6% 7.6%
Simpson 2008 General Practice 126,348
366,063
2001 0-4
5-14
13.0%*
13.0%*
6.3%
15.7%
1.0%*
4.5%*
Simpson 2008 General Practice 125,020
361,784
2005 0-4
5-14
18.0%*
19.0%*
4.2%
15.7%
1.4%*
6.7%*
Punekar 2009 General Practice 24,112 2008 0-18 36.5% 22.9% 11.4%
Austin 1999 Open Population 27,507 1995 12-14 22.5% 20.9% 34.9%
Jeffs 2000 Open Population 3,772 1995-1996 12-14 25.6% 19.1% 47.7%
Priftanji 2001 Open Population 1,050 1998-2001 13-14 27.1% 20.2% 19.5%
Anderson 2004 Open Population 15,083 1995 12-14 21.1% 20.6% 34.8%
Anderson 2004 Open Population 15,755 2002 12-14 24.3% 25.9% 37.4%
Austin 2005 Open Population 4,298 2002 12-15 25.0% 24.5% 34.1%
Shamssain 2007 Open Population 3,000
3,000
1995-1996 6-7
13-14
18.3%
17.2%
29.3%
31.6%
22.6%
33.7%
Shamssain 2007 Open Population 1,843
2,195
2001-2002 6-7
13-14
21.8%
16.5%
35.6%
30.5%
18.3%
25.6%
* Estimation based on graph
Atopic disorders in general practice and the open population  69
Figure 1. Annual prevalence in % (weighted mean): General Practice 
(GP) vs Open Population (OP) in UK (United Kingdom) and NL (The 
Netherlands). (AR = allergic rhinitis)
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Discussion
On average, the prevalence of all three atopic disorders was substantially higher 
in the open population compared to general practice. For example, the annual 
prevalence of asthma ranged from 3.0%-6.5% in general practice compared to 
12.3%-34.2% in the open population. At least a twofold difference. In both the 
Netherlands and the UK similar differences were found between the open population 
and the general practice population. Allergic rhinitis was an exception and was 
diagnosed more frequently in the UK by GPs (0.4% vs 2.4%) whereas a higher 
prevalence was found in the Netherlands in the open population (28,3% vs 19.3%). 
Our results implicate that data obtained in the open population cannot simply be 
extrapolated to the general practice setting. This should be taken into account 
when considering a research topic or requirements for policy development. General 
practitioners should be aware of possible underdiagnosis of allergic disorders in 
their practice. However, overestimation can also occur due to misclassification of the 
disorder by a GP (18, 19).
No articles were excluded in this review based on language restrictions. All articles 
were independently examined by two reviewers, all references of the included 
studies were also checked and all data extraction was done by two independent 
researchers.
The search strategy for the open population focused exclusively on the ISAAC 
database, with three related limitations. First, although the ISAAC study has yielded 
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many international publications, restricting our review to official ISAAC studies 
carries the risk of missing other relevant studies using different, but also validated, 
methodologies. A recently published meta-analysis based on both official and non-
official ISAAC questionnaires showed annual prevalences for atopic eczema, asthma 
and allergic rhinitis of 7.9%, 12.0% and 12.7%, respectively (2). These prevalences 
are lower than the average annual prevalences that were observed in this review. It 
suggests the possibility of an higher estimation of the prevalence of atopic disorders 
when only ISAAC studies are included. However, using one methodology allowed us 
to make safer comparisons, especially because ISAAC’s methodology is known to 
be solid. The second limitation is the ISAAC database itself, which we discovered is 
not 100% comprehensive. The third limitation is the cross-sectional design of ISAAC 
and of the studies in general practice. Okkes et al. studied the differences between 
general practice registration projects and a health survey (20). They considered an 
observation period of one year to be a source of problems; using data collected over 
a longer period of time showed more accuracy (20).
Since the definition of atopic disorders has changed over time, one could argue 
that the conclusions reached in this article do not take these changes into 
consideration. However, this argument does not hold for ISAAC, since ISAAC uses 
the same definition to define atopic disorders since its beginning in 1991. For 
studies conducted in general practice, this might be different, but cannot explain the 
remarkable difference between the two settings.
Finally, we included only two countries. We focused on general practice and not 
every country has a GP in its healthcare system. The use of other sources of primary 
care data is subject to more selection bias and was therefore avoided.
Existing literature provides various explanations for the wide variability found 
between the two settings. First, the worldwide prevalence of the three disorders 
have changed over time (3). The studies in this review were conducted between 
1970 and 2008 and the reported prevalence might in part, reflect this worldwide 
time trend. Another explanation for changing prevalences over time are a change 
in definitions of atopic disorders over time. Van Wonderen et al. found 60 different 
operational definitions used in the literature on asthma (21). Applied in a single 
cohort, there was a substantial variation in estimated prevalences depending on 
the operational definition used. To deal with the remarkable amount of different 
definitions in atopic disorders worldwide, expert teams were given the task of finding 
consensus. For example, in 2006 a consensus regarding the diagnosis and treatment 
of atopic dermatitis was developed for this reason (22). Furthermore, for the lifetime 
prevalence, the age groups differed between the studies, resulting in different 
prevalences. Finally, not all GPs may be fully aware of what their patients actually 
experience regarding allergic symptoms (23) which might lead to misclassification 
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of allergic and therefor atopic diagnoses. Especially allergic rhinitis might be 
underestimated, since anti-allergic medication (antihistamines) is freely available 
over-the-counter thereby limiting the necessity for patients to visit their GP for 
related symptoms.
Data from both sources have both advantages and disadvantages as proven by 
existing literature. Data obtained from general practice databases can be considered 
specific, but not very sensitive. This lack of sensitivity might be the result of 
underdiagnosis or misclassification (19). This risk is particularly true for asthma. 
Spirometry under the age of six years is not considered reliable, resulting in a 
probability or clinical diagnosis. In other cases, spirometry is often underused or the 
technique is poor (19). Misclassification can also be the result of the differences of 
‘conceptual vocabulary’ between parents and clinicians (24). On the other hand, a 
prevalence based on self-administered questionnaires will result in more sensitive 
data, but will be less specific. Questionnaires are often used in population studies 
mainly for epidemiological purposes. Although ISAAC put considerable effort into 
the validation of their questionnaires (25-28), external influences cannot be totally 
ruled out. The accuracy of data obtained from a questionnaire always depends 
on various influences, including the accuracy and knowledge of the responders 
and the definitions used. ISAAC uses dichotomous (Yes/No) definitions. There is 
evidence that suggests that using continuous (graded) definitions would result in 
better statistical power and will provide relevant additional information (29). Also 
the terminology used in a questionnaire influences the results. Wheeze for example 
is the cornerstone of asthma diagnosis. However, conceptual understandings 
of ‘wheeze’ differs between physicians, researchers and parents of children 
with reported wheeze. This difference will influence reported prevalences in the 
open population (using questionnaires) and clinical practice (using a physician 
interpretation of wheeze) (24). Dotterud et al. (30) considered questionnaires on 
atopic conditions a useful epidemiological tool for obtaining rough estimates of the 
prevalence of atopic disorders. They conclude that atopic eczema was generally 
underestimated and allergic rhinitis overestimated when using questionnaires in the 
open population (30); the present study seems to confirm their findings.
Furthermore, different prediction scores have been developed based on data from 
the open population and from general practice. For example, the PIAMA Risk Score, 
based on the open population, helps to predict which child with suggestive symptoms 
for asthma could develop asthma at school age (31), whereas the CAPS prediction 
score was developed in a primary care setting (32). Both models differ substantially 
with regard to the factors they take into account; this difference might be explained 
by the different reported prevalences. When using prediction scores, it is important 
to be aware of the setting in which they were developed and validated.
72  Chapter 4
The prevalences of the three atopic disorders were on average higher in the open 
population compared with general practice. However, the degree of difference varied 
depending on the specific disorder. Policymakers should be aware that survey based 
data, obtained in the open population, cannot simply be extrapolated to the general 
practice setting.
GPs should consider to critically reevaluate the already diagnosed atopic disorders 
in a patient’s medical record to reduce the risk of misclassification. The present 
data may also serve to prompt GPs to be more aware of possibly underdiagnosed 
atopic conditions in children. For example, a relatively large percentage of children 
in the open population reported symptoms of allergic rhinitis; confirming the results 
of Dotterud et al. based on survey data (30). The low prevalences found in general 
practice do not reflect this. Knowing that poorly regulated allergic rhinitis can have 
an influence on asthma regulation (33), our data emphasizes the importance of 
actively asking about allergic rhinitis symptoms in children with asthma. GPs should 
consider different atopic disorders when a child is already diagnosed with one, since 
the atopic disorders are closely related (2).
Future research could benefit from longitudinal research with standardizing 
diagnostic definitions and by standardized reporting (e.g. reporting lifetime 
prevalence’s at standardized ages). Diagnosing an atopic disorder in general practice 
can be difficult, even if a clear definition is used. GPs often work with probability 
diagnosis and have to label their consultations with a standardized code like the 
International Classification of Primary Care (ICPC). ICPC is accepted by the WHO for 
labeling primary care encounters (34). Using ICPC codes in epidemiological studies 
implies a risk of dealing with misclassification, since some of the diagnosis should 
be regarded as ‘probability diagnosis’ and not as ‘true diagnosis’. When analyzing 
electronic medical records from a GP with the use of ICPC codes; duration of follow-
up, number of consultations and number of relevant prescriptions for that specific 
ICPC code should be taken into account. In this way, ICPC codes could be corrected, 
reducing the risk of misclassification. Regarding allergic rhinitis there is also another 
problem. GP registrations could show an underestimation of the number of children 
with allergic rhinitis due to the availability of ‘over the counter’ (OTC) drugs for this 
disorder. This may explain the higher observed prevalences for allergic rhinitis in the 
open population.
Conclusions
In conclusion, significant differences exist between the self-reported prevalence 
of atopic disorders in the open population compared with physician diagnosed 
prevalence of atopic disorders in general practice. Data obtained in the open 
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population cannot simply be extrapolated to general practice setting. GPs should 
be aware of possible misclassification of allergic disorders in their practice. Some 
suggestions how to limit this risk of misclassification in epidemiological research are 
given.
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Appendix 1
Search strategy:
For Embase
(asthma/exp OR wheezing/de OR (asthma* OR wheez* OR hyperresponsiv* OR 
hypersensit* OR (hyper NEXT/1 (responsiv* OR sensitiv*))):ab,ti) AND (eczema/
de OR ‘atopic dermatitis’/de OR (eczem* OR (atopic NEAR/3 dermatit*)):ab,ti) 
AND (rhinitis/exp OR conjunctivitis/exp OR (rhinitis* OR rhinoconjunctivit* OR 
conjunctivit* OR (Pollen NEAR/3 Allerg*) OR Pollinos* OR ((hay) NEXT/1 (fever*)) 
OR hayfever):ab,ti) AND (Epidemiology/exp OR ‘epidemiological data’/exp OR 
epidemiology:lnk OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* 
OR relat* OR correlat* OR (case NEAR/3 (control* OR comparison OR referent)) 
OR epidemiolog* OR cohort* OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* 
OR aetiol* OR (natural NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR 
course*):ab,ti) AND (child/exp OR newborn/exp OR adolescent/exp OR adolescence/
exp OR ‘child behavior’/de OR ‘child parent relation’/de OR (adolescen* OR infan* 
OR newborn* OR (new NEXT/1 born*) OR baby OR babies OR neonat* OR child* 
OR kid OR kids OR toddler* OR teen* OR boy* OR girl* OR minors OR underag* OR 
(under NEXT/1 ag*) OR juvenil* OR youth* OR kindergar* OR puber* OR pubescen* 
OR prepubescen* OR prepubert* OR pediatric* OR paediatric* OR school* OR 
preschool* OR highschool*):ab,ti)
For Medline via OvidSP
(exp asthma/ OR (asthma* OR wheez* OR hyperresponsiv* OR hypersensit* 
OR (hyper ADJ (responsiv* OR sensitiv*))).ab,ti.) AND (exp Dermatitis, Atopic/ 
OR exp Eczema/ OR Eczem*.ab,ti. OR (atopic ADJ3 dermatit*).ab,ti.) AND (exp 
Rhinitis/ OR exp Conjunctivitis/ OR (rhinit* OR rhinoconjunctivit* OR conjunctivit* 
OR (Pollen ADJ3 Allerg*) OR Pollinos* OR hayfever* OR hay fever*).ab,ti.) AND 
(exp Epidemiologic Studies/ OR exp Epidemiologic Factors/ OR epidemiology.xs. 
OR (prevalenc* OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR 
correlat* OR (case ADJ3 (control* OR comparison OR referent)) OR epidemiolog* OR 
cohort* OR risk* OR caus* OR odds ratio* OR etiol* OR aetiol* OR natural histor* 
OR predict* OR prognos* OR outcome* OR course*).ab,ti.) AND (exp child/ OR exp 
infant/ OR (infan* OR newborn* OR new born* OR baby OR babies OR neonat* OR 
perinat* OR postnat* OR child* OR kid? OR toddler* OR teen* OR boy? OR girl? OR 
minor? OR underag* OR (under ADJ2 ag?) OR juvenil* OR youth? OR kindergar* 
OR puber* OR pubescen* OR prepubescen* OR prepuberty* OR pediatric* OR 
78  Chapter 4
peadiatric* OR school* OR preschool* OR highschool* OR suckling*).ab,ti. OR 
((adoles*.ab,ti. OR adolescent/) NOT exp adult/))
For Cochrane
((asthma* OR wheez* OR hyperresponsiv* OR hypersensit* OR (hyper 
NEXT/1 (responsiv* OR sensitiv*))):ab,ti) AND ((eczem* OR (atopic NEAR/3 
dermatit*)):ab,ti) AND ((rhinitis* OR rhinoconjunctivit* OR conjunctivit* OR (Pollen 
NEAR/3 Allerg*) OR Pollinos* OR ((hay) NEXT/1 (fever*)) OR hayfever):ab,ti) AND 
((prevalenc* OR inciden* OR trend* OR associat* OR comorbid* OR relat* OR 
correlat* OR (case NEAR/3 (control* OR comparison OR referent)) OR epidemiolog* 
OR cohort* OR risk* OR caus* OR (odds NEXT/1 ratio*) OR etiol* OR aetiol* OR 
(natural NEXT/1 histor*) OR predict* OR prognos* OR outcome* OR course*):ab,ti) 
AND ((adolescen* OR infan* OR newborn* OR (new NEXT/1 born*) OR baby OR 
babies OR neonat* OR child* OR kid OR kids OR toddler* OR teen* OR boy* OR 
girl* OR minors OR underag* OR (under NEXT/1 ag*) OR juvenil* OR youth* OR 
kindergar* OR puber* OR pubescen* OR prepubescen* OR prepubert* OR pediatric* 
OR paediatric* OR school* OR preschool* OR highschool*):ab,ti)
For PubMed publisher
(asthma[mh] OR (asthma*[tiab] OR wheez*[tiab] OR hyperresponsiv*[tiab] 
OR hypersensit*[tiab] OR hyper responsiv*[tiab] OR hyper sensitiv*[tiab])) 
AND (Dermatitis, Atopic[mh] OR Eczema[mh] OR Eczem*[tiab] OR (atopic AND 
dermatit*[tiab])) AND (Rhinitis[mh] OR Conjunctivitis[mh] OR (rhinit*[tiab] OR 
rhinoconjunctivit*[tiab] OR conjunctivit*[tiab] OR (Pollen AND Allerg*[tiab]) OR 
Pollinos*[tiab] OR hayfever*[tiab] OR hay fever*[tiab])) AND (Epidemiologic 
Studies[mh] OR Epidemiologic Factors[mh] OR epidemiology[sh] OR 
(prevalenc*[tiab] OR inciden*[tiab] OR trend*[tiab] OR associat*[tiab] OR 
comorbid*[tiab] OR relat*[tiab] OR correlat*[tiab] OR (case AND (control*[tiab] 
OR comparison OR referent)) OR epidemiolog*[tiab] OR cohort*[tiab] OR 
risk*[tiab] OR caus*[tiab] OR odds ratio*[tiab] OR etiol*[tiab] OR aetiol*[tiab] OR 
natural histor*[tiab] OR predict*[tiab] OR prognos*[tiab] OR outcome*[tiab] OR 
course*[tiab])) AND (child[mh] OR infant[mh] OR (infan*[tiab] OR newborn*[tiab] 
OR new born*[tiab] OR baby OR babies OR neonat*[tiab] OR perinat*[tiab] OR 
postnat*[tiab] OR child*[tiab] OR kid* OR toddler*[tiab] OR teen*[tiab] OR boy* 
OR girl* OR minor* OR underag*[tiab] OR under ag* OR juvenil*[tiab] OR youth* 
OR kindergar*[tiab] OR puber*[tiab] OR pubescen*[tiab] OR prepubescen*[tiab] 
OR prepuberty*[tiab] OR pediatric*[tiab] OR peadiatric*[tiab] OR school*[tiab] OR 
preschool*[tiab] OR highschool*[tiab] OR suckling*[tiab]) OR ((adoles*[tiab] OR 
adolescent[mh]) NOT adult[mh])) AND publisher[sb]
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For Google scholar
asthma eczema rhinitis prevalence | incidence | epidemiology |cohort | risk | 
etiology | prognosis | outcome adolescents | infants | children | newborns “family | 
general|primary physician | practice | doctor | care”
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Abstract
Purpose: Electronic health records (EHRs) stored in primary care databases might 
be a valuable source to study the epidemiology of atopic disorders and their impact 
on healthcare systems and costs. However, the prevalence of atopic disorders in such 
databases varies considerably and needs to be addressed.
Method: For this study, all children aged 0-18 years listed in a representative 
Primary Care Database in the period 2002-2014, with sufficient data quality, 
were selected. The effects of four different strategies on the prevalences of atopic 
disorders were examined: 1) the first strategy examined the diagnosis as recorded 
in the EHRs, whereas the 2) second used additional requirements (i.e. the patient 
had at least two relevant consultations and at least two relevant prescriptions). 
Strategies 3) and 4) assumed the atopic disorders to be chronic based on strategy 1 
and 2 respectively.
Results: When interested in cases with a higher probability of a clinically relevant 
disorder, strategy 2 yields a realistic estimation of the prevalence of atopic disorders 
derived from primary care data. Using this strategy, of the 478,076 included 
children, 28,946 (6.1%) had atopic eczema, 29,182 (6.1%) had asthma, and 
28,064 (5.9%) had allergic rhinitis; only 1,251 (0.3%) children had all three atopic 
disorders.
Conclusions: Prevalence rates are highly dependent on the clinical atopic definitions 
used. The strategy using cases with a higher probability of clinically relevant cases, 
yields realistic prevalences to establish the impact of atopic disorders on health-care 
systems. However, studies are needed to solve the problem of identifying atopic 
disorders that are missed or misclassified.
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Background
The rising prevalence of atopic disorders in children are an important global 
health problem (1, 2). Atopy is a (genetic) predisposition toward developing 
allergic hypersensitivity. The clinical manifestation of atopy is allergy. However, 
not all allergies are atopic. In this study the word ‘atopic’ refers to this genetically 
mediated predisposition, resulting in the clinical diagnosis by a GP of atopic 
eczema, asthma and allergic rhinitis. In many countries, primary care professionals, 
e.g., family doctors/general practitioners (GPs), diagnose and treat these atopic 
children. In the Netherlands, GPs, are in the frontline of the health care system, 
are freely accessible, and use uniform coding systems for recording diagnosis and 
prescriptions. In principle, all non-institutionalized residents in the Netherlands 
are registered in a general practice, even if they do not visit the GP. Therefore, 
the electronic health records (EHR) stored in primary care databases contain valid 
information about the epidemiological denominator, making it a potentially important 
source of epidemiological data.
A meta-analysis based on questionnaires in the ‘open population’, including children 
of all ages (0-18 years), showed average one-year worldwide prevalences for atopic 
eczema, asthma and rhinoconjunctivitis of 7.9%, 12.0% and 12.7%, respectively 
(3). However, the accuracy of data obtained from a questionnaire depends on various 
items, including the accuracy and knowledge of the responders, and the definitions 
used by the researcher (4). When comparing ‘open population’ data with data 
obtained from the EHRs of general practices, lower annual prevalences for atopic 
eczema, asthma and rhinoconjunctivitis were found, ranging (on average) from 1.8-
9.5%, 3.0-6.5% and 0.4-4.1%, respectively (5). Since these diagnoses are based 
on the assessment of a physician, these data could potentially form a more specific 
epidemiological source. Unfortunately, the annual prevalences of atopic disorders in 
general practice databases vary considerably (5); moreover, since these differences 
cannot be fully explained by country or year of study, this variation needs further 
consideration. Part of this variation might be explained by the fact that GPs often 
work with a ‘probability diagnosis’ which inevitably creates a risk of misclassification, 
which could result in either over- or underestimation. Other possible explanations 
could be a variation in clinical knowledge and skills of the GP. Furthermore, there 
might also be some coding difficulties, when coding diseases in electronic health 
records.
Some studies using primary care data have presented life-time cumulative 
prevalences (6-9); the prevalences found for atopic eczema, asthma and 
rhinoconjunctivitis ranged (on average) from 7.2-36.5%, 4.2-22.9% and from 1.0-
11.4%, respectively. However, the question arises as to what extent these life-time 
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cumulative prevalences provide relevant information compared with annual point 
prevalences, knowing that these disorders are not always chronic.
To establish the impact of atopic disorders on healthcare systems and their related 
costs, a more accurate estimation is required of the prevalence of atopic disorders 
derived from general practice databases. This study investigates the risk of 
misclassification which could either result in overestimation or underestimation of 
atopic disorders. The results for annual point prevalence versus life-time cumulative 
prevalence were compared using four different strategies using an extensive and 
representative primary care database.
Method
Study population
The Netherlands Institute for Health Services Research-Primary Care Database 
(NIVEL-PCD) is based on routinely recorded data in EHRs of all listed patients in 
the participating practices. In 2014, about 500 general practices participated, 
including data of about 1,700,000 patients (www.nivel.nl/en/dossier/nivel-primary-
care-database). EHR data include a variety of information regarding type of 
consultation, morbidity, and prescriptions. Data were available from 2002–2014 and 
are representative for the Dutch population (10). Primary care physicians recorded 
morbidity using the International Classification of Primary Care (ICPC-1). The ICPC 
is a classification method for primary care encounters and is accepted by the WHO 
(11). Dutch GPs cluster relevant consultations, prescriptions and referrals in ICPC 
classified episodes of care.
For the present study, we only used morbidity data from the EHRs of general 
practices with sufficient data quality, fulfilling the following criteria: at least 500 
listed patients (standard practice: 2,350 patients), complete morbidity registration 
(defined as ≥ 46 weeks/year), and sufficient ICPC coding of diagnostic information 
(defined as ≥ 70% of the recorded disease episodes labeled with an ICPC code).
Selection of atopic children
From the general practices in NIVEL-PCD, all listed children (aged 0-18 years) with 
sufficient data (in the period 2002-2014) were selected. For each child, a minimum 
follow-up of 3 years was required to reduce the risk of registration bias. According 
to NIVEL, Dutch GPs see about 77% of their patients at least once a year (12); 
therefore, a 3-year follow-up allows the GP sufficient time to diagnose a child with 
atopic disorders. Follow-up ends when a child would change to a GP that is not 
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working in a NIVEL-PCD clinic, or when the child would have died. For these children 
the following descriptive data were routinely collected: period in which the individual 
child was registered in the clinic, unique code of the GP practice, sex, and year and 
quarter of birth. For all these children ICPC-coded episodes regarding atopic eczema 
(S87), asthma (R96) and allergic rhinitis (R97) were extracted when applicable with 
their starting and closing dates.
Episode (re)construction
At each new encounter in general practice, a Dutch GP starts a new episode of care. 
If the patient returns to the GP for the same disorder, or when the patient orders 
(repeat) medication relevant to that disorder, it should be recorded as a follow-up 
contact within that specific episode of care.
In the present study, four different strategies were examined with the aim to obtain 
a better understanding of prevalence estimates based on primary care data: two 
strategies are related to the beginning of an episode of care and the other two are 
related to the ending of an episode of care. Table 1 presents a summary of the 
strategies.
Concerning the start of an episode, either the episodes of care were used as 
recorded in the database and one accepts the risk of overestimation due to working 
with ‘probability diagnoses’, or these episodes of care were corrected by applying 
selection criteria, focusing on cases with higher probability of a clinical relevant 
disorder (see below). With respect to the ending of an episode of care, two identical 
strategies were applied. Either the episodes of care were used as recorded or these 
episodes of care were corrected by extending the closing date, assuming that atopic 
disorders were chronic.
Table 1. Summary of the four strategies examined.
Strategy 1 Presents the prevalence based on the recorded episodes of care.
Strategy 2 Presents the prevalence based on corrected episodes of care (by applying selection criteria: at 
least two relevant consultations and at least two relevant prescriptions)
Strategy 3 Presents the prevalence based on the recorded episodes of care, but the disorders are considered 
to be chronic.
Strategy 4 Presents the prevalence based on corrected episodes of care (by applying selection criteria from 
strategy 2), but the disorders are considered to be chronic.
Start of an episode of care
Strategy 1 uses the episode of care as recorded in the EHRs of the GP and accepts a 
risk of overestimation. In the second strategy (strategy 2), correcting for a possible 
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overestimation, different selection criteria were taken into consideration based on 
our previous review (5). Using these criteria, ICPC codes and their related episodes 
of care can be corrected, reducing the risk of misclassification and selecting cases 
with a higher probability of a clinical relevant disorder. For example, if a GP suspects 
that a child has asthma and labels the encounter accordingly with R96, this can later 
be corrected as not having asthma if this child never visits the GP again for this 
problem or never receives the appropriate medication. In practice this implies the 
following requirements: at least two episode-related contacts (either consultations, 
home visits, telephone calls, or prescriptions) and a minimum of two relevant 
prescriptions had to be prescribed. The Anatomical Therapeutic Chemical (ATC) 
Classification System was used to identify relevant prescriptions. For atopic eczema 
the ATC code D07 (dermatological corticosteroids) was used, for asthma the ATC 
code R03 (drugs for obstructive airway diseases) was used, and for allergic rhinitis 
the ATC codes R01AC (nasal preparation of antiallergic agents, excl. corticosteroids), 
R01AD (nasal preparation of corticosteroids) and R06 (antihistamines for systemic 
use) were used. These medication proxies have been tested by Mulder et al. (13). 
Since some EHRs do not routinely link relevant prescriptions in the correct episodes, 
all recorded prescriptions in the EHRs were studied. When a patient could not meet 
the criteria of having at least two contacts and two relevant prescriptions, the 
patient is considered to be a child in the ‘population at risk’.
Closure of an episode of care
In the present study, two strategies (3 and 4) considered the atopic disorders to 
be chronic for research purposes. Since data is available for all patients in our 
database regarding the first date on which a diagnosis was made (each child could 
be incident only once in its life), it is possible to determine the number of children 
diagnosed at each year and for each age. When adding these annual numbers for 
the consecutive years of interest, one in fact calculates a cumulative incidence. Since 
no data is missing regarding the first date of the disorder, this cumulative incidence 
will approximate a cumulative life-time prevalence. Strategy 3 shows the cumulative 
incidences based on strategy 1, and in strategy 4 it is based on strategy 2.
Atopic triad
Finally, ‘atopic triad’ episodes were created for research purposes, based on a 
suggestion reported in a meta-analysis (3). Such an episode was only created when 
a child was diagnosed with all three atopic disorders. The first date when a child 
was diagnosed with at least one of the disorder, is considered the starting date of 
the ‘atopic triad’ episode. The closing date of the episode is equal to the last contact 
date recorded for one of the atopic disorders.
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Statistical analyses
Annual point prevalence rates were calculated as percentages on the first of 
January for each age (0-18 years). The denominators for the calculations were 
also determined on this date. Cumulative life-time prevalences, based on the 
assumption that the disorder is chronic, are based on the cumulative incidences 
(strategy 3 and 4). This cumulative incidence equals a life time prevalence, since 
the complete medical history of a patient is available in the EHRs. To calculate the 
interrelationships between the atopic disorders, for every child’s EHR with sufficient 
data quality and at least 3 years of follow-up, it was determined whether he/she had 
one or more atopic disorders or not, in the period from 2002-2014. All calculations 
were conducted in Stata 13 and Excel 2010.
Ethical approval
Dutch law allows the use of anonymous EHR data for research purposes under 
certain conditions. According to this legislation, it is not necessary to obtain informed 
consent from patients or approval from a medical ethics committee for this type 
of observational study that contains no directly identifiable data (Dutch Civil Law, 
Article 7: 458). Therefore, no waiver of ethical approval was obtained from an 
Institutional Review Board (IRB) or ethics committee. The authors did not have 
access to identifying information at any moment during the analysis of the data.
Results
Patient selection
A total of 660,512 eligible children (aged 0-18 years) were derived from the NIVEL-
PCD (period 2002-2014). Of these, 24,477 (3.7%) children did not pass the data 
quality checks (Appendix 1) and 157,959 (23.9%) children were excluded because 
they had less than 3 years of follow-up. The final study group included 478,076 
children, of whom 51.1% were male. Mean age of the children when entering the 
NIVEL-PCD was 7.2 (SD 6.0) years: mean follow-up time was 6.6 (SD 4.7) years.
Prevalence of atopic eczema (Fig. 1)
According to strategy 1 and 2, the point prevalence rises to a maximum at age 2 
years of 9.0% and 6.9%, respectively. At age 18 years this prevalence drops to 
3.0% and 2.5%, respectively. However, if the disorder is considered to be chronic for 
research purposes, based on strategy 3 and 4 the lifetime cumulative incidences at 
age 18 years ranges from 24.0-43.8%.
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Figure 1. Prevalence by age for atopic eczema
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Prevalence of asthma (Fig. 2)
The point prevalence of asthma shows a steep rise in the first two years of life with 
a maximum prevalence at age 7 years according to strategy 1 (5.5%) and strategy 
2 (4.9%), and drops slightly at age 18 years to 4.3% and 3.6%, respectively. The 
(for research purposes) calculated lifetime cumulative incidences at age 18 year is 
19.3-26.8%.
Figure 2. Prevalence by age for atopic asthma
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Prevalence of allergic rhinitis (Fig. 3)
In contrast to atopic eczema and asthma, allergic rhinitis shows a relatively 
consistent rise in prevalence over the years. For strategy 1 and 2 the maximum 
prevalence at age 18 years is 6.2% and 5.7%, respectively. Assuming allergic rhinitis 
to be a chronic disorder for research purposes, the lifetime cumulative incidence also 
reaches its maximum at age 18 years, but is substantially higher, i.e. 16.0-22.5%.
Figure 3. Prevalence by age for al lergic rhinitis
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Prevalence of atopic triad (Fig. 4)
The atopic triad is estimated for research purposes. Depending on the strategy used, 
the maximum prevalence for strategy 1 (0.8%) is reached at age 6 years and that 
for strategy 2 (0.4%) at 7 years. Both scenarios show a decrease resulting in a point 
prevalence at age 18 years of 0.5% and 0.3%, respectively. For all four strategies, a 
maximum prevalence of 1.4% is observed.
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Figure 4. Prevalence by age for atopic triad
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Interrelationship between the atopic disorders (Fig. 5)
Interrelationships between atopic disorders are well known. Of the 478,076 children, 
based on strategy 2 28,946 children (6.1%) had atopic eczema, 29,182 (6.1%) had 
asthma, and 28,064 (5.9%) had allergic rhinitis. Only 1,251 (0.26%) children had all 
three atopic disorders. This is a 12-fold higher prevalence than could be expected by 
chance (0.022%) based on the three prevalences of the individual atopic disorders. 
Figure 5. Venn diagram of the overall prevalence (total population: 
478,076 children)
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In total 21,862 children had atopic eczema only, 20,382 children had asthma only, 
and 19,835 children had allergic rhinitis only and no other atopic comorbidity. Of all 
children with asthma, 19.2% also had allergic rhinitis.
Discussion
To retrieve more relevant data from primary care databases, four different strategies 
were explored. Based on the results of this study, strategy 2, which at least selects 
cases with potentially more clinically relevant disorders and does not assume that a 
child will have the disorder for life, seems preferable when interested in the current 
burden of atopic disorders. Of the 478,076 children finally included, after applying 
strategy 2, 6.1% had atopic eczema, 6.1% had asthma and 5.9% had allergic 
rhinitis; these annual point prevalences are in accordance with those found in a 
recent systematic review (5). Only 0.26% children had all three atopic disorders; 
this is a 12-fold higher prevalence than could be expected by chance based on the 
three individual prevalences of the atopic disorders (0.022%). This phenomenon was 
recently described in a meta-analysis (3) and supports the hypothesis that there 
could be a fourth distinct group of atopic children that have all three disorders, i.e. 
they may have their own unique characteristics.
Showing the data simply as recorded in the GP’s database (strategy 1) will result in 
a risk of overestimation. A possible solution was offered in the literature by applying 
two selection criteria, i.e. at least two relevant consultations and at least two 
relevant prescriptions. When applying these criteria, the annual point prevalences 
only dropped slightly (as expected), but potentially show more clinically relevant 
cases. The results now more closely approach the annual point prevalences reported 
in the literature (5). However, ideally a gold standard is needed to identify atopic 
children. Such a gold standard could probably be the evidence of sensitisation by 
specific IgE (14). Checking specific IgE is now a requirement of assessment of the 
patient with asthma. When studying the observed differences between annual point 
prevalence and cumulative life-time prevalence, a greater understanding of the 
natural course of these atopic disorders is required. In Germany, Illy et al. studied 
the natural course of atopic dermatitis in a cohort of 1,314 children from the general 
population, until age 7 years (15). The prevalence increased to 21.5% at 2 years 
of age, but 43.2% were in complete remission by age 3 years. Regarding asthma, 
Jenkins et al. screened 7-year-olds for this condition (16). The study was repeated 
25 years later in a random sample (n=750); a quarter of those who had asthma as 
a child, reported asthma in adulthood. According to Sears, about half to two-thirds 
of the children with asthma recover (17). An explanation for this observed recovery 
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could be that viral infections are the main cause of wheeze before the age of six 
rather than allergic asthma. This is supported by data from a different Dutch primary 
care study, which showed that for those children diagnosed with asthma between 
the age of 0-4 years, ≥ 60% were no longer known as such by the GP after two 
years, and after 10 years 80% no longer carried this diagnosis (18). When the 
same children were screened for asthma at a later age (10-23 years), 45% still had 
asthma (19). Finally, regarding allergic rhinitis, a prospective study on the course 
of hay fever in 738 individuals (with an average follow-up of 23 years) showed 
that in a majority of the adult patients the symptoms of hay fever reduce over 
the years (20). Another prospective study (n=257, mean follow-up to 8 years) on 
various forms of allergic rhinitis (confirmed by the presence of specific IgE to pollen, 
pets or dust mites), looked at the percentage of patients with complete remission 
of symptoms (21). This study found complete remission of symptoms in 12% of 
patients with pollen allergy, in 19% of patients with an allergy to pets, and in 38% of 
patients with house dust allergy. The third and fourth strategy assumed that a child 
would have the atopic disorder for life, resulting in cumulative life-time prevalences 
that are substantially higher than those reported in the literature (5). Based on all 
the available evidence, it seems incorrect to conclude that atopic disorders are by 
definition chronic and, therefore, we consider strategies 3 and 4 to be less reliable 
and are not recommended. Even though the underlying assumptions made for 
strategies 3 and 4 are not realistic, the differences found between strategy 2 and 4 
nevertheless provide an estimation of the number of children that show complete 
reduction of symptoms. This results in remission rates of 84%, 68% and 43% at age 
10 years and 90%, 81% and 64% at age 18 years for atopic eczema, asthma and 
allergic rhinitis, respectively.
For the present investigation we used an extensive and representative primary 
care database; the number of included cases gives this study substantial power. 
The potential for using primary care databases of routinely collected clinical data 
for epidemiology and health policy is therefore enormous. However, to use this 
potential, sound methodologies are needed to turn the huge amount of raw data into 
meaningful information. An easy to apply strategy is presented in this study to select 
potentially more clinical relevant cases.
Unfortunately, there is an important limitation. The present study is based on the 
assumption that the relevant ICPC codes are not missed. For example, a child that 
has ICPC code R03 (wheezing) and regularly uses inhalation corticosteroids probably 
has asthma. However, when the child is not coded correctly as having R96 (asthma), 
or is not coded at all, it will not be possible to identify this child as having asthma. 
To include this child as an asthmatic patient, a new or adjusted episode R96 needs to 
be created by the researcher. Although this is a complex problem, there are different 
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ways to deal with it. The most sensitive method is to study the complete EMR of 
the individual patient; unfortunately, this is very time consuming and raises privacy 
issues. Another option is to use computer software that analyses free text; however, 
the accuracy of this method is determined by the quality of the script used. A faster 
and probably more consistent way of identifying a child, is to use ‘templates’ that are 
based on a combination of routinely and standardized coded data from EHRs such as 
standardized measurements, ICPC-coded comorbidity, and ATC-coded prescriptions. 
According to a recent study (13) based on general practice data, children diagnosed 
with asthma can be reliably identified with a range of medication proxies (sensitivity 
54% and PPV 84%). However, the use of prescription data for the identification of 
children diagnosed with atopic eczema and allergic rhinitis is more problematic; one 
reason for this is that (some) reliever medication is freely available over the counter. 
Comorbidity data could also be used as a source to identify misclassified children. 
However, although many studies have shown a relationship between different 
comorbidities and atopic disorders, to our knowledge no study has used comorbidity 
to identify atopic disorders.
Food allergies are also closely associated with atopic disorders. Unfortunately, in this 
study it was not possible to reliably analyze food allergies, since the ICPC-1 coding 
system does not have specific codes for food allergies.
The results of this study emphasize the importance of better coding. Further 
research is needed to create proxies based on standardized coded variables to 
identify atopic disorders in order to address the risk of underestimation. Some 
attempts have been made, such as AsthmaCritic (a decision-support system for 
asthma and chronic obstructive pulmonary disease) (22), which aims to generate 
patient-specific feedback based on routinely recorded data in EMRs. In order to 
address the risk of overestimation, future clinical guidelines should also include 
criteria that help physicians to identify atopic diagnoses which are no longer clinically 
relevant.
In the future, research using extensive databases will become more popular due to 
their increased availability. Epidemiological studies on atopic disorders are reaching 
the limit of what can be achieved through conventional hypothesis-driven research 
(23). This new era of ‘big data’ allows smarter and more powerful statistical analysis, 
especially when analyzing metadata. Future collaborative analysis could also 
facilitate interdisciplinary dialogue between clinicians and scientists.
Conclusions
In conclusion, research using extensive databases will become more popular due to 
their increased availability; we are now in the era of ‘big data’. Future collaborative 
94  Chapter 5
(meta)analysis on the valid use of routinely recorded clinical data from big databases 
is needed in order to be able to develop valid search strategies to identify atopic 
children. This study contributes to a better understanding of the use of primary care 
data. Based on the results of this study, strategy 2, which at least corrects for the 
risk of overestimation due to misclassification and does not assume that a child will 
have the disorder for life, seems preferable and can easily be applied. The limitations 
of primary care data that result in underestimation are more challenging, since some 
patients are also able to self-manage their disorder. Studies are required to create 
proxies based on routinely recorded and standardized clinical coded data that can 
help identify atopic disorders that are missed or misclassified.
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Appendix 1.
Flowchart showing inclusion of the study population
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 practice 20,726 
- Episodes starting before birth: 483 
Did not have 3-year follow-up: 157,959 
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Abstract
Purpose: This study aimed to investigate both atopic and non-atopic comorbid 
symptoms and diseases in children with physician-diagnosed atopic disorders (atopic 
eczema, asthma and allergic rhinitis).
Method: All children aged 0-18 years listed in a nationwide primary care database 
(NIVEL-PCD) with routinely collected health care data in 2014 were selected. Atopic 
children were matched on age and gender with non-atopic controls within the same 
general practice. A total of 404 ICPC codes were examined. Logistic regression 
analyses were performed to examine the associations between the presence of 
atopic disorders and (non-)atopic symptoms and diseases by calculating odds ratios 
(OR).
Results: Having one of the atopic disorder significantly increased the risk of having 
other atopic-related symptoms, even if the child was not registered as having the 
related atopic disorder. Regarding non-atopic comorbidity, children with atopic 
eczema (n=15,530) were at significantly increased risk for (infectious) skin diseases 
(OR: 1.2-3.4). Airway symptoms or (infectious) diseases (OR: 2.1-10.3) were 
observed significantly more frequently in children with asthma (n=7,887). Children 
with allergic rhinitis (n=6,835) had a significantly distinctive risk of ear-nose-throat 
related symptoms and diseases (OR: 1.5-3.9). Neither age nor gender explained 
these increased risks.
Conclusions: General practitioners are not always fully aware of relevant atopic 
and non-atopic comorbidity. In children known to have at least one atopic disorder, 
specific attention is required to avoid possible insufficient treatment and unnecessary 
loss of quality of life.
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Background
Atopic disorders represent an important health problem in general practice. Acute 
upper airway infections, middle ear infections, warts, asthma, and atopic eczema 
represent the five most prevalent pediatric diseases diagnosed in general practice 
(1); allergic rhinitis is on the 12th place in this list. However, limited data are 
available on the co-morbidities of atopic children in primary care. In the present 
study we refer to atopy as one or more of the following established diagnosis: atopic 
eczema, asthma and/or allergic rhinitis.
Associations have been shown between atopic disorders and other diseases in 
children, but in different clinical settings (e.g. birth cohorts, hospitals, or pediatric 
clinics). Demonstrated interrelations exist with (among others) diabetes (2-4), 
ADHD (5-7), autism (8-10), and obesity (11-13). According to other studies, the 
presence of some comorbidities may even influence the course of atopic disorders. 
For example, acute upper airway infections, especially in early childhood, are related 
to atopic disorders later in life (14, 15). Acute viral ‘non-respiratory syncytial virus’ 
bronchiolitis in infants aged <6 months is linked with an increased risk of developing 
asthma (16). The developing immune system of a child might be affected by 
frequent or severe infections of the middle ear, resulting in increased risk for asthma 
and atopic eczema (17). On the other hand, otitis media with effusion is associated 
with allergic rhinitis (18-20). The quality of life of an atopic child can be significantly 
improved by providing sufficient treatment.
To our knowledge no study has investigated the complete range of potential 
comorbidities in atopic children in a general practice setting. A relevant question 
could be: Are atopic children at increased risk for non-atopic symptoms or diseases? 
Awareness by GPs of these risks may reduce the probability that relevant comorbidity 
is not diagnosed. To study possible associations between atopic disorders and 404 
different symptoms and diseases, an extensive and representative nationwide general 
practice database is explored using a cross-sectional design. The design of this study 
allows new hypotheses to be generated, providing valuable input for future research.
Method
Study population
All non-institutionalized residents in the Netherlands are registered in a general 
practice, even if they do not visit the GP on a regular basis. The Netherlands 
Institute for Health Services Research-Primary Care Database (NIVEL-PCD) is based 
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on routinely recorded data in electronic health records (EHRs) of all listed patients 
in the participating practices. In 2014, about 500 general practices participated, 
including data of about 1,700,000 patients (www.nivel.nl/en/dossier/nivel-primary-
care-database), which is over 10% of the total Dutch population. EHR data include 
a variety of information regarding type of consultation, morbidity, and prescriptions. 
Data available for 2014 are representative for the Dutch population (21). Primary 
care physicians (gatekeepers for the Dutch healthcare system) recorded morbidity 
using the International Classification of Primary Care (ICPC), a classification method 
for primary care that is accepted by the WHO (22). Dutch GPs cluster relevant 
consultations, prescriptions and referrals, in ICPC classified ‘episodes of care’. An 
episode of care is a health problem or disease from its first presentation to the GP to 
the last presentation for the same problem. Atopic disorders are labeled with ICPC 
codes: S87 (atopic eczema), R96 (asthma) and R97 (allergic rhinitis). ICPC-codes 
specific for food-allergies are not available.
For the present study, only morbidity data from EHRs of general practices with 
sufficient data quality were used that fulfilled the following criteria: i) at least 500 
listed patients (standard practice: 2,350 patients), ii) complete morbidity registration 
(defined as ≥ 46 weeks/year), and iii) sufficient ICPC coding of diagnostic 
information (defined as ≥ 70% of the recorded disease episodes labeled with an 
ICPC code; average ICPC coding in a Dutch general practice is >95%). The following 
descriptive data were routinely collected: period in which the individual child was 
registered in the general practice, the unique code of the GP practice, the child’s 
gender, and year and quarter of birth.
Atopic children
For each child (0-18 years), a minimum follow-up of 3 years was required (e.g. 
data had to be available for 2012-2014) for the present study to reduce the risk 
of registration bias. For this reason, only data for children aged ≥ 2 years are 
presented here. In the Netherlands, GPs see about 72% of their patient population 
at least once a year (23). We considered a 3-year follow-up period to be sufficient 
time for a GP to diagnose a child with (atopic) disorders. Furthermore, in order not 
to miss any relevant atopic diagnosis, when available, the EHRs from 2002-2014 
were examined. Since GPs inevitably work with probability diagnoses, there is a risk 
of misclassification. To select cases with a higher probability of a clinically relevant 
disorder, ICPC codes and their related episodes of care can be corrected. In practice, 
an atopic episode of care was maintained if (between 2002-2014) the child had 
at least contacted the GP twice in that episode of care and had received at least 
two relevant prescriptions. If the child did not meet these criteria, the child was 
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considered not to have that atopic disorder (24) and was excluded from the study 
(this child could not be used as a control patient, to make sure that controls did not 
have any atopic disorder). If a child was diagnosed with an atopic disorder for the 
first time during 2014, the child was considered to have the atopic disorder that 
whole year. In the present study, the atopic diagnosis was based on the physician’s 
assessment and was considered to be a chronic problem.
Atopic triad
A recent meta-analysis supported the hypothesis that there might be a fourth 
distinct group of children with all three atopic disorders, in contrast to the traditional 
classification of children with asthma or allergic rhinitis or atopic eczema (25). To 
learn more about this potentially unique group of children, ‘atopic triad’ episodes 
were developed for research purposes. These episodes were only created when a 
child was diagnosed with all three atopic disorders, based on available data from 
EHRs in the period 2002-2014.
Symptoms and diseases studied
After establishing which child had an atopic disorder (see above), a child was 
considered prevalent for a specific symptom or disease if the child had at least one 
active episode of care for that symptom or disorder between January and December 
of 2014. All ICPC codes that describe a symptom or a disease were examined, with 
the exception of trauma-related ICPC codes, ICPC codes not relevant for children (e.g. 
presbyacusis), pregnancy, childbearing, family planning, sexual transmitted diseases 
and social problems, leaving 404 different ICPC codes. Furthermore, since different 
classifications are used for eczema, there is a risk of misclassification. The ICPC 
system distinguishes the codes S86 (seborrheic dermatitis), S87 (atopic eczema), 
S88 (contact dermatitis / eczema another) and S89 (diaper rash). Since clinical 
differentiation can be very difficult, especially between S87 and S88, S88 was excluded 
from our analyses, to get more reliable results for ‘true’ atopic eczema (S87).
Design
A nested case-control study design was used. For each atopic child, one matched 
control patient was selected (not diagnosed with an atopic disorder) within the same 
general practice, based on age and gender in 2014. Controls were only matched 
if a 100% match on age, gender and general practice with an atopic child was 
determined. Odds ratios (ORs) were calculated for children that solely had atopic 
eczema, asthma, or allergic rhinitis and therefore no other atopic comorbidity. 
Appendix 1 presents a list of all the ICPC codes that were examined. A 1:1 ratio 
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was chosen to be able to include as many pairs of cases and controls as possible, 
allowing the results to carry more weight and making the conclusions more 
generalizable to future populations. In the present study, a 1:2 ratio would have 
resulted in dropping over 40% of the cases.
Statistical analyses
Logistic regression analysis was performed to study associations between the presence 
of atopic disorders and (non-)atopic comorbid symptoms and diseases in children. 
Similarly, associations between atopic triad and the above-mentioned comorbid 
symptoms and diseases were examined. Due to multiple testing, only associations 
with p ≤0.001 were considered statistically significant. All associations were tested 
for the modifying effects of age and gender. In case of a significant effect (p ≤0.01), 
associations were also presented for subgroups for age (2-6 vs. 7-12 vs. 13-18 
years) and gender (boy vs. girl). Finally, due to the hierarchical structure of the data 
(patients registered in general practices), a multi-level logistic regression analysis was 
performed to test whether clustering effects influenced our findings. All analyses were 
conducted in Stata 13 and Excel 2010. Prevalence rates are presented in percentages.
Ethical approval
Dutch law allows the use of EHRs for research purposes under certain conditions. 
According to this legislation, it is not necessary to obtain informed consent from 
patients or approval from a medical ethics committee for this type of observational 
study that contains no directly identifiable data (Dutch Civil Law, Article 7: 458). 
Therefore, no waiver of ethical approval was obtained from an Institutional Review 
Board (IRB) or ethics committee. The authors had no access to any identifying 
information at any moment during the analysis of the data.
Results
General characteristics (Table 1)
409,312 children were identified in the NIVEL-PCD in 2014, initially including 
70,494 atopic children with at least one atopic disorder. However, for an atopic 
child to be included in this study, one matched control patient had to be available 
(i.e. a child without an atopic disorder). There were 21,285 children with atopic 
eczema identified, of which 15,530 children had atopic eczema without another 
atopic disorder. For asthmatic children, 13,196 children were identified, of which 
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7,887 had asthma only and no other atopic disorders. In children with AR, 11,483 
were identified of which 6,835 had AR without another atopic disorder. Finally, 559 
children had all three atopic disorders. All the children in these groups were selected 
from 316 different general practices participating in NIVEL-PCD. Clustering effects 
did not influence our findings.
Atopic eczema (Table 2)
A substantial part of the significantly related comorbidity for children with atopic 
eczema concerns skin diseases such as (among others): warts (OR: 1.2), localized 
Table 1. General characteristics of the total study population
n Age in years
(SD)
Male
Only atopic eczema 15,530 8.7 (4.5) 48.2%
Only asthma 7,887 10.7 (4.5) 59.0%
Only allergic rhinitis 6,835 13.5 (3.5) 57.8%
Atopic triad 559 11.6 (4.0) 61.4%
NB. Children in the first three groups had only one of the three atopic disorders: i.e. they had 
the disorder mentioned, but none of the other disorders, whereas children in the atopic triad 
group had all three disorders.
Table 2. Significantly (p ≤0.001) associated comorbidity in children 
diagnosed with only atopic eczema (Ec) and at least three year fol low-up 
versus controls (non-atopic children) (n=31,060).
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
Ec No Ec boy girl 2-6 7-12 13-18
Skin-related diseases and symptoms
S03 1.15 1.06 – 1.26 7.85 6.88 Warts
S06 1.51 1.25 – 1.82 1.76 1.18 1.11 2.02 1.29 1.54 2.30 Rash localized *,†
S99 1.57 1.24 – 2.00 1.12 0.71 Skin disease, other
S02 1.71 1.31 – 2.23 0.97 0.57 Pruritus
S84 1.71 1.54 – 1.90 6.23 3.75 1.54 1.78 2.72 Impetigo†
S04 1.76 1.30 – 2.39 0.73 0.42 Lump/swelling localized
S74 1.76 1.54 – 2.00 4.20 2.44 Dermatophytosis
S98 1.77 1.50 – 2.09 2.49 1.42 Urticaria
S21 1.89 1.49 – 2.40 1.26 0.67 Skin texture symptom/complaint
S95 1.92 1.69 – 2.19 4.44 2.38 Molluscum contagiosum
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Table 2 (continued)
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
Ec No Ec boy girl 2-6 7-12 13-18
S86 2.31 1.87 – 2.84 1.89 0.83 Dermatitis seborrhoeic
S91 3.36 2.23 – 5.06 0.64 0.19 Psoriasis
Airway-related diseases and symptoms
R05 1.29 1.17 – 1.43 5.94 4.67 Cough
R74 1.33 1.23 – 1.43 10.42 8.13 Upper respiratory infection acute
R78 1.49 1.22 – 1.80 1.66 1.13 Acute bronchitis/bronchiolitis
R04 1.55 0.97 – 2.48 0.29 0.19 0.91 3.58 Breathing problem, other *
R03 1.95 1.30 – 2.92 0.45 0.23 Wheezing
Ear-nose-throat-related diseases and symptoms
H71 1.20 1.09 – 1.31 7.46 6.35 Acute otitis media/myringitis
H72 1.40 1.21 – 1.62 2.92 2.11 Serous otitis media
H01 1.43 1.24 – 1.65 3.01 2.13 Ear pain/earache
H04 1.47 1.17 – 1.86 1.13 0.77 Ear discharge
R21 1.50 1.27 – 1.78 2.13 1.43 Throat symptom/complaint
H70 1.56 1.27 – 1.90 1.58 1.02 Otitis externa
R07 1.95 1.32 – 2.89 0.48 0.24 Sneezing/nasal congestion
Gastro-intestinal-related diseases and symptoms
D01 1.27 1.12 – 1.45 3.61 2.85 Abdominal pain/cramps general
D12 1.32 1.19 – 1.47 5.29 4.07 Constipation
D87 1.48 0.87 – 2.51 0.22 0.15 0.69 3.29 Stomach function disorder *
D99 2.28 1.51 – 3.44 0.48 0.21 Disease digestive system. other
Musculoskeletal
L17 1.30 1.15 – 1.48 3.50 2.71 Foot/toe symptom/complaint
L98 1.39 1.20 – 1.60 2.90 2.11 Acquired deformity of limb
Miscellaneous
A04 1.25 1.09 – 1.44 3.07 2.47 Weakness/tiredness general
S12 1.41 1.19 – 1.66 2.24 1.60 Insect bite / sting
F72 1.53 1.22 – 1.93 1.20 0.79 0.96 2.79 1.76 Blepharitis/stye/chalazion†
F70 1.53 1.29 – 1.81 2.18 1.44 Conjunctivitis infectious
Y81 1.83 1.47 – 2.72 1.49 0.83 Phimosis/redundant prepuce
F71 1.99 1.59 – 2.49 1.45 0.73 Conjunctivitis allergic
A12 3.11 2.62 – 3.69 3.42 1.13 Allergy
* significant (p ≤0.01) influence of gender; † signif icant (p ≤0.01) influence of age; Italics: 
Overall model not signif icant
Risks for comorbidity in atopic children  107
rash (OR: 1.5), pruritus (OR: 1.7), impetigo (OR: 1.7), dermatophytosis (OR: 1.8), 
urticaria (OR: 1.8), molluscum contagiosum (OR: 1.9) and psoriasis (OR: 3.4). 
Otitis externa (OR: 1.6) and blepharitis (OR: 1.5) were also significantly associated 
with atopic eczema. The symptom diagnosis of wheezing (OR: 2.0), that could be 
attributed to asthma, is noteworthy since these children were not diagnosed or 
coded in the EHRs with asthma. The same applies to symptoms associated with 
allergic rhinoconjunctivitis, such as sneezing/nasal congestion (OR: 2.0) and allergic 
conjunctivitis (OR: 2.0). Older children with atopic eczema were at increased risk 
to develop a localized rash (OR: 1.3->2.3) and impetigo (OR: 1.5->2.7). Compared 
to boys, girls had an increased risk, to develop a localized rash (OR: 2.0 vs. 1.1), 
breathing problems (OR: 3.6 vs. 0.9) and stomach function disorder (OR: 3.3 vs. 0.7).
Asthma (Table 3)
Noteworthy are asthma-related symptoms that were diagnosed separately, such 
as shortness of breath/dyspnea (OR: 7.7) and wheezing (OR: 10.3). Furthermore, 
asthmatic children consulted their GP more frequently for airway-related infections 
such as: acute laryngitis/tracheitis (OR: 2.3), acute upper respiratory infection (OR: 
2.4), pneumonia (OR: 4.0) and acute bronchitis (OR: 4.8). In children with asthma, 
there seems to be a higher risk for the development of gastrointestinal symptoms, 
e.g.: general abdominal pain/cramps (OR: 1.4), localized abdominal pain (OR: 1.4), 
Table 3. Significantly (p ≤0.001) associated comorbidity in children 
diagnosed with only asthma (As) and at least three year fol low-up 
versus controls (non-atopic children) (n=15,774)
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
As No As boy girl 2-6 7-12 13-18
Skin-related diseases and symptoms
S98 2.10 1.61 – 2.73 2.21 1.07 Urtiacaria
Airway-related diseases and symptoms
R05 2.14 1.86 – 2.46 7.99 3.93 Cough
R77 2.34 1.54 – 3.56 0.94 0.41 Laryngitis/tracheitis acute
R74 2.35 2.09 – 2.64 12.34 5.78 Upper respiratory infection
R81 4.04 3.03 – 5.37 2.97 0.76 Pneumonia
R78 4.80 3.78 – 6.11 4.79 1.05 3.74 5.63 8.09 Acute bronchitis/bronchiolitis†
R91 5.66 3.14–10.23 0.93 0.16 Chronic bronchitis
R02 7.74 5.05–11.87 2.31 0.30 Shortness of breath/dyspnoea
R03 10.30 4.73–22.42 0.90 0.09 Wheezing
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Table 3 (continued)
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
As No As boy girl 2-6 7-12 13-18
Ear-nose-throat-related diseases and symptoms
H76 0.86 0.40 – 1.85 0.15 0.18 2.51 0.20 Foreign body in ear *
H01 1.45 1.16 – 1.81 2.46 1.71 Ear pain/earache
H71 1.52 1.32 – 1.76 6.44 4.4 Acute otitis media/myringitis
H70 1.60 1.22 – 2.08 1.79 1.13 Otitis externa
R75 1.90 1.32 – 2.75 1.05 0.56 Sinusitis acute/chronic
Gastro-intestinal-related diseases and symptoms
D89 0.76 0.37 – 1.57 0.16 0.22 0.27 4.52 Inguinal hernia *
D01 1.40 1.16 – 1.69 3.32 2.40 Abdominal pain/cramps general
D06 1.43 1.15 – 1.77 2.59 1.83 Abdominal pain localized other
D12 1.44 1.22 – 1.70 4.43 3.12 Constipation
D73 1.60 1.25 – 2.05 2.10 1.33 Gastroenteritis, infection
D10 2.02 1.37 – 2.97 0.99 0.49 Vomiting
D99 2.70 1.52 – 4.79 0.55 0.20 Disease digestive system, other
Musculoskeletal
L15 1.11 0.90 – 1.37 2.42 2.18 1.34 1.49 0.97 Knee symptom/complaint†
L12 1.37 1.09 – 1.71 2.27 1.67 1.00 2.13 Hand symptom/complaint*
L98 1.40 1.16 – 1.68 3.54 2.56 Acquired deformity of limb
L99 1.52 1.22 – 1.89 2.66 1.78 Musculoskeletal disease, other
L11 1.98 1.48 – 2.65 1.71 0.87 Wrist symptom/complaint
Miscellaneous
P21 1.34 1.13 – 1.58 4.18 3.17 ADHD
A04 1.39 1.17 – 1.65 4.04 2.97 Weakness/tiredness general
N01 1.51 1.21 – 1.89 2.49 1.66 Headache
F70 1.72 1.31 – 2.27 1.78 1.04 Conjunctivitis infectious
T10 1.82 1.35 – 2.44 1.60 0.89 Growth delay
T83 2.09 1.41 – 3.10 0.98 0.47 Overweight
T82 2.47 1.50 – 4.05 0.68 0.28 Obesity
F71 2.55 1.85 – 3.49 1.72 0.68 Conjunctivitis allergic
A12 3.40 2.74 – 4.23 4.55 1.38 Allergy
* significant (p ≤0.01) influence of gender; †significant (p ≤0.01) influence of age; Italics: 
Overall model not signif icant
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constipation (OR: 1.4) and vomiting (OR: 2.0). Acute bronchitis (OR: 3.7->8.1) was 
diagnosed more often in older children. Inguinal hernias were seen more frequently 
in girls than in boys (OR: 4.5 vs. 0.3).
Allergic rhinitis (Table 4)
Children with allergic rhinitis visit their GPs more frequently for ear-nose-throat 
related symptoms and diseases. Among others, the following were diagnosed more 
often: throat symptom/complaint (OR: 1.5), ear pain/earache (OR: 1.9), hypertrophy 
tonsils/adenoids (OR: 1.9), acute/chronic sinusitis (OR: 2.0), nose symptom (OR: 
2.6) and sneezing/nasal congestion (OR: 3.9). Furthermore, symptoms associated 
with atopic eczema (pruritus; OR: 2.2) and asthma [shortness of breath/dyspnea 
(OR: 2.7) and wheezing (OR: 4.3)] were seen more frequently. Also, when a child was 
diagnosed with allergic rhinitis, there was a substantial risk for the development of 
gastrointestinal symptoms [constipation (OR: 1.5) and localized abdominal pain (OR: 
1.8)]. Hypertrophy of the tonsils was diagnosed less frequently when children got older 
Table 4. Significantly (p ≤0.001) associated comorbidity in children 
diagnosed with only allergic rhinitis (AR) and at least three year fol low-
up versus controls (non-atopic children) (n=13,670)
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
AR No AR boy girl 2-6 7-12 13-18
Skin-related diseases and symptoms
A76 0.86 0.47 – 1.60 0.28 0.32 0.32 0.64 4.51 Viral exanthem other†
S03 1.26 1.10 – 1.43 7.65 6.20 Warts
S74 1.39 1.15 – 1.68 3.85 2.79 Dermatophytosis
S82 1.39 1.15 – 1.67 3.99 2.91 Naevus/mole
S84 1.71 1.35 – 2.15 2.87 1.71 Impetigo
S98 1.71 1.31 – 2.23 2.15 1.27 Urticaria
S86 1.86 1.38 – 2.53 1.76 0.95 Dermatitis seborrheic
S02 2.21 1.44 – 3.38 0.99 0.45 Pruritus
Airway-related diseases and symptoms
R05 1.89 1.58 – 2.25 5.24 2.85 Cough
R74 1.92 1.66 – 2.23 8.00 4.35 Upper respiratory infection acute
R78 2.32 1.60 – 3.37 1.35 0.59 Acute bronchitis/bronchiolitis
R02 2.67 1.74 – 4.11 1.13 0.42 Shortness of breath/dyspnoe
R80 3.89 1.79 – 8.47 0.45 0.12 Influenza
R03 4.30 1.89 – 9.80 0.44 0.10 Wheezing
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(OR: 3.2->1.0). On the other hand, children were more frequently diagnosed with a 
viral exanthema when they became older (OR: 0.3->4.5). A presumed gastro-intestinal 
infection (OR: 3.4 vs. 1.3), speech disorder (OR: 2.4 vs. 0.9) and blepharitis/style/
chalazion (OR: 3.3 vs. 1.2) were diagnosed more frequently in girls with allergic rhinitis.
Table 4 (continued)
ICPC OR 95% CI Prevalence OR per 
sex group
OR within age Description ICPC codes
AR No AR boy girl 2-6 7-12 13-18
Ear-nose-throat-related diseases and symptoms
R21 1.48 1.20 – 1.84 3.13 2.14 Throat symptom/complaint
H01 1.87 1.36 – 2.56 1.62 0.88 Ear pain/earache
R90 1.92 1.34 – 2.74 1.30 0.69 3.22 2.80 1.04 Hypertrophy tonsils/adenoids†
R75 1.95 1.45 – 2.63 1.89 0.98 Sinusitis acute/chronic
R08 2.62 1.72 – 4.00 1.14 0.44 Nose symptom/complaint other
R07 3.93 2.57 – 6.01 1.54 0.40 Sneezing/nasal congestion
Gastro-intestinal-related diseases and symptoms
D12 1.50 1.23 – 1.82 3.79 2.57 Constipation
D06 1.76 1.39 – 2.22 2.90 1.67 Abdominal pain localized other
D73 1.96 1.42 – 2.71 1.59 0.82
1.29 3.39 Gastroenteritis presumed 
infection *
Musculoskeletal
L98 1.36 1.15 – 1.62 4.54 3.37 Acquired deformity of limb
L17 1.42 1.19 – 1.70 4.40 3.15 Foot/toe symptom/complaint
L13 2.80 1.66 – 4.74 0.78 0.28 Hip symptom/complaint
Miscellaneous
N19 1.18 0.85 – 1.65 1.17 0.99 0.89 2.43 Speech disorder *
N01 1.45 1.18 – 1.78 3.29 2.30 Headache
P24 1.45 1.18 – 1.78 3.37 2.37 Specific learning problem
A04 1.58 1.35 – 1.85 6.10 3.96 Weakness/tiredness general
F70 1.73 1.28 – 2.32 1.76 1.02 Conjunctivitis infectious
S12 1.92 1.40 – 2.63 1.67 0.88 Insect bite/sting
F72 1.95 1.36 – 2.79 1.27 0.66 1.21 3.29 Blepharitis/stye/chalazion *
A12 4.02 3.15 – 5.13 4.70 1.21 Allergy
F71 5.44 4.08 – 7.25 4.29 0.82 Conjunctivitis allergic
* significant (p ≤0.01) influence of gender; †significant (p ≤0.01) influence of age; Italics: 
Overall model not signif icant
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Atopic triad (Table 5)
Having all three atopic disorders is relatively rare, with only a few symptoms and 
diseases being significantly related. The risk for developing an ‘allergy’, that the GP 
considers relevant to register in the EHR can be considered high (OR: 17.8). Allergic 
conjunctivitis (OR: 6.8) is also frequently seen in children with all three atopic 
disorders.
Table 5. Significantly (p≤0.001) associated comorbidity in children 
diagnosed with Atopic Triad (AT) and at least three year fol low-up versus 
controls (non-atopic children) (n=1,118)
ICPC OR 95% CI Prevalence Description ICPC codes
AT No AT
R05 2.42 1.43 – 4.10 8.59 3.76 Cough
L17 3.25 1.63 – 6.50 6.08 1.97 Foot/toe symptom/complaint
R74 3.75 2.33 – 6.04 14.13 4.29 Upper respiratory infection acute
F71 6.79 2.35 – 19.60 4.65 0.72 Conjunctivitis allergic
A12 17.83 7.15 – 44.43 13.77 0.89 Allergy
Discussion
Main findings
The present study used an extensive and representative general practice database 
(21). The large number of children gives the study substantial power and 
generalizability. This could also allow evaluation of possible links between atopic 
disorders and rare childhood diseases. This study showed that atopic children have 
an increased risk for the development of both atopic and non-atopic diseases and 
symptoms. Children diagnosed with one atopic disorder were frequently diagnosed 
by their GP with symptoms associated with one of the other atopic disorders. This 
suggests that GPs are not always fully aware of relevant atopic comorbidity, or at 
least do not label it correctly. Two examples support this hypothesis. First of all, 
a child diagnosed with atopic eczema is also diagnosed with pruritus, suggesting 
possible misclassification. Secondly, a child with atopic eczema that presents with 
‘wheeze’ or ‘dyspnea’ is at a higher risk for the development of asthma compared 
to a child without atopic eczema. A GP should be aware of this increased risk, since 
it could result in insufficient treatment of a child. However, a GP could also use 
symptom-related ICPC-codes deliberately when the purpose is to record a provisional 
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diagnosis (e.g. wheeze as the provisional diagnosis of asthma). Regarding non-
atopic co-morbidity, strong associations were found between the atopic disorder 
and diseases and symptoms related to the same organ system. For example, 
children with atopic eczema are at increased risk for the development of other 
skin diseases, asthmatic children are at risk of other airway diseases, and children 
with allergic rhinitis are at risk of ear-nose-throat-related symptoms and diseases. 
Gastro-intestinal and musculoskeletal diseases and symptoms were also seen more 
frequently in atopic children. When exploring possible interactions of age and gender 
in children with one atopic disorders, no clear patterns arose.
Interpretation of findings in relation to previously published work
Children with atopic eczema had an increased risk of developing infectious skin 
diseases such as warts, impetigo, dermatophytosis and molluscum contagiosum. The 
common etiology could be the barrier dysfunction of the skin in children with atopic 
eczema. This barrier dysfunction is also seen in psoriasis, a disease that, according 
to the present study, is associated with atopic eczema (OR: 3.4). They share some 
common pathological backgrounds such as barrier dysfunction and enhanced IL-22 
expression (26). Although the clinical pictures of these two diseases can be very 
different, the observed association could also suggest misclassification among these 
two chronic skin diseases that are often confused for one another. Otitis externa and 
blepharitis both had significant ORs. These disorders could in fact be an expression 
of atopic eczema.
Children with asthma seem to have consulted their GP more frequently for airway-
related infections such as acute laryngitis/tracheitis, acute upper respiratory 
infection, pneumonia and bronchitis. An explanation for this could be that airway 
infections increase asthma symptoms or vice versa, that asthma resulted in 
increased susceptibility for infection, which increased their motivation to visit the GP. 
Furthermore, the awareness of parents is likely to be increased when a child suffers 
from asthma, since such an infection could predispose for an asthma exacerbation.
Children with allergic rhinitis consulted their GPs more frequently for ear-nose-
throat-related symptoms and diseases. However, even more striking are the asthma-
related symptoms. Both shortness of breath (OR: 2.7) and wheeze (OR: 4.3) were 
frequently seen in children with allergic rhinitis. There is strong evidence that allergic 
rhinitis has an adverse impact on asthma severity (27). Because allergic rhinitis 
can provoke asthma symptoms, allergic rhinitis symptoms should be taken more 
seriously by GPs to reduce insufficient treatment.
Gastrointestinal-related symptoms are also frequently diagnosed by GPs in atopic 
children. This is in accordance with a study in adults in a primary care setting 
Risks for comorbidity in atopic children  113
(28). These symptoms could be related to IgE-mediated food allergies or in rare 
cases even to eosinophilic esophagitis that are associated with atopic disorders 
(29); however, in children, abdominal pains can also be a general expression 
of not feeling well. Unfortunately, the ICPC classification system does not cover 
the above-mentioned gastrointestinal diseases with unique code and, therefore, 
gastrointestinal-related symptoms might have been used by the GP to label these 
diseases.
Some associations described in the literature were not confirmed in the present 
study, e.g. serous otitis media in patients with allergic rhinitis (18, 20), and 
inflammatory bowel disease (30, 31), leukemia (32, 33) and diabetes (34, 35) 
in atopic patients. The prevalence rates of some of these disorders are low and a 
cross-sectional design (as used in the present study), might not have enough power 
to prove these relationships.
Strengths and limitations of this study
Using general practice databases (by means of a cross-sectional design) also has 
its limitations. First of all, a limitation for the present study is the GP’s choice 
for ICPC coding of an episode of care. For example, a child with a wheeze could 
either be labeled as ‘asthma’ (R96) or labeled as ‘wheeze’ (R03). This could result 
in both overestimation or underestimation of asthma. To decrease this risk of 
overestimation regarding atopic disorders, some episodes were corrected in order 
to increase the clinical relevance of the atopic disorder of interest. However, the risk 
of underestimation was not tackled, since too many assumptions need to be made. 
The second limitation regarding this type of explorative study is the unavoidable 
multiple testing. Although conservative p-values were used, type 1 errors cannot be 
avoided. In this study, some suggested associations might in fact reflect these type 
1 errors. Thirdly, because data on socioeconomic status, tobacco smoke exposure 
and other lifestyle-related risk factors are not recorded in NIVEL-PCD, we cannot 
rule out the effect of these risk factors on the observed relations. However, since the 
children with atopic disorders were matched with controls within the same general 
practice, all children are most likely living in the same neighborhoods and therefore 
the effect of most of the earlier mentioned risk factors is expected to be small. 
Fourthly, atopic children might visit the GP more frequently than non-atopic children. 
And although this may be more representative of parental fears, rather than an 
indication of morbidity, it can result in more detected morbidity in atopic children 
and could partly explain some of the associations found. In future research, the 
number of consultations might need to be taken into account in the analyses. Fifth 
of all, in the present study the diagnosis are based on a physician’s assessment and 
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not on confirmed sensitization pattern for allergens. According to the Dutch medical 
guideline for eczema (36), GPs are not advised to determine these sensitization 
patterns, since this doesn’t have any clinical consequences. Although atopy is 
clearly associated with atopic eczema, the role of IgE sensitization in atopic eczema 
still needs further study (37). Also in children with AR, sensitization patterns don’t 
have added value if the medical history clearly suggests e.g. a pollen allergy (38). 
Only when the cause of the rhinitis is uncertain, the determination of sensitization 
patterns adds value. The medical guidelines for asthma in children advises to 
determine sensitization patterns (39), since it can help diagnose allergic asthma 
(40) and because it could have clinical consequences. Finally, it is important to 
acknowledge the uncertainty of general practitioners to make a diagnosis of asthma 
or AR in young children (e.g. under the age of six).
Implications for future research and practice
First of all, could comorbidity data be used to create proxies that could support 
GPs in identifying atopic children that are not labeled as such? For example, could 
comorbidity data be incorporated in ‘clinical decision support systems’ to improve 
early diagnosis of both atopic and non-atopic disorders. Second of all, how is the 
quality of life of these atopic children affected by the associated comorbidity? GPs 
should be aware of the described associations when treating an atopic child, since 
the quality of life of an atopic child could be improved by paying more attention to 
diagnosis and treatment of these related disorders. Furthermore, one must be aware 
that atopic disorders and associated symptoms and diseases may well persist into 
adulthood.
Conclusions
The present study shows that atopic children have an increased risk of clinically 
relevant comorbidity, both atopic and non-atopic. General practitioners may not 
always be fully aware of relevant atopic and non-atopic comorbidity. In children 
known to have at least one atopic disorder, specific attention is required to avoid 
possible insufficient treatment and unnecessary loss of quality of life.
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Appendix 1
ICPC 
codes Description
A03 Fever
A04 Weakness/tiredness general
A12 Allergic reaction
A15 Excessive crying infant
A16 Irritable infant
A70 Tuberculosis
A71 Measles
A72 Chickenpox
A73 Malaria
A74 Rubella
A75 Infectious mononucleosis
A76 Viral exanthem other
A77 Viral disease other/NOS
A78 Infectious disease other/NOS
A79 Malignancy NOS
A84 Poisoning by medical agent
A85 Adverse effect medical agent
A86 Toxic effect non-medicinal substance
A87 Complication of medical treatment
A88 Adverse effect physical factor
A90 Congenital anomaly OS/multiple
A92 Allergy/allergic reaction NOS
A93 Premature newborn
A94 Perinatal morbidity other
A95 Perinatal mortality
A96 Death
B02 Lymph gland(s) enlarged/painful
B70 Lymphadenitis acute
B71 Lymphadenitis non-specific
B72 Hodgkin’s disease/lymphoma
B73 Leukaemia
B74 Malignant neoplasm blood other
B75 Benign/unspecified neoplasm blood
B78 Hereditary haemolytic anaemia
ICPC 
codes Description
B79 Congen.anom. blood/lymph other
B80 Iron deficiency anaemia
B81 Anaemia, Vitamin B12/folate def.
B82 Anaemia other/unspecified
B83 Purpura/coagulation defect
B84 Unexplained abnormal white cells
B87 Splenomegaly
B90 HIV-infection/aids
D01 Abdominal pain/cramps general
D02 Abdominal pain epigastric
D03 Heartburn
D04 Rectal/anal pain
D05 Perianal itching
D06 Abdominal pain localized other
D07 Dyspepsia/indigestion
D08 Flatulence/gas/belching
D09 Nausea
D10 Vomiting
D11 Diarrhoea
D12 Constipation
D13 Jaundice
D22 Parasites
D70 Gastrointestinal infection
D71 Mumps
D72 Viral hepatitis
D73 Gastroenteritis presumed infection
D74 Malignant neoplasm stomach
D75 Malignant neoplasm colon/rectum
D76 Malignant neoplasm pancreas
D77 Malig. neoplasm digest other/NOS
D78 Neoplasm digest benign/uncertain
D79 Foreign body digestive system
D81 Congen. anomaly digestive system
D83 Mouth/tongue/lip disease
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ICPC 
codes Description
D84 Oesophagus disease
D85 Duodenal ulcer
D86 Peptic ulcer other
D87 Stomach function disorder
D88 Appendicitis
D89 Inguinal hernia
D90 Hiatus hernia
D91 Abdominal hernia other
D92 Diverticular disease
D93 Irritable bowel syndrome
D94 Chronic enteritis/ulcerative colitis
D95 Anal fissure/perianal abscess
D96 Worms/other parasites
D97 Liver disease NOS
D98 Cholecystitis/cholelithiasis
D99 Disease digestive system, other
F01 Eye pain
F02 Red eye
F03 Eye discharge
F04 Visual floaters/spots
F05 Visual disturbance other
F70 Conjunctivitis infectious
F71 Conjunctivitis allergic
F72 Blepharitis/stye/chalazion
F73 Eye infection/inflammation other
F74 Neoplasm of eye/adnexa
F75 Contusion/haemorrhage eye
F76 Foreign body in eye
F80 Blocked lacrimal duct of infant
F81 Congenital anomaly eye other
F82 Detached retina
F83 Retinopathy
F84 Macular degeneration
F85 Corneal ulcer
F86 Trachoma
F91 Refractive error
ICPC 
codes Description
F92 Cataract
F93 Glaucoma
F94 Blindness
F95 Strabismus
F99 Eye/adnexa disease, other
H01 Ear pain/earache
H02 Hearing complaint
H03 Tinnitus, ringing/buzzing ear
H04 Ear discharge
H05 Bleeding ear
H70 Otitis externa
H71 Acute otitis media/myringitis
H72 Serous otitis media
H73 Eustachian salpingitis
H74 Chronic otitis media
H75 Neoplasm of ear
H76 Foreign body in ear
H77 Perforation ear drum
H80 Congenital anomaly of ear
H81 Excessive ear wax
H82 Vertiginous syndrome
H83 Otosclerosis
H86 Deafness
K01 Heart pain
K02 Pressure/tightness of heart
K04 Palpitations/awareness of heart
K05 Irregular heartbeat other
K07 Swollen ankles/oedema
K29 Cardiovascular sympt./complt. other
K70 Infection of circulatory system
K71 Rheumatic fever/heart disease
K72 Neoplasm cardiovascular
K73 Congenital anomaly cardiovascular
K74 Ischaemic heart disease w. angina
K75 Acute myocardial infarction
K76 Ischaemic heart disease w/o angina
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ICPC 
codes Description
K77 Heart failure
K78 Atrial fibrillation/flutter
K79 Paroxysmal tachycardia
K80 Cardiac arrhythmia NOS
K81 Heart/arterial murmur NOS
K82 Pulmonary heart disease
K83 Heart valve disease NOS
K84 Heart disease other
K85 Elevated blood pressure
K86 Hypertension uncomplicated
K87 Hypertension complicated
K88 Postural hypotension
K89 Transient cerebral ischaemia
K90 Stroke/cerebrovascular accident
K91 Cerebrovascular disease
K92 Atherosclerosis/PVD
K93 Pulmonary embolism
K94 Phlebitis/thrombophlebitis
K95 Varicose veins of leg
K96 Haemorrhoids
K99 Cardiovascular disease other
L01 Neck symptom/complain
L02 Back symptom/complaint
L03 Low back symptom/complaint
L04 Chest symptom/complaint
L05 Flank symptom/complaint
L06 Axilla symptom/complaint
L07 Jaw symptom/complaint
L08 Shoulder symptom/complaint
L09 Arm symptom/complaint
L10 Elbow symptom/complaint
L11 Wrist symptom/complaint
L12 Hand/finger symptom/complaint
L13 Hip symptom/complaint
L14 Leg/thigh symptom/complaint
L15 Knee symptom/complaint
ICPC 
codes Description
L16 Ankle symptom/complaint
L17 Foot/toe symptom/complaint
L18 Muscle pain
L19 Muscle symptom/complaint NOS
L20 Joint symptom/complaint NOS
L70 Infections musculoskeletal system
L71 Malignant neoplasm musculoskeletal
L82 Congenital anomaly musculoskeletal
L83 Neck syndrome
L84 Back syndrome w/o radiating pain
L85 Acquired deformity of spine
L86 Back syndrome with radiating pain
L87 Bursitis/tendinitis/synovitis NOS
L88 Rheumatoid/seropositive arthritis
L92 Shoulder syndrome
L93 Tennis elbow
L94 Osteochondrosis
L95 Osteoporosis
L97 Neoplasm benign/unspec musculo.
L98 Acquired deformity of limb
L99 Musculoskeletal disease, other
N01 Headache
N02 Tension headache
N03 Pain face
N04 Restless legs
N05 Tingling fingers/feet/toes
N06 Sensation disturbance other
N07 Convulsion/seizure
N16 Disturbance of smell/taste
N17 Vertigo/dizziness
N18 Paralysis/weakness
N19 Speech disorder
N70 Poliomyelitis
N71 Meningitis/encephalitis
N72 Tetanus
N73 Neurological infection other
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ICPC 
codes Description
N74 Malignant neoplasm nervous system
N75 Benign neoplasm nervous system
N76 Neoplasm nervous system unspec.
N85 Congenital anomaly neurological
N86 Multiple sclerosis
N87 Parkinsonism
N88 Epilepsy
N89 Migraine
N90 Cluster headache
N91 Facial paralysis/bell’s palsy
N92 Trigeminal neuralgia
N93 Carpal tunnel syndrome
N94 Peripheral neuritis/neuropathy
N99 Neurological disease, other
P01 Feeling anxious/nervous/tense
P02 Acute stress reaction
P03 Feeling depressed
P04 Feeling/behaving irritable/angry
P06 Sleep disturbance
P10 Stammering/stuttering/tic
P11 Eating problem in child
P12 Bedwetting/enuresis
P13 Encopresis/bowel training problem
P20 Memory disturbance
P21 ADHD
P22 Child behaviour symptom/complaint
P23 Adolescent behav. Symptom/complt.
P24 Specific learning problem
P71 Organic psychosis other
P72 Schizophrenia
P73 Affective psychosis
P74 Anxiety disorder/anxiety state
P75 Somatization disorder
P76 Depressive disorder
P78 Neuraesthenia/surmenage
P79 Phobia/compulsive disorder
ICPC 
codes Description
P85 Mental retardation
P98 Psychosis NOS/other
P99 Psychological disorders, other
R01 Pain respiratory system
R02 Shortness of breath/dyspnoea
R03 Wheezing
R04 Breathing problem, other
R05 Cough
R06 Nose bleed/epistaxis
R07 Sneezing/nasal congestion
R08 Nose symptom/complaint other
R09 Sinus symptom/complaint
R21 Throat symptom/complaint
R22 Tonsils symptom/complaint
R23 Voice symptom/complaint
R24 Haemoptysis
R25 Sputum/phlegm abnormal
R29 Respiratory symptom/complaint oth.
R70 Tuberculosis airways
R71 Whooping cough
R72 Strep throat
R73 Boil/abscess nose
R74 Upper respiratory infection acute
R75 Sinusitis acute/chronic
R76 Tonsillitis acute
R77 Laryngitis/tracheitis acute
R78 Acute bronchitis/bronchiolitis
R80 Influenza
R81 Pneumonia
R82 Pleurisy/pleural effusion
R83 Respiratory infection other
R84 Malignant neoplasm bronchus/lung
R85 Malinant neoplasm respiratory, other
R86 Benign neoplasm respiratory
R87 Foreign body nose/larynx/bronch
R89 Congenital anomaly respiratory
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ICPC 
codes Description
R90 Hypertrophy tonsils/adenoids
R91 Chronic bronchitis
R93 Pleural effusion
R95 Chronic obstructive pulmonary dis
R96 Asthma
R97 Allergic rhinitis
R98 Hyperventilation syndrome
R99 Respiratory disease other
S01 Pain/tenderness of skin
S02 Pruritus
S03 Warts
S04 Lump/swelling localized
S05 Lumps/swellings generalized
S06 Rash localized
S07 Rash generalized
S08 Skin colour change
S09 Infected finger/toe
S10 Boil/carbuncle
S11 Skin infection post-traumatic
S12 Insect bite/sting
S13 Animal/human bite
S14 Burn/scald
S15 Foreign body in skin
S20 Corn/callosity
S21 Skin texture symptom/complaint
S22 Nail symptom/complaint
S23 Hair loss/baldness
S24 Hair/scalp symptom/complaint
S70 Herpes zoster
S71 Herpes simplex
S72 Scabies/other acariasis
S73 Pediculosis/skin infestation other
S74 Dermatophytosis
S75 Moniliasis/candidiasis skin
S76 Skin infection other
S77 Malignant neoplasm of skin
ICPC 
codes Description
S78 Lipoma
S79 Neoplasm skin benign/unspecified
S80 Solar keratosis/sunburn
S81 Haemangioma/lymphangioma
S82 Naevus/mole
S83 Congenital skin anomaly other
S84 Impetigo
S85 Pilonidal cyst/fistula
S86 Dermatitis seborrhoeic
S87 Dermatitis/atopic eczema
S89 Diaper rash
S90 Pityriasis rosea
S91 Psoriasis
S92 Sweat gland disease
S93 Sebaceous cyst
S94 Ingrowing nail
S95 Molluscum contagiosum
S96 Acne
S97 Chronic ulcer skin
S98 Urticaria
S99 Skin disease, other
T01 Excessive thirst
T02 Excessive appetite
T03 Loss of appetite
T04 Feeding problem of infant/child
T05 Feeding problem of adult
T06 Anorexia nervosa
T07 Weight gain
T08 Weight loss
T10 Growth delay
T11 Dehydration
T15 Tumor thyroid
T70 Endocrine infection
T71 Malignant neoplasm thyroid
T72 Benign neoplasm thyroid
T73 Neoplasm endocrine oth/unspecified
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ICPC 
codes Description
T78 Thyroglossal duct/cys
T80 Congenital anom endocrine/metab
T81 Goitre
T82 Obesity
T83 Overweight
T85 Hyperthyroidism/thyrotoxicosis
T86 Hypothyroidism/myxoedema
T87 Hypoglycaemia
T88 Renal glycosuria
T89 Diabetes insulin dependent
T90 Diabetes non-insulin dependent
T91 Vitamin/nutritional deficiency
T92 Gout
T93 Lipid disorder
T99 Endocrine/metab/nutrit. dis. other
U01 Dysuria/painful urination
U02 Urinary frequency/urgency
U04 Incontinence urine
U05 Urination problems other
U06 Haematuria
U07 Urine symptom/complaint other
U13 Bladder symptom/complaint other
U14 Kidney symptom/complaint
U70 Pyelonephritis/pyelitis
ICPC 
codes Description
U71 Cystitis/urinary infection other
U72 Urethritis
U75 Malignant neoplasm of kidney
U76 Malignant neoplasm of bladder
U77 Malignant neoplasm urinary other
U78 Benign neoplasm urinary tract
U79 Neoplasm urinary tract NOS
U85 Congenital anomaly urinary tract
U88 Glomerulonephritis/nephrosis
U90 Orthostatic albumin/proteinuria
U95 Urinary calculus
U98 Abnormal urine test NOS
U99 Urinary disease, other
X83 Congenital anomaly genital female
X84 Vaginitis/vulvitis NOS
X85 Cervical disease NOS
X99 Genital disease female, other
Y74 Orchitis/epididymitis
Y75 Balanitis
Y81 Phimosis/redundant prepuce
Y82 Hypospadias
Y83 Undescended testicle
Y84 Congenital genl anomaly (m) other
Y99 Genital disease male, other
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Abstract
Purpose: A comprehensive and representative nationwide general practice database 
was explored to study associations between physician diagnosed atopic disorders and 
prescribed medication in children.
Method: All children aged 0-18 years listed in the NIVEL Primary Care Database in 
2014 were selected. Atopic children with atopic eczema, asthma and allergic rhinitis 
(AR) were matched with controls (not diagnosed with any of these disorders) within 
the same general practice on age and gender. Logistic regression analyses were 
performed to study the differences in prescribed medication between both groups by 
calculating odds ratios (OR); 93 different medication groups were studied.
Results: A total of 45,964 children with at least one atopic disorder were identified 
and matched with controls. Disorder-specific prescriptions seem to reflect evidence-
based medicine guidelines for atopic eczema, asthma and AR. However, these 
disorder-specific prescriptions were also prescribed for children who were not 
registered as having that specific disorder. For eczema-related medication, about 
3.7-8.4% of the children with non-eczematous atopic morbidity received these 
prescriptions, compared to 1.4-3.5% of the non-atopic children. The same pattern 
was observed for anti-asthmatics (having non-asthmatic atopic morbidity: 0.8-6.2% 
vs. controls: 0.3-2.1%) and AR-related medication (having non-AR atopic morbidity: 
4.7-12.5% vs. controls: 2.8-3.1%). Also, non-atopic related medication, such as 
laxatives and antibiotics were more frequently prescribed for atopic children.
Conclusions: The present study shows that atopic children received more 
prescriptions, compared to non-atopic children. Non-atopic controls frequently 
received specific prescriptions for atopic disorders. This indicates that children with 
atopic disorders need better monitoring by their GP.
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Background
Many children are diagnosed with atopic disorders (1, 2) and are likely to consult 
their general practitioners (GP) for atopic-related symptoms. In the present study, 
we refer to atopy as one or more of the following established diagnoses: atopic 
eczema, asthma and/or allergic rhinitis (AR).
Evidence-based medicine guidelines support Dutch GPs in the decision-making 
process when prescribing medication (3-5). According to these guidelines, the 
cornerstone for the treatment of atopic eczema in children are emollients and 
corticosteroid crèmes, prescribed in a stepwise approach (3). When anti-asthmatic 
inhalation medication is needed, a GP will start with a short-acting beta agonist, 
followed by inhaled corticosteroids when indicated (4). For AR, treatment will depend 
on the severity of symptoms. Intermittent symptoms are often treated with local or 
oral antihistamines on demand, while moderate to severe symptoms will be treated 
with corticosteroid nasal sprays (5). How often these atopic-related prescriptions are 
also given to children that are not labeled/diagnosed with a specific atopic disorder is 
not yet known and could reflect underdiagnosis or insufficient coding.
Atopic disorders are associated with comorbidity (6), and this can result in non-
atopic related prescriptions for these atopic children as well. However, to what 
extent these atopic children have a higher risk to receive more (non-)atopic related 
prescriptions has not yet been examined in general practice. Knowing more about 
these differences can help a GP to provide better care for his atopic patients.
Therefore, in this study, an extensive and representative nationwide general 
practice database was used to investigate associations between atopic disorders 
and prescribed medications. Two research questions were formulated: i) Which 
medications are prescribed by GPs for atopic disorders? ii) What kind of other 
medications do atopic children receive?
Method
Study population
All non-institutionalized Dutch inhabitants are compulsorily listed with a general 
practice, including patients who do not visit their GP on a regular basis. The 
Netherlands Institute for Health Services Research-Primary Care Database (NIVEL-
PCD) uses the electronical health records (EHRs) of all listed patients in participating 
practices for research purposes. The data are representative for the Dutch population 
(7) and based on routinely recorded data (type of consultation, morbidity, and 
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prescriptions). In 2014, about 500 general practices participated, including data of 
about 1,700,000 patients (www.nivel.nl/en/dossier/nivel-primary-care-database), 
i.e. over 10% of the total Dutch population. Morbidity is recorded by GPs (frontline 
for the Dutch healthcare system) using the International Classification of Primary 
Care-1 (ICPC-1). This is a classification method for primary care and accepted by the 
WHO (8). Relevant consultations, prescriptions and referrals are clustered in ICPC 
classified episodes of care. Atopic episodes of care are labeled with ICPC codes: S87 
(atopic eczema), R96 (asthma) and R97 (allergic rhinitis). ICPC codes specific for 
food allergies are not available.
Only data from EHRs of general practices with sufficient data quality were used. They 
had to fulfill the following criteria: at least 500 listed patients (standard practice 
size: 2350 patients), complete morbidity registration (defined as ≥ 46 weeks per 
year) and sufficient ICPC coding (defined as ≥ 70% of the recorded disease episodes 
labeled with an ICPC code). The following descriptive data were routinely collected: 
gender, year and quarter of birth, period in which the individual child was registered 
in the general practice, and the unique code of the general practice.
Identification of atopic children
To reduce the risk of registration bias for physician based atopic disorders, a 
minimum follow-up of 3 successive years (e.g. data had to be available for 2012-
2014) was required for each child (age range 0-18 years). We considered a 3-year 
follow-up sufficient time for a GP to diagnose a child with atopic disorders, since a 
Dutch GP sees about 72% of pediatric patients at least once a year (9). Furthermore, 
when available, the EHRs from 2002-2014 were examined in order not to miss any 
relevant atopic diagnosis. Because there is a risk of misclassification (GPs work with 
probability diagnoses), ICPC codes and their related episodes of care were corrected 
in order to select cases with a higher probability of a clinically relevant disorder (2). 
In practice, an atopic episode of care was maintained if (based on available data 
from EHRs in the period 2002-2014) the child had at least two contact moments in 
that episode of care and had received at least two relevant prescriptions. If the child 
did not meet these criteria, the child was considered not to have that atopic disorder 
(2). It was not a requirement that the patient had visited the GP in 2014 for that 
specific atopic disorder.
Atopic triad
A forth distinct group of children, with all three atopic disorders, might exist 
according to a meta-analysis (1). This is in contrast to the traditional classification of 
children with atopic eczema or asthma or AR. ‘Atopic triad’ episodes were developed 
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for research purposes in order to learn more about this potentially unique group 
of children and were only created when a child was diagnosed with all three atopic 
disorders(based on available data from EHRs in the period 2002-2014).
Studied medication
GPs recorded prescriptions using the Anatomical Therapeutic Chemical (ATC) 
Classification System. This system is controlled by the World Health Organization 
Collaborating Centre for Drug Statistics Methodology (WHOCC), and was first 
published in 1976. All ATC codes were examined at the second level, indicating the 
therapeutic main group and consisting of two digits. In some cases, a subgroup 
analysis was done at the ATC 3 level, indicating the therapeutic/pharmacological 
subgroup and consisting of one letter. All 93 ATC codes at the ATC 2 level were 
studied (Appendix 1). Prescription data from 2014 were examined.
Design
In a nested case-control study design, for each atopic child one matched control 
patient was selected (not diagnosed with an atopic disorder) within the same general 
practice, based on age and gender (in 2014). In order to include as many pairs 
of cases and controls as possible, a 1:1 ratio was chosen. This allows the results 
to carry more weight and make the conclusions better generalizable to future 
populations. When using a 1:2 ratio, over 40% of the cases had to be dropped.
Statistical analyses
To study associations between the presence of physician based atopic disorders 
and prescriptions in children, logistic regression analyses were performed for 
children that solely had atopic eczema, asthma, or AR and therefore no other atopic 
comorbidity. The same analyses were performed for the atopic triad. As a result 
of multiple testing, the level of significance was set on p≤0.001. Modifying effects 
of age and gender were tested for all associations. When the effect was significant 
(p≤0.01), associations were also presented for subgroups for age (2-6 vs. 7-12 vs. 
13-18 years) and gender (boy vs. girl). All analyses were conducted in Stata 13 and 
Excel 2010. Prevalences are presented in percentages.
Ethical approval
Dutch law allows the use of EHRs for research purposes under certain conditions. 
According to this legislation, it is not necessary to obtain informed consent from 
patients or approval from a medical ethics committee for this type of observational 
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study that contains no directly identifiable data (Dutch Civil Law, Article 7: 458). No 
waiver of ethical approval was therefore obtained by an Institutional Review Board or 
ethics committee. The authors did not have access to identifying information at any 
moment during the analysis of the data.
Results
General characteristics (Table 1)
409,312 children were identified in the NIVEL-PCD, initially including 70,494 atopic 
children with at least one atopic disorder in 2014. However, for an atopic child to 
be included in this study, one matched control patient had to be available (i.e. a 
child without an atopic disorder). A total of 45,964 children with at least one atopic 
disorder could be identified and matched with controls. After selecting children with 
an atopic disorder and with a higher probability of a clinically relevant disorder 
and with at least three years follow-up, 21,285 children with atopic eczema were 
identified, of which 15,530 children had atopic eczema only and no other atopic 
disorders. For asthmatic children, 13,196 children were identified, of which 7,887 
had asthma only and no other atopic disorders. In children with AR, 11,483 were 
identified of which 6,835 had AR only and no other atopic disorders. Finally, 559 
children had all three atopic disorders. All the children in these groups were selected 
from 316 different general practices participating in NIVEL-PCD.
Table 1 Overall characteristics of the total study population
n Age in years
(SD)
Male
Only atopic eczema 15,530 8.7 (4.5) 48.2%
Only asthma 7,887 10.7 (4.5) 59.0%
Only allergic rhinitis 6,835 13.5 (3.5) 57.8%
Atopic triad 559 11.6 (4.0) 61.4%
NB. Children in the first three groups had only one of the three atopic disorders: i.e. they had 
the disorder mentioned, but none of the other disorders, whereas children in the Atopic triad 
group had all three disorders.
Children registered with only atopic eczema (Table 3)
A child with atopic eczema received on average 1.5 different prescriptions in 
2014, compared to 0.7 different prescriptions for the controls; this difference was 
significant (Table 2). In total, 61% of all children with atopic eczema did not receive 
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Table 2 Number of different prescriptions received in 2014
Disorder Index patients Control patients
Only atopic eczema* 1.5 0.7
Only asthma* 1.8 0.7
Only allergic rhinitis* 2.2 0.8
* the child did not have any of the other atopic disorder
Table 3 Signif icantly (p≤0.001) associated medication in children 
registered with only atopic eczema (Ec) versus controls (non-atopic 
children) (n=31,060)
ICPC OR 95%-CI Prevalence 
(%)
OR per 
sex group
OR within age Description ICPC codes
Ec No Ec boy girl 2-6 7-12 13-18
Atopic eczema related medication
D02 13.09 11.58 – 14.80 19.85 1.87 11.68 12.63 20.00 Emollients and protectives†
D07 12.52 11.45 – 13.68 32.91 3.78 11.18 11.87 16.80 Corticosteroids, dermatological 
preparations†
Asthma related medication
R03 1.97 1.72 – 2.26 3.98 2.07 Anti-asthmatics
Allergic rhinitis related medication
R01 1.54 1.37 – 1.73 4.72 3.12 Nasal preparations
R06 2.90 2.59 – 3.24 7.72 2.81 Antihistamines for systemic use
Medication related to atopic disorders
A06 1.35 1.21 – 1.50 5.48 4.13 Laxatives
J01 1.35 1.26 – 1.44 15.30 11.86 Antibacterial for systemic use
N05 1.43 1.17 – 1.75 1.48 1.04 Psycholeptics
S02 1.48 1.30 – 1.68 3.83 2.63 Otologicals
S01 1.64 1.46 – 1.84 5.14 3.21 Ophthalmologicals
D01 1.68 1.50 – 1.87 5.85 3.57 Antifungals for dermatological 
use
D06 1.87 1.71 – 2.05 9.29 5.21 Antibiotics and chemothera-
peutics for dermatological use
D04 1.89 1.34 – 2.65 0.62 0.33 Antipruritic, including antihista-
mines, anaesthetics, etc.
L04 2.37 1.17 – 4.80 0.17 0.07 0.50 1.00 6.36 Immunosuppressive agents†
D08 2.64 1.69 – 4.11 0.46 0.17 Antiseptics and disinfectants
D11 2.79 2.24 – 3.47 1.94 0.71 Other dermatological 
preparations
D05 4.11 2.06 – 8.21 0.26 0.06 Antipsoriatics
C01 6.44 3.73 – 11.10 0.62 0.10 Cardiac therapy (e.g. 
epinephrine auto-injectors)
† signif icant (p≤0.01) influence of age; Italic: overall model not signif icant
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relevant medication for atopic eczema in 2014. The highest ORs (12.5-13.1) were 
observed for atopic eczema related medication: emollients (D02) and dermatological 
corticosteroids (D07).
Other dermatological preparations were also frequently prescribed, e.g. antifungals 
(OR: 1.7), antipruritics (OR: 1.9), antibiotics (OR: 1.9), antiseptics (OR: 2.6), 
antipsoriatics (OR: 4.1) and other dermatological preparations (OR: 2.8), e.g. agents 
for dermatitis, excluding corticosteroids. Although less frequently prescribed, a high 
OR of 6.4 was observed for ATC code C01 (88% concerned epinephrine auto-injectors).
Children with atopic eczema received significantly more emollients (OR: 11.7->20.0) 
and dermatological corticosteroids (OR: 11.2->16.8) at older age. This also applied 
for immunosuppressive agents (OR: 0.5->6.4). Sex did not influence prescriptions in 
children with atopic eczema.
Eczema-related medication was also prescribed for children that were not registered 
as having atopic eczema. For eczema-related medication, about 3.7-8.4% of the 
children with atopic comorbidity received these prescriptions compared to 1.4-3.5% 
of the non-atopic children. Anti-asthmatics were used by 4% of the children with 
atopic eczema (OR: 2.0) even though the GP did not register them as having 
asthma. This same pattern is seen for medication related to AR (OR: 1.5-2.9).
Children registered with only asthma (Table 4)
A child with asthma received on average 1.8 different prescriptions in 2014 compared 
to 0.7 different prescriptions for the controls; this difference was significant (Table 
2). Of the asthmatic children, 47% did not receive any asthma-related prescription 
at all in 2014. A high OR of 56.2 was observed for anti-asthmatics (R03). Examining 
R03 at the ATC 3 level, adrenergic inhalants (e.g. selective beta-2 adrenoreceptor 
agonists) were given to 46.1% of the children diagnosed with asthma during our 
1-year observation period. Of the asthmatic children, 28.9% received (also) different 
inhalants (e.g. inhaled corticosteroids) for obstructive airway diseases. Only 2.0% 
of the children received other systemic drugs for airway diseases (e.g. leukotriene 
receptor antagonists). More than 3% received at least one short course of steroid 
tablets during the 1-year observation period (OR: 12.0).
According to our analysis (Table 4), asthmatic children use more hormonal 
contraceptives (G03A) (5.9% vs. 4.6%), received more viral vaccines (4.2% vs. 
0.8%) and used more ADHD-related medication (OR 1.4). These asthmatic children 
also received more analgesics prescribed by the GP (M01 and N02) compared to 
children without asthma. This will most likely concern the prescription of paracetamol 
and NSAIDs.
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Table 4 Signif icantly (p≤0.001) associated medication in children 
registered with only asthma (As) versus controls (non-atopic children) 
(n=15,774)
ICPC OR 95%-CI Prevalence 
(%)
OR per 
sex group
OR within age Description ICPC codes
As No As boy girl 2-6 7-12 13-18
Atopic eczema related medication
D02 2.54 2.04 – 3.14 3.73 1.51 Emollients and protectives
D07 2.32 2.00 - 2.68 7.67 3.46 Corticosteroids, dermatological 
preparations
Asthma related medication
H02 11.96 7.65 – 18.70 3.09 0.27 Corticosteroids for systemic use
R03 56.17 47.58 – 66.32 52.63 1.94 26.85 62.93 116.91 Anti-asthmatics†
Allergic rhinitis related medication
R01 4.61 3.99 – 5.34 12.49 3.00 2.65 5.41 5.47 Nasal preparations†
R06 4.45 3.85 – 5.14 12.24 3.04 2.55 5.77 4.88 Antihistamines for systemic 
use†
Medication related to atopic disorders
P02 1.36 0.81 – 2.29 0.43 0.32 3.44 0.55 Anthelmintic *
D06 1.36 1.17 – 1.57 5.64 4.23 Antibiotics and chemotherapeu-
tics for dermatological use
N06 1.41 1.21 – 1.65 5.07 3.66 Psychoanaleptic
M01 1.48 1.23 – 1.78 3.70 2.55 Anti-inflammatory and anti-
rheumatic products
G03 1.49 1.25 – 1.77 6.25 5.01 Sex hormones and modulators 
of the genital system
A06 1.52 1.29 – 1.77 5.08 3.42 Laxatives
S02 1.59 1.32 – 1.90 3.84 2.46 Otologicals
S01 1.68 1.43 – 1.98 4.97 3.02 Ophthalmologicals
J01 1.81 1.65 – 1.98 18.21 11.03 Antibacterial for systemic use
N02 2.00 1.52 – 2.62 2.00 1.01 Analgesics
A02 2.03 1.49 – 2.76 1.55 0.77 Drugs for acid-related disorders
A03 2.28 1.61 – 3.23 1.32 0.58 Drugs for functional 
gastrointestinal disorders
R05 2.37 1.86 – 3.03 2.75 1.18 Cough and cold preparations
J07 5.69 4.32 – 7.49 4.23 0.77 Vaccines
C01 13.01 6.02 – 28.08 1.14 0.09 Cardiac therapy (e.g. 
epinephrine auto-injectors)
* significant (p≤0.01) influence of gender; † signif icant (p≤0.01) influence of age; Italic: 
overall model not signif icant
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In asthmatic patients, anti-asthmatics (OR: 26.9->116.9) were more often 
prescribed at older age.
Asthma-related medication was also prescribed for children that were not registered 
as having asthma. For anti-asthmatics about 0.8-6.2% of the children with atopic 
comorbidity received these prescriptions, compared to 0.3-2.1% of the non-atopic 
children. Medications related to atopic eczema (OR: 2.3-2.5) and AR (OR: 4.5-4.6) 
were more frequently prescribed for children with asthma.
Children registered with only allergic rhinitis (Table 5)
A child with AR received on average 2.2 different prescriptions in 2014, compared 
to 0.8 different prescriptions for the controls; this difference was significant (Table 
2). Only 30% of these children did not receive any relevant AR prescription. High 
ORs are seen for medication prescribed by GPs to relieve AR symptoms (OR: 
21.4-40.8). Looking at the prescribed nasal preparations, these refer to R01A (OR: 
21.4; decongestants and other nasal preparations for topical use) and represent the 
prescription of anti-allergic agents and corticosteroids.
Ophthalmological medications prescribed for these children refer to the prescription 
of anti-infectives (2.6% vs. 1.6%) and of anti-allergics (17.8% vs. 0.7%). Also, 
these children used more analgesics (M01 and N02) and systemic antibiotics (13.3% 
vs. 9.9%) compared to children without AR.
Table 5 Signif icantly (p≤0.001) associated medication in children 
registered with only Allergic Rhinitis (AR) versus controls (non-atopic 
children) (n=13,670)
ICPC OR 95%-CI Prevalence 
(%)
OR per 
sex group
OR within age Description ICPC codes
AR No AR boy girl 2-6 7-12 13-18
Atopic eczema related medication
D02 3.36 2.66 – 4.25 4.46 1.38 Emollients and protectives
D07 2.74 2.34 – 3.22 8.38 3.23 Corticosteroids, dermatological 
preparations
Asthma related medication
H02 3.26 1.89 – 5.62 0.80 0.25 Corticosteroids for systemic use
R03 4.42 3.55 – 5.51 6.20 1.48 Anti-asthmatics
Allergic rhinitis related medication
R01 21.36 18.55 – 24.60 42.09 3.29 Nasal preparations
R06 40.77 35.02 – 47.46 53.59 2.78 Antihistamines for systemic use
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Sex or age did not influence the prescription of AR-related medication in children 
clearly with AR.
AR-related medication was also prescribed for children that were not registered as 
having AR. For AR-related medication about 4.7-12.5% of the children with atopic 
comorbidity received these prescriptions, compared to 2.8-3.1% of the non-atopic 
children. Medication related to atopic eczema (OR: 2.7-3.4) and asthma (OR: 
3.3-4.4) were prescribed more frequently in children with AR.
Atopic triad (Table 6)
In total 559 children, who had all three atopic disorders, received more 
atopic-related prescriptions compared to non-atopic children (94% vs. 10%). 
Dermatological corticosteroids were prescribed more often for these children 
compared to non-atopic children (56.4% vs. 3.2%; OR 39.3). Also, the prescription 
of anti-asthmatics is much higher in these children compared to non-atopic 
Table 5 (continued)
ICPC OR 95%-CI Prevalence 
(%)
OR per 
sex group
OR within age Description ICPC codes
AR No AR boy girl 2-6 7-12 13-18
Medication related to atopic disorders
N03 0.82 0.47 – 1.43 0.34 0.41 0.50 0.20 1.25 Antiepileptic†
D11 1.27 0.91 – 1.76 1.19 0.94 2.01 2.40 0.96 Other dermatological 
preparations†
D06 1.38 1.16 – 1.65 4.49 3.29 Antibiotics and chemotherapeu-
tics for dermatological use
J01 1.41 1.27 – 1.57 13.30 9.85 Antibacterial for systemic use
M01 1.43 1.22 – 1.67 5.98 4.30 Anti-inflammatory and anti-
rheumatic products
D01 1.46 1.23 – 1.75 4.54 3.15 Antifungals for dermatological 
use
N02 1.51 1.18 – 1.92 2.44 1.64 Analgesics
A06 1.51 1.27 – 1.81 4.62 3.12 Laxatives
A02 1.68 1.28 – 2.19 2.11 1.27 Drugs for acid-related disorders
R05 1.80 1.40 – 2.31 2.55 1.43 Cough and cold preparations
S01 8.89 7.61 – 10.37 20.51 2.82 Ophthalmologicals
C01 10.31 3.69 – 28.80 0.60 0.06 Cardiac therapy (e.g. epinephrine 
auto-injectors)
V01 # # – # 1,43 0,00 Allergens (e.g. immunotherapy)
† signif icant (p≤0.01) influence of age; # OR could not be calculated; Italic: overall model not 
signif icant
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children (68.3% vs. 1.3%; OR: 176.1). This pattern is also seen for antihistamines 
(62.8% vs. 2.2%; OR: 82.5). Antibiotics, especially penicillin and macrolides, were 
prescribed more frequently in children with all three atopic disorders.
Discussion
The present study shows that atopic children received both more atopic and 
non-atopic prescriptions, compared to non-atopic children. Age and gender did not 
clearly explain these differences. The prescriptions provided by a GP to relieve atopic 
symptoms seem to reflect preferred medication in relevant evidence-based medicine 
guidelines.
For atopic eczema the combination of emollients (cornerstone of the treatment) 
and corticosteroid crèmes are advised (3). However, a corticosteroid crème was 
prescribed more frequently than an emollient. An explanation could be the freely 
Table 6 Signif icantly (p≤0.001) associated medication in children 
diagnosed with Atopic Triad (AT) (p≤0.001) (n=1,118)
ATC OR 95% CI Prevalence (%) Description ATC codes
AT No AT
Atopic eczema related medication
D02 21.73 12.42 – 38.01 35.42 2.50 Emollients and protectives
D07 39.29 23.84 – 64.75 56.35 3.22 Corticosteroids, dermatological preparations
Asthma related medication
H02 28.56 3.86 – 211.08 4.83 0.18 Corticosteroids for systemic use
R03 176.13 81.65 – 379.94 68.34 1.25 Anti-asthmatics
Allergic rhinitis related medication
R01 36.84 20.74 – 65.45 46.69 2.33 Nasal preparations
R06 82.50 45.16 – 150.70 62.79 2.15 Antihistamines for systemic use
Medication related to atopic disorders
J01 2.10 1.47 – 2.99 18.25 9.66 Antibacterials for systemic use
D06 2.93 1.71 – 5.02 9.30 3.40 Antibiotics and chemotherapeutics for dermatological use
S01 6.17 3.94 – 9.66 22.36 4.47 Ophthalmologicals
D11 6.28 2.16 – 18.24 4.29 0.72 Other dermatological preparations
J07 17.21 4.10 – 72.30 5.72 0.36 Vaccines
C01 # # – # 5.90 0.00 Cardiac therapy (e.g. epinephrine auto-injectors)
# OR could not be calculated
Atopic children and use of prescribed medication  137
available emollients at pharmacies or drugstores, which were not systematically 
registered in our database.
Anti-asthmatics are prescribed in accordance with the guidelines (4). This clear 
reflection of the guideline could be the result of the policy that anti-asthmatics are 
not freely available. However, since inhaled corticosteroids are the cornerstone of 
asthma treatment, the relatively low use (29%) of inhaled corticosteroids (ICS) is 
remarkable. There are three possible explanations for this observation. Primarily, 
GPs will treat more children with mild intermittent asthma and don’t see more severe 
cases that justify (continuous) ICS use. Unfortunately, results from e.g. the ‘Asthma 
Control Questionnaire’ were not available to check this assumption. Secondly, there 
could be an overestimation of asthma diagnoses in the EHRs, since a proportion of 
the children will outgrow asthma. Finally, it could also reflect insufficient treatment, 
which could be supported by the observation that 3.1% received a short course 
of steroid tablets. All three explanations raise the question as to whether GPs 
adequately monitor the asthmatic children registered in their practice
Although oral antihistamines for AR are freely available, >70% of the patients still 
consult their GP for advice regarding AR-relevant medication. A systematic review 
(1) reported that the prevalence of AR in the open population, compared to the 
prevalence of AR in a primary care clinic, is much higher; therefore, we assume 
that only more severe cases visited the GP. This could explain the high number of 
prescriptions. Possibly because the free available antihistamines were not sufficient 
in the treatment of AR symptoms. Although the prescribed medication for AR also 
reflects the guideline (5), more information on the severity and type of symptoms of 
patients is needed to make a clearer judgement.
Finally, the existence of a fourth distinct group of atopic children is supported by the 
observation that children with all three atopic disorders receive more atopic-related 
prescriptions (94%) (with a distinct pharmacological profile) from their GP compared 
to non-atopic children or children with only one atopic disorder. This suggests that 
children with all three atopic disorders have a different phenotype. The GP seems to 
be aware of this, considering the high rate of prescriptions given to these children. 
However, since there is evidence for insufficient labeling of atopic disorders, this 
group might be even larger than observed in the present study.
This study shows that specific ATC codes are often prescribed for specific atopic 
disorders. Nevertheless, GPs did prescribe atopic-related medication to atopic 
children, even when they were not registered with that specific atopic disorder. 
Taking into account that the three atopic disorders are closely related, we postulate 
that when a child is already diagnosed with at least one atopic disorder and that 
child uses atopic-related medication for the other atopic disorders, it is plausible 
that the child will in fact have these other atopic disorders. For example, a child 
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is diagnosed with eczema and receives anti-asthmatics, it is likely that this child 
will also have asthma. Non-atopic children also receive prescriptions for specific 
atopic-related medication. Both of these observations might reflect underdiagnosis, 
or at least insufficient registration. A different study design is needed to prove 
this hypothesis. According to Mulder et al. (10), children diagnosed with asthma 
can be reliably identified with a range of medication proxies. However, the use of 
prescription data for the identification of children diagnosed with atopic dermatitis 
and AR remains questionable.
This study also shows that atopic children received more non-atopic related 
medication. For example, the prescription of dermatologicals is particularly 
increased in children with atopic eczema. The main indication seems to be the 
treatment of skin infections (antifungals, antibiotics, antiseptics). In children with 
atopic eczema the skin barrier function is negatively affected, causing an increased 
risk of secondary skin infections. All atopic children received more oral antibiotic 
prescriptions. GPs either consider these children to be at increased risk for a 
complicated course of an infection, or these children indeed have more bacterial 
superinfections that justify the oral antibiotics. Antibiotics are particularly interesting 
to study, since their use is associated with an increased risk for the development 
of atopic disorders, in particular asthma (11, 12). Or the relation between atopic 
disorders and antibiotics is a result of the confounding effect of early respiratory 
infections (13). Future research should focus on the reason why these atopic children 
receive more antibiotics and whether this is indeed necessary. When examining the 
data in more detail, one specific pattern stands out. Although in absolute terms not 
frequently prescribed, there appears to be a stronger indication for the prescription 
of epinephrine auto-injectors (C01) in children with atopic disorders. The only 
indication for such medication is the treatment of anaphylaxis. Apparently, these 
children are at higher risk for the development of severe allergic reactions (possibly 
due to a food allergy or insect bites), a well-known comorbidity for atopic children. 
These IgE-mediated food allergies could also explain gastro-intestinal symptoms that 
are frequently observed in atopic children (14, 15), which might explain prescriptions 
related to the gastro-intestinal system (e.g. laxatives). The possibility that 
gastrointestinal symptoms might be a manifestation of adverse reactions to drugs 
prescribed for e.g. asthma and AR, was considered. However, Powel et al. (14) found 
this unlikely, as the prevalence of gastrointestinal symptoms in patients with asthma 
treated with inhaled adrenergics, inhaled corticosteroids or neither of these drugs, 
showed no significant differences. Unfortunately, the ICPC-1 coding system does not 
allow the registration of food allergies, so this could not be explored. Overall, atopic 
children receive more (different) prescriptions compared to non-atopic children, 
indicating that children with atopic disorders should be better monitored by their GP.
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For the present study we used an extensive and representative general practice 
database (7). The large number of children gives the study substantial power 
and generalizability. This allowed evaluation of links between atopic disorders 
and rare prescriptions, such as ‘epinephrine auto-injectors’ and immunotherapy, 
both of which were associated with atopic disorders in this study. Using only data 
from general practices with sufficient data quality increases the reliability of this 
study. Furthermore, ATC codes were automatically attached when a GP prescribed 
medication using the electronical medical record system.
A limitation of the present study is related to which ICPC code the GPs uses for the 
episodes of the atopic disorders. For example, a child with a wheeze could be labeled 
either as ‘asthma’ (R96) or labeled as ‘wheeze’ (R03). This could result in both 
overestimation or underestimation of asthma. To decrease this risk of overestimation 
of atopic disorders, some episodes were corrected to select more severe cases. 
Furthermore, due to the hierarchical structure of the data (patients registered in 
general practices), a multi-level logistic regression analysis was performed to test 
whether clustering effects influenced our findings. Since this was not the case, only 
the results of the logistic regression analyses were presented. Another limitation 
regarding this type of explorative study is the unavoidable multiple testing. 
Therefore, a low p-value was used. Furthermore, the aim of this study was only 
to explore associations and interactions in atopic children and not to test specific 
hypotheses. Therefore, type 1 errors cannot be avoided; some associations emerging 
from this study might in fact reflect these type 1 errors such as antiepileptic and 
anthelmintic prescriptions. Finally, atopic children might visit the GP more frequently 
than non-atopic children. This can result in more prescriptions for atopic children and 
might partly explain some of the associations found. In future research, the number 
of prescriptions might need to be taken into account in the analyses.
Conclusions
The prescriptions provided by a GP to relieve atopic symptoms seem to reflect 
preferred medication in relevant evidence-based medicine guidelines. The present 
study shows that specific atopic-related prescriptions are prescribed for atopic 
as well as for non-atopic children that are not registered as having that specific 
atopic disorder. This observation might reflect underdiagnosis or at least insufficient 
registration and the GP needs to be aware of this. Overall, atopic children receive 
more (different) prescriptions compared to non-atopic children. This indicates that 
children with atopic disorders need better monitoring by their GP.
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Appendix 1
ATC Codes Description
Alimentary tract and metabolism
A01 Stomatological preparations
A02 Drugs for acid related disorders
A03 Drugs for functional gastrointestinal disorders
A04 Antiemetic and antinauseants
A05 Bile and liver therapy
A06 Laxatives
A07 Antidiarrheal, intestinal anti-inflammatory/anti-infective agents
A08 Antiobesity preparations, excluding diet products
A09 Digestives, including enzymes
A10 Drugs used in diabetes
A11 Vitamins
A12 Mineral supplements
A13 Tonics
A14 Anabolic agents for systemic use
A15 Appetite stimulants
A16 Other alimentary tract and metabolism products
Blood and blood forming organs
B01 Antithrombotic agents
B02 Antihemorrhagics
B03 Antianemic preparations
B05 Plasma substitutes and perfusion solutions
B06 Other haematological agents
Cardiovascular system
C01 Cardiac therapy
C02 Antihypertensives
C03 Diuretics
C04 Peripheral vasodilators
C05 Vasoprotectives
C07 Beta blocking agents
C08 Calcium channel blockers
C09 Agents acting on the renin-angiotensin system
C10 Lipid modifying agents
Dermatologicals
D01 Antifungals for dermatological use
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ATC Codes Description
D02 Emollients and protectives
D03 Preparations for treatment of wounds & ulcers
D04 Antipruritics, incl antihistamines, anaesthetics, etc.
D05 Antipsoriatics
D06 Antibiotics and chemotherapeutics for dermatological use
D07 Corticosteroids, dermatological preparations
D08 Antiseptics and disinfectants
D09 Medicated dressings
D10 Anti-acne preparations
D11 Other dermatological preparations
Genito-urinary system and sex hormones
G01 Gynaecological anti-infectives and antiseptics
G02 Other gynaecologicals
G03 Sex hormones and modulators of the genital system
G04 Urologicals
Systemic hormonal preparations, excluding sex hormones and insulins
H01 Pituitary and hypothalamic hormones
H02 Corticosteroids for systemic use
H03 Thyroid therapy
H04 Pancreatic hormones
H05 Calcium homeostasis
Anti-infective for systemic use
J01 Antibacterials for systemic use
J02 Antimycotics for systemic use
J04 Antimycobacterials
J05 Antivirals for systemic use
J06 Immune sera and immunoglobulins
J07 Vaccines
Antineoplastic and immunomodulating agents
L01 Cytostatics
L02 Endocrine therapy
L03 Immunomodulating agents
L04 Immunosuppressive agents
Musculo-skeletal system
M01 Anti-inflammatory and anti-rheumatic products
M02 Topical products for joint and muscular pain
M03 Muscle relaxants
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ATC Codes Description
M04 Antigout preparations
M05 Drugs for treatment of bone diseases
M09 Other drugs for disorders of the musculo-skeletal system
Nervous system
N01 Anaesthetics
N02 Analgesics
N03 Antiepileptics
N04 Anti-Parkinson drugs
N05 Psycholeptics
N06 Psychoanaleptics
N07 Other nervous system drugs
Antiparasitic products, insecticides and repellents
P01 Antiprotozoals
P02 Antihelmintics
P03 Extoparasiticides, incl. scabicides, insecticides and repellents
Respiratory system
R01 Nasal preparations
R02 Throat preparations
R03 Anti-asthmatics
R05 Cough and cold preparations
R06 Antihistamines for systemic use
R07 Other respiratory system products
Sensory organs
S01 Ophthalmologicals
S02 Otologicals
S03 Ophthalmologicals and otologicals preparations
Various
V01 Allergens
V03 All other therapeutic products
V04 Diagnostic agents
V06 General nutrients
V07 All other non-therapeutic products
V08 Contrast media
V09 Diagnostic radiopharmaceuticals
V10 Therapeutic radiopharmaceuticals
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Abstract
Purpose: To investigate the use of general practice resources (i.e. consultation 
visits, telephone contacts and home visits) in children with physician-diagnosed 
atopic disorders compared with non-atopic children.
Method: All children (aged 0-18 years) listed in a representative general practice 
database were selected in 2014. Children diagnosed with atopic eczema, asthma, 
allergic rhinitis or ‘having all three atopic disorders’ were matched on age and 
gender with non-atopic controls within the same practice. For all these different 
groups, the number and frequency of children contacting the general practitioner 
(GP) were calculated.
Results: Of the children with atopic eczema (n=15,202), 80% consulted the GP 
compared with 67% of their matched controls. Also, of the asthmatic children 
(n=7,754) 80% consulted the GP compared with 65% of their matched controls, 
and for children with allergic rhinitis (n=6,710) this was 82% (controls: 66%). 
Children with all three atopic disorders consulted the GP most often in 2014 (91%), 
compared with 68% of their matched controls. On average a child with atopic 
eczema contacted the GP 2.8 times a year (controls: 1.9), for asthmatic children the 
contact frequency was 3.0 (controls: 1.9), and for allergic rhinitis 3.2 (controls: 1.9). 
For having all three atopic disorders the contact frequency was 4.3 (controls: 2.0). 
Consultations related to the atopic disorders investigated only explain a smaller part 
of the increased healthcare utilisation in atopic children.
Conclusions: Atopic children use more general practice resources compared to 
non-atopic children, although this is not explained by regular follow-up visits of the 
atopic children.
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Background
Atopic eczema, asthma and allergic rhinitis (AR) are among the most common 
chronic disorders in children (1, 2). As they are all associated with atopy (i.e. the 
tendency to develop an IgE-mediated immune response to allergens) they are 
often referred to as ‘atopic disorders’. Although these atopic disorders in children 
represent a burden on general practice resources, the extent to which is largely 
unknown. A recent study examined healthcare utilisation in atopic children in a 
general practice setting. This study, based on health surveys, showed that children 
with atopic eczema, asthma, and AR used more healthcare resources than children 
without these disorders (3). However, questionnaire-based diagnoses cannot 
be simply inter-changed with physician-based diagnoses (1). When studying 
healthcare utilisation in a general practice setting, a diagnosis based on a physician’s 
assessment, e.g. general practitioner (GP), provides more realistic results and 
should therefore be preferred. Previous studies examining healthcare utilisation of 
atopic children were often conducted in different clinical settings (e.g. birth cohorts). 
Also, whereas most of the studies on healthcare utilisation have focused on asthma 
(3-9), only a few focused on atopic eczema (3, 10) and allergic rhinitis (3). All these 
studies demonstrated that the healthcare utilisation of atopic children is significantly 
higher compared with non-atopic children. However, to our knowledge no study has 
examined to what extent this increased use of healthcare resources reflects extra 
consultations regarding the atopic disorders (e.g. consultations for follow-up), or 
reflects consultations regarding (non-)atopic comorbidity (e.g. consultations for 
common symptoms occurring in childhood).
Additional knowledge on healthcare utilisation in general practice is important for the 
planning of healthcare services and the workforce required. Therefore, the present 
study aimed to quantify the current health burden posed by atopic eczema, asthma, 
AR and children having all three atopic disorders, on general practice resources, as 
based on electronic health records. Furthermore, a differentiation is made between 
atopic-related consultations and non-atopic related consultations.
Methods
NIVEL Primary Care Database
Generally, all non-institutionalized residents in the Netherlands are registered in 
a general practice, even if they do not contact the GP. Since 2001, NIVEL-Primary 
Care Database (NIVEL-PCD) includes routinely extracted data from electronic 
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health records (EHRs) from a representative sample of Dutch general practices 
(11), including information about declared encounters, prescribed medication, and 
diagnoses. Diagnoses were recorded and classified according to the International 
Classification of Primary Care 1 (ICPC-1) (12). In 2014, we used data from all NIVEL-
PCD practices (at least 500 listed patients; standard practice size: 2,350 patients) 
with sufficient data quality, fulfilling the following criteria: complete medical and 
financial registration of encounters (defined as ≥ 46 weeks per year), and sufficient 
ICPC coding of diagnostic information (defined as ≥ 70% of the recorded encounters 
with an ICPC code). An additional requirement was a minimum follow-up of three 
years for an individual child (e.g. data had to be available for 2012-2014), to reduce 
the risk of registration bias; for this reason, only data for children aged ≥ 2 years 
are presented here.
Dutch law allows the use of extracts of EHRs for research purposes under certain 
conditions. According to Dutch legislation, for the present type of observational 
study, neither informed consent nor approval from a medical ethics committee was 
required (Dutch Civil Law, Article 7:458).
Atopic children
When available, the EHRs from 2002-2014 were examined to avoid missing any 
relevant atopic diagnosis made in the past. Since GPs inevitably work with probability 
diagnoses, there is a risk of misclassification. Therefore, ICPC codes (e.g. S87: 
atopic dermatitis; R96: asthma; R97: AR) and their related episodes of care were 
corrected to select cases with a higher probability of the clinically relevant disorder. 
This method is described in detail elsewhere (2). In practice, an atopic episode of 
care was maintained if (based on available data from EHRs in the period 2002-2014) 
the child had at least two contact moments in that episode of care (e.g. S87; R96; 
R97) and had received at least two relevant prescriptions. In the Dutch setting, 
prescriptions are linked with a code based on the Anatomical Therapeutic Chemical 
(ATC) Classification System, making the identification of these relevant prescriptions 
possible. For atopic eczema the ATC code D07 (dermatological corticosteroids) was 
used, for asthma the ATC code R03 (drugs for obstructive airway diseases) was 
used, and for allergic rhinitis the ATC codes R01AC (nasal preparation of antiallergic 
agents, excluding corticosteroids), R01AD (nasal preparation of corticosteroids) and 
R06 (antihistamines for systemic use) were used. These medication proxies have 
been tested by Mulder et al. using registered diagnoses as a gold standard (13). If 
the child did not meet these criteria, the child was considered not to have that atopic 
disorder. It was not a requirement that the patient had contacted the GP in 2014 for 
that specific atopic disorder.
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Atopic triad
In contrast to the traditional classification of children with atopic eczema or asthma 
or AR, according to a meta-analysis a fourth distinct group of children, with all three 
atopic disorders, might exist (1). Therefore, ‘atopic triad’ episodes were developed 
for research purposes to learn more about this potentially unique group of children. 
An atopic triad was only defined when a child was diagnosed with all three atopic 
disorders (corrected to select cases with a higher probability of the clinically relevant 
disorder), based on available data from EHRs in the period 2002-2014.
Design
In a nested case-control study design, for each atopic child one matched control 
patient was selected (not diagnosed with an atopic disorder) within the same 
general practice, based on age and gender (in 2014). When studying children with 
atopic eczema, asthma or AR for this study, only those children that had one atopic 
disorder were selected.
Statistical analyses
In the Netherlands, a financial declaration is automatically created in the EHRs 
at the end of every consultation (i.e. consultation visits, telephone contacts and 
home visits; the ordering of repeat medication was excluded). Financial declaration 
recordings from the year 2014 where therefore used to determine healthcare 
utilisation in general practice. Diagnoses were linked with declared encounters on 
the same day. If a child consulted the GP for both an atopic-related problem as well 
as for a non-atopic-related problem, the declared encounter was considered atopic 
related. All patients aged between 0 and 18 years were selected. Two different 
epidemiological markers were calculated: i) the percentage of patients consulting 
the GP in one year, including the percentage of patients consulting the GP for the 
specific atopic disorder of interest, and ii) contact frequency, defined as the number 
of declared encounters overall, including the number of declared encounters for a 
specific atopic disorder in one year.
For the year 2014, health care utilisation and contact frequency rates were calculated 
for atopic eczema, asthma, AR and the atopic triad in males and females for the 
age groups 2-6 years, 7-12 years, 13-18 years and 2-18 years. For the analyses of 
children with either atopic eczema or asthma or AR, the child was not diagnosed with 
any of the other atopic disorders. Statistical differences between the groups were 
tested using chi-square tests (the percentage of patients consulting) and t-tests 
(contact frequency). Due to multiple testing, differences were considered statistically 
significant with a p-value < 0.001. All analyses were performed with Stata 14.1.
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Results
General characteristics
In 2014, 409,312 children were identified from the NIVEL-PCD. From this group 
children were identified fulfilling the selection criteria with: i) only eczema 
(n=15,202), ii) only asthma (n=7,754), iii) only AR (n=6,710) and iv) all three 
atopic disorders (n=555). For all these atopic children, one control patient (not 
diagnosed with an atopic disorder) was matched. For this study, 307 different 
general practices were involved. Of the included children with only atopic eczema, 
only asthma, only AR and with all three atopic disorders, 48.2%, 58.9%, 57.9% and 
61.6%, respectively, were male.
In both the atopic and non-atopic group, girls visited the GP more often compared 
with boys. When examining age in more detail, boys showed an overall decrease 
in consultation rates as they became older, whereas girls showed a dip in the 
consultation rate just before adolescence (7-12 years). Both these trends were the 
same in atopic as well as non-atopic children (Tables 1 and 2).
Children with only atopic eczema
In 2014, 80% of the children diagnosed with only atopic eczema consulted their 
GP, compared with 67% in the control group (p<0.001). Of the children with 
atopic eczema, only 24% consulted their GP because of their atopic eczema. When 
examining the contact frequency, children with atopic eczema consulted their GP 
on average 2.8 times/year, compared with 1.9 consultations a year in the control 
group (difference 0.9 times/year; p<0.001). The average contact frequency for 
atopic eczema-related consultations was only 0.4 times/year; therefore, 0.5 of 
the additional consultations a year were due to non-atopic related reasons for 
consultation. The differences in contact frequencies (presented here and also below) 
are not explained by the few children who consulted their GP very often.
Children with only asthma
In 2014, 80% of the asthmatic children consulted their GP (not having another 
atopic diagnosis), compared with 65% in the control group (p<0.001). Only 28% 
of the asthmatic children had asthma related consultations with their GP. Asthmatic 
children consulted their GP on average 3.0 times/year, compared to 1.9 consultations 
a year in the control group (difference 1.1 times/year; p<0.001). Since an asthmatic 
child consulted their GP for asthma-related problems only 0.5 times/year, this 
implies that an atopic child consults the GP 0.6 times/year extra for other morbidity.
Healthcare utilisation among atopic children  151
Table 1 Healthcare uti l isation in 2014 for children with only atopic 
eczema, only asthma, only allergic rhinitis (AD: atopic disorder).
Total no. of 
children
Children
consulting
a GP
(%) *
Children 
consulting a 
GP for disorder 
(%)
Contact
frequency
(contact/
year) *
Contact 
frequency for 
disorder (contact/
year)
n No AD AD AD No AD AD AD
Atopic eczema
Male 14,662 66 78 22 1.8 2.6 0.3
Male 2-6 years 6,264 72 84 24 2.1 3.0 0.4
Male 7-12 years 5,322 63 75 21 1.6 2.3 0.3
Male 13-18 years 3,076 60 73 23 1.5 2.2 0.3
Female 15,742 68 81 26 2.1 3.0 0.4
Female 2-6 years 5,728 71 82 27 2.1 3.0 0.4
Female 7-12 years 6,126 62 77 23 1.7 2.5 0.3
Female 13-18 years 3,888 72 85 31 2.5 3.6 0.5
Total group 30,404 67 80 24 1.9 2.8 0.4
Asthma
Male 9,132 62 78 27 1.6 2.7 0.5
Male 2-6 years 2,174 72 86 32 2.1 3.4 0.6
Male 7-12 years 3,698 60 78 28 1.4 2.5 0.5
Male 13-18 years 3,260 59 73 23 1.5 2.3 0.4
Female 6,376 69 83 30 2.2 3.5 0.6
Female 2-6 years 1,440 73 86 35 2.3 3.5 0.7
Female 7-12 years 2,292 63 79 24 1.7 2.7 0.4
Female 13-18 years 2,644 73 85 32 2.5 4.2 0.7
Total group 15,508 65 80 28 1.9 3.0 0.5
Allergic rhinitis
Male 7,766 62 79 35 1.6 2.7 0.5
Male 2-6 years 326 75 94 52 2.3 4.4 1.0
Male 7-12 years 2,682 64 82 42 1.6 2.8 0.7
Male 13-18 years 4,758 59 77 30 1.5 2.4 0.4
Female 5,654 71 87 39 2.4 3.8 0.6
Female 2-6 years 218 77 95 48 2.2 5.0 0.9
Female 7-12 years 1,608 63 82 41 1.7 3.0 0.7
Female 13-18 years 3,828 74 88 38 2.7 4.1 0.6
Total group 13,420 66 82 37 1.9 3.2 0.6
* All differences are signif icant (p <0.001)
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Children with only allergic rhinitis
In 2014, 82% of the children diagnosed with only AR consulted their GP (controls 
66%; p<0.001). Of the children with only AR, 37% consulted their GP because of 
this condition. Contact frequency of children with AR was on average 3.2 times/year, 
compared with 1.9 consultations a year in the control group (difference 1.3 times/
year; p<0.001). Therefore, 0.6 times/year, such a consultation can be attributed to 
AR, whereas 0.7 times/year this is due to other health related reasons.
Children with all three atopic disorders
In 2014, only a small group of children were identified as being diagnosed with all 
three atopic disorders, of which 91% consulted their GP (controls: 68%; p<0.001). 
Examining how often these children consulted their GP in 2014 for atopic eczema, 
asthma and AR, revealed percentages of 32%, 37% and 37%, respectively. The 
contact frequency of children with all three atopic disorders was on average 4.3 
times/year, compared with 2.0 consultations a year in the control group (p<0.001). 
The contact frequency for atopic eczema-related consultations was 0.5 times/year. 
For asthma-related consultations this contact frequency was 0.7 and for AR it was 
0.6. Therefore, of the excess consultation rate of 2.3 times/year in this group, 1.8 is 
caused by the three atopic disorders and 0.5 is due to non-atopic related reasons for 
consultation.
Discussion
Main findings
This study is the first to examine healthcare utilisation of all three atopic disorders in 
a general practice setting, using physician based diagnoses. This study contributes 
new and detailed data on the increased healthcare utilisation associated with atopic 
eczema, asthma, and AR in a representative sample of Dutch children, selected 
from a representative general practice database. Children with atopic disorders use 
more general practice resources compared with children without atopic disorders. 
Remarkably, the excess consultation rates in children with only atopic eczema, only 
asthma and only AR, are mainly due to (non-)atopic symptoms and diagnoses (i.e. 
not labeled as any of the studied atopic disorders). In children with all three atopic 
disorders, a comparable excess rate (0.5 times/year) is caused by this (non-)atopic 
morbidity, suggesting that excess morbidity occurred in all four groups at an equal 
frequency. Nevertheless, children with all three atopic disorders consulted the GP 
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most frequently, indicating that this might be a unique group. Atopic disorders did not 
explain the trends regarding age and gender, that were observed in the present study.
Interpretation of findings in relation to previously published work
Our findings are in agreement with other studies (3-10) that also concluded that 
atopic children utilised more healthcare; however, we extended their findings by 
examining whether the extra consultations are a result of a child’s specific atopic 
disorder or are due to other symptoms or diseases. Based on the present study, ≤ 
50% of the extra consultations can be explained by atopic eczema, asthma and AR-
related consultations. Therefore, the remainder of the consultations can be attributed 
to other symptoms or diseases. Although part of these consultations could still be 
related to atopy (i.e. food allergy or symptoms of undiagnosed atopic disorders), 
also non-atopic-related morbidity will most likely explain an important part of 
it. Future research might further unravel the precise reasons for the increased 
healthcare utilisation.
In 2015, a Dutch child (aged 5-17 years) consulted the GP (on average) twice a 
year (14), which is in accordance with the contact frequency of the control groups 
in the present study and endorses the conclusions that atopic children utilise more 
healthcare due to their atopic constitution. In contrast, senior elderly (>85 years) 
had 13 consultations a year (14). Unfortunately, it is not possible to compare the 
healthcare utilisation of atopic children with other chronic conditions in paediatric 
patients. Diseases like diabetes, auto-immune disorders and other serious chronic 
diseases in children are treated by experienced physicians (e.g. paediatricians), 
since the prevalence rates of these diseases are too low for GPs to gain the 
necessary experience. Therefore, problems associated with these chronic conditions 
in children will most likely be handled in secondary healthcare. Healthcare utilisation 
of children with these chronic conditions in general practice can therefore not be 
compared with atopic disorders (that are mostly treated by GPs). However, when 
comparing healthcare utilisation of atopic disorders with adult patients with chronic 
obstructive pulmonary disease (COPD) and diabetes mellitus (DM), an interesting 
difference emerges. Of the atopic children, at least 24-37% consulted their GP once 
a year for their specific atopic disorder. This is substantially lower compared to the 
54% of COPD patients consulting their GP for COPD-related problems at least once 
a year (15) or even the 85% of diabetic patients that consults the GP at least once 
a year for this disease (16). The most likely explanations for this observation is 
that, in the Netherlands, adult patients with COPD and DM receive routine follow-up 
consultations as a result of ‘integrated multidisciplinary care’. Unfortunately, such 
a follow-up system is not implemented for paediatric patients in general practice. 
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However, identifying asthmatic patients with insufficient follow-up and improving 
their medication management in accordance with asthma clinical guidelines is 
likely to result in lower healthcare utilisation (5) and may improve the quality of 
life of these children. The Dutch asthma guideline for children recommended at 
least one evaluation a year (17). As shown by others (18, 19), unawareness and 
undertreatment of asthma and AR is common and needs to be addressed. The 
problem of undertreatment becomes even more relevant when considering that 
when, for example, AR is undertreated, this can have a negative impact on asthma 
control (20, 21). Therefore, we suggest that atopic children will probably benefit 
from better follow-up (e.g. as part of ‘integrated multidisciplinary care’) and thereby 
provide them with the care they deserve.
Children with all three atopic disorders seem to have a different phenotype compared 
with children having one atopic disorder (22); the present study is in agreement with 
the conclusions of previous reports. Children with all three atopic disorders consult 
their GP more often than children with only one disorder. Only a minority of the extra 
consultations can be attributed to the specific atopic disorders of these children, 
suggesting that also most of these children consult the GP for associated morbidity. 
Therefore, children with all three atopic disorders should be considered by GPs as a 
separate group requiring additional attention.
Study strengths and limitations
The present study used an extensive and representative primary care database; 
the number of included children gives this study substantial power. Data from 
databases are generally considered reliable and there is no risk of recall bias. 
Furthermore, the present study included only practices with complete data regarding 
declared consultations. Using physician-based diagnosis of atopic disorders and 
selecting cases with a higher probability of a clinically relevant disorder (at least 
2 consultations and 2 relevant prescriptions) made this study highly relevant for 
studying healthcare utilisation in the general practice setting.
Some limitations also need to be discussed. The present study is based on the 
assumption that the relevant ICPC codes are not missed; however, this risk 
cannot be excluded, neither can it be quantified. This study also lacks an objective 
measure of atopic disorders, such as lung function or allergy tests and the results 
of simple questionnaires to measure the severity of the disorder. For both index 
patients and controls, the lack of these details could mean that we did not correct 
for an important confounder. The study might also have included some children 
not currently affected, possibly due to insufficient follow-up by the GP. Finally, 
although our findings support the hypothesis that childhood atopic disorders increase 
156  Chapter 8
healthcare utilisation, we did not examine the effect on health service costs or, the 
precise comorbidity causing the increased healthcare utilisation.
Conclusion
Atopic children use significantly more primary healthcare resources compared with 
non-atopic children. Remarkably, consultations related to atopic disorders only 
explained a smaller part of the increased healthcare utilisation in atopic children. 
The majority of the excess consultations were therefore related to (non-)atopic 
comorbidity. Moreover, the present study provides evidence of insufficient follow-up 
of atopic children. Since this could result in insufficient treatment (and unnecessary 
loss of quality of life), we urge GPs to be more aware of their atopic children and 
take appropriate action so that atopic children can also benefit from ‘integrated 
multidisciplinary care’.
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Epidemiological data are widely used to support general practitioners (GPs) in their 
daily practice, e.g. as a guide to the management of patients in whom disease has 
already developed and/or to develop strategies to prevent illness. Epidemiological 
data are also used by researchers to develop and prioritise research questions, 
and by policymakers to plan healthcare services and the workforce required. 
Although atopic disorders (atopic eczema, asthma, and allergic rhinitis) in children 
are an important health problem, epidemiological data for this group in a general 
practice setting are still scarce (Chapter 4). Therefore, the first part of this thesis 
provides an overview of the epidemiological data currently available (Chapters 2 
and 4); then, the knowledge obtained from these reviews is used to acquire more 
reliable prevalence rates from the extensive and representative NIVEL Primary Care 
Database (Chapter 5). In the second part of this thesis, various characteristics of 
atopic children in general practice are explored, focusing on comorbidity, medication 
use and healthcare utilisation.
This final chapter is divided into two parts. The first part provides a brief overview 
of the main results emerging from this thesis. In the second part, the wider 
implications of the combined results are discussed and interpreted in the light of 
existing literature. Methodological issues are addressed, implications for the GP 
are discussed, and recommendations are made for future research. To guide the 
discussion, the second part focuses on the following research questions: i) How 
useful are general practice search filters in daily practice? ii) Are atopic children 
adequately identified by their GPs? and iii) Is there a unique fourth group of atopic 
children that requires special attention?
Main results
This thesis is divided into two parts. The first part (Chapters 2-5) discusses 
prevalence rates based on an overview of the literature and on the analyses of the 
NIVEL-Primary Care Database. In the second part of this thesis (Chapters 6-8), 
different characteristics of atopic children in general practice are explored, focusing 
on comorbidity, medication use, and healthcare utilisation.
In Chapter 2, a meta-analysis based on ISAAC questionnaires showed that the 
worldwide annual prevalence rates in the open population for atopic eczema, asthma 
and allergic rhinitis are: 7.88% (95% CI: 7.88-7.89), 12.00% (95% CI: 11.99-
12.00) and 12.66% (95% CI: 12.65-12.67), respectively. The observed prevalence 
[1.17% (95% CI: 1.17-1.17)] of having all three disorders was almost 10 times 
higher than could be expected by chance. Chapter 3 presents the development of 
two well-validated search filters that reliably identified studies that were conducted 
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in, or apply or refer to family medicine/general practice. The specific filter had 
a specificity of 97.4% with an adequate sensitivity of 90.3%. The sensitive filter 
had a sensitivity of 96.8% with an adequate specificity of 74.9%. As a result of 
applying the sensitive search filter, in Chapter 4 only 37% of the initially identified 
articles needed to be reviewed. The systematic review presented in Chapter 4 
demonstrates a substantial difference between annual prevalence rates of atopic 
disorders retrieved in the open population setting versus the general practice setting. 
The annual prevalence rate of atopic eczema in a general practice setting ranged 
from 1.8%-9.5%, that of asthma from 3.0%-6.5%, and that of allergic rhinitis 
ranged from 0.4%-4.1%. The prevalence rates in the open population were, on 
average, substantially higher; thus, data obtained in the open population cannot 
simply be extrapolated to the general practice setting. Therefore, new and up-to-
date epidemiological data in a general practice setting would be of additional value. 
Chapter 5 contributes to a better understanding of the use of general practice 
databases. Based on the results of Chapter 5, the strategy identifying cases with 
a higher probability of clinically relevant cases yields realistic prevalence rates and 
is also easy to apply. This strategy corrects for the risk of overestimation due to 
misclassification and does not assume that a child will have the disorder for life 
(i.e. the patient had at least two relevant consultations and at least two relevant 
prescriptions). Of all the included children, 6.1% had eczema, 6.1% had asthma, and 
5.9% had allergic rhinitis; only 0.3% of these children had all three atopic disorders. 
Chapter 6 shows that having one of the atopic disorders significantly increased the 
risk of also having other atopic-related symptoms, even if the child was not recorded 
(in the health records) as having the other related atopic disorder(s). Regarding non-
atopic comorbidity, children with atopic eczema had an increased risk for (infectious) 
skin diseases (OR: 1.2-3.4). Airway symptoms or (infectious) airway diseases (OR: 
2.1-10.3) were observed significantly more frequently in children with asthma. 
Children with allergic rhinitis had a significantly distinctive risk of ear-nose-throat 
related symptoms and diseases (OR: 1.5-3.9). According to Chapter 7, disorder-
specific prescriptions seem to reflect evidence-based medicine guidelines for atopic 
eczema, asthma and allergic rhinitis. However, these disorder-specific prescriptions 
were also prescribed for children who were not recorded as having that specific 
disorder, which might be a sign of underdiagnosis. In addition, non-atopic related 
medication, such as laxatives and antibiotics, were more frequently prescribed for 
atopic children. Finally, healthcare utilisation is studied in Chapter 8. In 2014, of 
the children with atopic eczema, 80% visited the GP (controls: 67%), for asthmatic 
children this was also 80% (controls: 65%), for children with allergic rhinitis this 
was 82% (controls: 66%) and for the children with all three disorders, 91% visited 
the GP (controls: 68%). With regard to contact frequency: on average a child with 
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eczema visits the GP 2.8 times a year (controls: 1.9), for asthmatic children this is 
3.0 (controls: 1.9), for allergic rhinitis this is 3.2 (controls: 1.9), and for having all 
three atopic disorders the contact frequency is 4.3 (controls: 2.0). Atopic children 
use significantly more general practice resources compared to non-atopic children. 
Remarkably, in atopic children, non-atopic comorbidity is the most important reason 
for the increased healthcare utilisation. In addition, the follow-up of atopic disorders 
does not seem to be sufficient. Moreover, the results in Chapters 6-8 provide more 
evidence that children having all three atopic disorders should be considered as a 
unique group.
Wider implications of the combined results
I. How useful are general practice search filters in daily practice?
Although many physicians use online medical databases to obtain biomedical 
information for clinical practice (1-3), the enormous volume and diversity of the 
available literature makes this a challenging process. Lack of time and skills, as well 
as a clear preference for asking an expert colleague or consulting a print source, are 
considered as barriers to the use of online literature databases (4, 5). Nevertheless, 
an effective retrieval of literature is essential to conduct health research, and 
develop teaching materials and health policy, as well as to support healthcare 
decision-making by a physician at the point of care (6).
Electronic search filters are frequently used to identify relevant studies in online 
medical literature databases and thereby support physicians, teachers, policymakers 
and researchers. A specific search filter might enhance the retrieval of appropriate 
articles at the point of care by the physician. On the other hand, researchers in the 
field of family medicine/general practice who are conducting a systematic review 
will need a ‘sensitive’ search tool to avoid missing relevant articles. Until now, all 
the electronic search filters that were developed for general practice have lacked 
adequate sensitivity (7-10). The same applies to search strategies in the Cochrane 
Reviews used for general practice (11-15). In both cases, these filters are likely 
to miss relevant publications due to low sensitivity. There is a need for a validated 
‘general practice’ search filter to support, among others, GPs and researchers. Our 
specific filter was developed to help GPs find answers to clinical questions at the 
point of care when time is limited; however, this filter has a small risk of missing 
relevant articles. If an answer to the question is not found using the specific filter, 
use of the sensitive filter could be the next step. For example, our sensitive filter 
offers researchers conducting a systematic review two advantages. In the first 
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place, the sensitive filter provides considerable efficiency, as demonstrated in the 
systematic review presented in Chapter 4. As a result of applying the sensitive 
search filter, only 37% of the initially identified articles needed to be reviewed and, 
more importantly, no relevant articles would have been missed. Secondly, when 
conducting a review, if a researcher uses search filters that lack sufficient sensitivity, 
it can be assumed that relevant references will be missed. However, when applying 
our sensitive search filter, the risk of missing relevant references is very small.
Chapter 3 presents a carefully developed method and validation process, both of 
which were unique and resulted in an optimally sensitive and optimally specific filter 
with better performance compared to the existing search filters. However, we noticed 
that, in many cases, the title and abstract did not disclose sufficient information to 
determine whether (or not) an article was relevant for general practice. In many 
cases the setting and/or relevance to general practice could only be determined 
by scrutinising the full text; this omission will influence both the sensitivity and 
specificity of a search filter. Therefore, we emphasise that mentioning the research 
setting in the title or abstract will help to find all relevant literature available for 
family medicine/general practice. Nevertheless, since relevant articles can still be 
missed if researchers fail to mention the research setting of their study in the title or 
abstract, checking the reference lists of the included studies is still recommended.
II. Are atopic children adequately identified by their GPs?
Atopic disorders are among the most frequent chronic conditions in children. It is 
known that atopic eczema, asthma and allergic rhinitis have a significant impact 
on the quality of life of children (and their parents) (16-18). The quality of life 
of an atopic child can be significantly improved by adequate treatment of the 
symptoms caused by these disorders, avoiding both insufficient treatment as well as 
overtreatment. However, when comparing prevalence rates obtained from biomedical 
literature (Chapters 2 and 4), these rates were substantially higher in the open 
population compared to the general practice setting (see Main Results). This raises 
the question: are atopic children adequately identified by their GPs?
Various explanations are proposed for the differences found between the two 
research settings. In the first place, the studies examined in this thesis were 
conducted between 1970 and 2014 and the reported prevalence rates might, in part, 
reflect a worldwide time trend (19). Therefore, when comparing the prevalence rates 
of the two research settings (i.e. open population vs. general practice setting), it 
should be established whether the time of ‘data inclusion’ was about the same in 
both settings, otherwise differences found between the prevalence rates could partly 
reflect this worldwide time trend. Secondly, differences also exist in the operational 
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definitions used between the different clinical settings and over time. For example, 
Van Wonderen et al. found that 60 different operational definitions were used in 
the literature on asthma (20); applied in a single cohort, there was a substantial 
variation in the estimated prevalences, depending on the operational definition used.
There are also setting-dependent explanations for the differences found in 
prevalence rates between the two research settings. The incorrect classification 
of atopic symptoms in the open population, as a result of using health surveys, is 
also likely to explain some of the differences. This incorrect classification can be 
due to differences in the ‘conceptual vocabulary’ used by parents as compared to 
clinicians (21). For example, a ‘runny nose’ can be caused by allergic rhinitis or by 
a viral upper-airway infection; distinguishing between these two different causes 
may be difficult for a patient when completing a questionnaire. Although ISAAC 
put considerable effort into the validation of their questionnaires (22-25), other 
external influences cannot be totally ruled out. The accuracy of data obtained from 
a questionnaire depends on the accuracy and knowledge of the responders, and the 
definitions used by researchers. Dotterud et al. (26) considered questionnaires on 
atopic conditions to be a useful epidemiological tool to obtain rough estimates of 
the prevalence of atopic disorders. They concluded that, when using questionnaires 
in the open population, eczema was generally underestimated and allergic rhinitis 
overestimated.
General practice databases are a valuable source of longitudinal primary care records 
and are increasingly used for epidemiological research. When assessed against a 
gold standard (validation using GP questionnaire, primary care medical records, 
or hospital correspondence), most of the diagnoses were accurately recorded in 
the patient’s electronic health record (EHR) (27, 28). However, misclassification 
of atopic disorders (or their related symptoms) by GPs could still occur and might 
also explain part of the differences found; these misclassifications might be a result 
of unawareness. Although the more severe cases are not likely to be missed by 
the GP (with the reservation that the patient visits the GP for this problem), less 
severe cases are likely to be missed for two reasons. First, the necessity for patients 
to visit their GP for atopic-related symptoms is sometimes limited. For example, 
allergic rhinitis might be underestimated by a GP since anti-allergic medication 
(e.g. antihistamines) is freely available over-the-counter, adequately dealing with 
the symptoms. The same applies to atopic eczema, for which emollients are freely 
available. Second, the GP might misinterpret the symptoms of less severe cases as 
being non-atopic related: for example, a child with a recurrent running and itchy 
nose for over 3 months, may be diagnosed as having a common cold.
Taking the above into consideration, data obtained in the open population, although 
widely available, cannot be simply extrapolated into the general practice setting. 
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Therefore, new epidemiological data, supplementing the limited epidemiological data 
available from previous general practice research, are needed.
Since there is evidence of insufficient recording of the ICPC codes of atopic disorders 
in general practice databases, a better understanding of a general practice database 
is needed. To achieve this, in this thesis, data from the extensive and representative 
NIVEL-Primary Care Database were analyzed; the number of included children 
(n=478,076) gave the studies in this thesis substantial statistical power. However, to 
properly apply the potential of such a representative database, sound methodologies 
are needed to convert the huge amount of raw data into meaningful and valid 
information. This means that, in the EHR of a patient, potential misclassification of 
an atopic disorder by a GP needs to be addressed. Such misclassification could result 
in either overestimation (29-31) or underestimation of prevalence rates (Chapter 4).
Overestimation can be the result of not adequately dropping a diagnosis in an 
older child when he/she has outgrown the specific atopic disorder, or not dropping 
a probability diagnosis when the child did not eventually meet the diagnostic 
criteria of that specific atopic disorder. A recent study in a general practice setting 
demonstrated that in over 50% of the children with an ICPC code for asthma, the 
signs and symptoms reported in the EHR made asthma unlikely and, thus, this 
diagnosis was most likely overdiagnosed (31). The analyses in Chapter 5 provided 
an estimation of the number of children that show complete reduction of symptoms. 
This resulted in remission rates of 84%, 68% and 43% at age 10 years, and of 
90%, 81% and 64% at age 18 years, for atopic eczema, asthma and allergic rhinitis, 
respectively. Overdiagnosis can lead to unnecessary treatment, disease burden, and 
impact on quality of life. In Chapter 5, an easy-to-apply strategy is presented to 
deal with part of this risk of overestimation and, thereby, to select potentially more 
clinically relevant cases. In this strategy, an atopic diagnosis is only maintained if the 
child consulted the GP at least twice and received at least two relevant prescriptions, 
dealing with part of the problem of working with a ‘probability diagnosis’. Applying 
this strategy resulted in annual point prevalences for the Dutch GP setting, i.e. 
6.1% had eczema, 6.1% had asthma and 5.9% had allergic rhinitis. As a result 
of this strategy, at the most, the prevalence rates dropped by 23% compared to 
the original data. Although this selection might still be too conservative in relation 
to what published reports suggest (31), it is a safe step in the right direction. 
The ‘true prevalence rates’ of atopic disorders in a general practice setting are 
likely to be slightly higher than the ones we presented in Chapter 5 (as a result of 
underdiagnosis) and will almost certainly be lower than the prevalence rates found in 
the open population (Chapter 2). Since the ratio of overdiagnosis to underdiagnosis 
is unknown, it is not possible to give more reliable estimations. More data are 
required on the risk of both overdiagnosis and underdiagnosis.
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Addressing the risk of underdiagnosis proves to be even more challenging than 
addressing the risk of overdiagnosis. Since some ICPC codes are missing in the 
EHRs, we need a way to fill in these missing codes. The most sensitive method to 
address underdiagnosis would be to examine the entire EHR of the individual patient 
to reveal clues that might suggest an atopic diagnosis; unfortunately, this is very 
time consuming and privacy issues are involved if this meticulous work is carried 
out by a third party. Another option is to use computer software that analyses free 
texts; however, the accuracy of this method will be determined by the quality of 
the script used. A study in primary care on heart failure in adult patients examined 
the EHRs of over 50,000 primary care patients. Heart failure signs and symptoms 
were frequently identified through automated text and data mining of the EHRs. This 
frequent identification of signs and symptoms demonstrates the rich data available 
within the EHRs (32). Although this technique requires further development it has 
the potential to help develop predictive models, also for atopic disorders in children. 
With the increased availability of extensive and representative general practice 
databases, a faster and probably more consistent way of identifying an atopic child 
is to use a combination of routinely and standardized coded data from EHRs such as 
standardised measurements, ICPC-coded comorbidity, and ATC-coded prescriptions. 
Analysing routinely recorded data in EHRs to identify undiagnosed asthmatic patients 
has been demonstrated (33), but no proxies are available for atopic eczema or 
allergic rhinitis. Although, ‘computer-based decision-support systems’ may support 
GPs in their daily practice to adequately identify atopic disorders, successful 
implementation depends on several factors: i) The right combinations of routinely 
recorded data need to be identified in (future) research. ii) A decision-support 
system needs to be integrated with EHRs. If such an integration is absent, GPs 
have to record data already available in the EHRs a second time, which significantly 
reduces the chance of successful implementation. iii) A decision-support system 
has to fit the daily practice: i.e. the GP should be able to control the system to 
match his/her available time and needs at any moment. Unfortunately, until now, 
the introduction of a decision-support system has been generally disappointing. To 
increase the chance of successful introduction of such a decision-support system, a 
better understanding of how these routinely recorded data can be used to identify 
underdiagnosed children is an essential first step.
Possibilities using routinely recorded data in general practice databases
Chapter 2 demonstrates that prevalence rates in the open population setting depend 
on age. Therefore, in Chapter 5, the influence of age on the prevalence rates of 
atopic disorders in the general practice setting was studied in more detail. The 
results of this study suggest that age can help in the prediction of having an atopic 
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disorder. For example, with increasing age the risk of a child having allergic rhinitis 
increases, whereas the opposite applies for atopic eczema.
In Chapter 6 it was demonstrated that children diagnosed with one atopic disorder 
were frequently diagnosed by their GP with symptoms associated with one of the 
other atopic disorders. For example, a child with atopic eczema that presents with 
‘wheeze’ must be at a higher risk (OR: 2.0) for also having asthma, compared to a 
child with the same symptoms but without atopic eczema. The results emerging from 
this study suggest that comorbidity can help to predict atopic disorders.
In Chapter 7 we examined the use of medication in children. This chapter shows 
that specific drugs are often prescribed for specific atopic disorders. Nevertheless, 
GPs did prescribe atopic-related medication to atopic children, even when they 
were not recorded with that specific atopic disorder. Taking into account that the 
three atopic disorders are closely related (Chapter 2), we postulate that when a 
child is already diagnosed with at least one atopic disorder and that child uses 
atopic-related medication for the other atopic disorders, it is plausible that the child 
will in fact have these other atopic disorders. For example, a child is diagnosed with 
eczema and receives anti-asthmatic prescriptions, it is likely that this child will also 
have asthma (but is not coded as such). The results of this chapter suggest that 
prescriptions can help in the prediction of having an atopic disorder.
In Chapter 8 we described healthcare utilisation among atopic children. Although 
these data are more complicated to use for the identification of unlabelled atopic 
disorders, they can still support an ‘automated decision-support system’. As shown 
in Chapter 8, atopic children consult their GP more often than non-atopic children. 
Therefore, above average healthcare utilisation should trigger a decision-support 
system to consider the possibility that a child might have an atopic disorder. Since 
frequent consultation can also be a sign of other chronic disorders (34) or even 
parental fears (rather than an indication of comorbidity), more supporting evidence 
of an atopic disorder should also be present.
In conclusion, there is evidence to support the hypothesis that GPs do not fully 
recognise atopic-related symptoms in children already diagnosed with an atopic 
disorder. However, more importantly, the routinely and standardised coded data 
from EHRs, such as ICPC-coded comorbidity and ATC-coded prescriptions, can be 
an important source to identify undiagnosed atopic disorders using a (yet to be 
developed) automated decision-support system. Therefore, the effort to examine the 
potential of such a system seems well justified.
Limitations using general practice databases
Limitations are encountered when using and exploring existing general practice 
databases. The studies presented in Chapters 5-8 are based on the assumption 
General discussion  169
that all relevant ICPC codes are recorded in the EHRs. However, as discussed 
above, it is reasonable to assume that there is a relevant risk of misclassification; 
both physicians and researchers should be aware of this limitation. Also, the 
completeness of registration of (for example,) other routinely recorded data might 
be questionable, since GPs do not always register everything. Other limitations 
relevant for the epidemiological exploration of general practice databases are: i) 
the unavoidable multiple testing involved in the studies presented in this thesis, i.e. 
over 9,000 different analyses were performed for the studies in Chapters 6 and 7 
alone. Although conservative p-values were used in this thesis, type 1 errors cannot 
be avoided and some of the suggested associations might in fact reflect these type 
1 errors. On the other hand, the explorative nature of these studies did not aim to 
test hypotheses, but rather to suggest new hypotheses that may warrant further 
investigation. Moreover, when focusing on clinically relevant differences, the risk of 
incorrect conclusions is limited. ii) No data were available on socioeconomic status, 
family history, tobacco smoke exposure and other lifestyle-related risk factors, 
whereas these risk factors (among others) can influence atopic disorders (35-40). 
Unfortunately, we could not correct for these risk factors, and their potential impact 
on the observed relations and healthcare utilisation cannot be ruled out. On the 
other hand, since all children with atopic disorders were matched with controls from 
the same general practice, all these children probably live in the same neighborhood 
and the effect of most of the mentioned risk factors is expected to be small. iii) 
Atopic children might visit the GP more frequently than non-atopic children (Chapter 
8). This can result in more diagnoses and/or prescriptions in atopic children and 
might partly explain some of the associations found. For example, if an asthmatic 
child has an upper airway infection, the parents might visit the GP much sooner due 
to fear of an asthma exacerbation. iv) Finally, the extent to which successful data 
extraction can be accomplished will depend on the type of electronic health record 
used.
Implications for general practice
The results of the studies presented in this thesis emphasize the importance of 
better coding by GPs. Furthermore, the results should serve to prompt GPs to be 
more aware of the possible underdiagnosis of atopic conditions in children and, more 
specifically, in children already known with one atopic disorder. Our results also 
indicate that children with atopic disorders need more effective monitoring by their 
GP, since the results of the study in Chapter 8 indicate that these children might 
have insufficient follow-up.
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Therefore, based on the results of this thesis, we suggest that a few easy-to-
implement recommendations might help GPs in their daily practice (possibly 
supported, in the future, by a decision-support system):
– When a child is diagnosed with one atopic disorder, GPs should always be aware 
of the possibility of other atopic disorders.
– Provide routine follow-up consultations as a part of ‘integrated multidisciplinary 
care’ at least once a year, as already suggested for asthma (41).
 •  critically re-evaluate the present atopic diagnosis (e.g. can the atopic 
diagnosis be dropped or inactivated?)
 •  evaluate the presence of atopic-related symptoms (including recorded 
symptom diagnoses in the previous year that could reflect an atopic disorder) 
to identify signs of undertreatment of the present atopic disorder, or to 
identify unclassified atopic comorbidity
 •  evaluate medication use (including freely available over-the-counter drugs) 
to identify unclassified atopic comorbidities, and to evaluate whether the 
atopic-related medications are still needed or can be stopped.
We believe that atopic children should be entitled to the same healthcare standards 
that adults receive through structured ‘integrated multidisciplinary care’ for chronic 
diseases like asthma, COPD, diabetes and cardiovascular diseases. Despite that GPs 
are very busy (42), we nevertheless encourage them to start an active follow-up 
policy for their atopic children. Based on relevant medical guidelines, an evaluation 
at least once a year seems to be preferred (41, 43-45). Since Dutch GPs already 
deliver ‘integrated multidisciplinary care’ for chronic diseases in adults, for which 
yearly follow-up contacts are a requirement, the logistical tools required are already 
in place. Furthermore, in absolute terms, this will not concern a large number 
of children. The current practice of ‘case finding’ is by no means an acceptable 
alternative, since the study in Chapter 8 showed that (in 2014) a substantial 
percentage of the children was not adequately monitored. Fortunately, nowadays, 
identifying children with recorded atopic disorders in a general practice is not 
complicated. EHRs allow GPs to easily obtain lists of patients diagnosed with specific 
ICPC codes, which can be used to invite these children for a follow-up consultation.
We offer three practical solutions that might assist the GP in achieving an active 
follow-up of their atopic children. 1) Although future research should develop and 
validate a questionnaire in which symptom scores are obtained for all three atopic 
disorders, a few questionnaires are already available. These questionnaires could be 
used to monitor and control atopic symptoms (22-25, 46, 47), even though not all 
of them are validated for this purpose. These questionnaires might also help GPs to 
prioritise which children need to be evaluated first and to efficiently spread the flow 
of these consultations over a longer period; this initial inventory of symptoms (by 
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mail, or by telephone) can be performed by the doctor’s assistant. 2) A physician-
assistant could evaluate atopic disorders within the context of clearly-defined 
protocols that have to be developed for this purpose and which should be based on 
the existing medical guidelines (43-45). 3) Use the tools provided for structured 
‘integrated multidisciplinary care’ for chronic diseases in adults, and for asthma in 
children, to more effectively manage these children.
Implications for future research
To support the GP in identifying undiagnosed atopic disorders, further research is 
needed to create proxies based on standardised and routinely recorded data in the 
EHRs. This will enable a decision-support system to be developed which can support 
GPs to better recognise atopic disorders. Although some attempts have been made 
for asthma (33, 48), to our knowledge no useful proxies have been created for atopic 
eczema and allergic rhinitis.
Since epidemiological studies on atopic disorders are reaching the limit of what can 
be achieved through conventional research (49), collaborative research is likely 
to be the future trend. The interdisciplinary exchange of ideas between general 
practitioners, statisticians and computer scientists can be stimulated when different 
research groups combine their data in data repositories. This new era of ‘big data’ 
will allow smarter and more powerful statistical analyses, especially when analysing 
metadata. Although several initiatives are underway to explore the possibility of 
merging databases, it is even more important to use unified datasets to be able to 
merge all these databases in the future. Therefore, epidemiological research in the 
general practice setting will benefit from standardising diagnostic definitions and 
standardised recordings of routinely registered data. Labelling consultations with a 
standardised code, like the International Classification of Primary Care (ICPC) (50), 
will allow a better exchange of data between research groups. For prescriptions, the 
Anatomical Therapeutic Chemical Classification System (ATC code) could be used 
(51). Data related to healthcare utilisation might be more complicated, since every 
country uses its own system; however, a ‘conversion table’ might be a solution to 
this problem. Regarding standardised measurements (e.g. weight and height), it is 
advised to use the recommended system of ‘units of measurement’.
Albeit the ISAAC study has become the largest worldwide collaborative research 
project ever undertaken in the open population, we would support the development 
of an international collaborative research project based on general practice 
databases. The power of such a collaborative project would allow to analyse various 
research questions and aims, such as:
– Describe the differences between prevalence rates of atopic eczema, asthma and 
allergic rhinitis between countries.
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– Estimate to what extent the observed variation in prevalence rates of atopic 
disorders can be explained by differences in known or suspected risk factors, or 
by differences in disease management.
– Explore new aetiological hypotheses regarding the development of atopic 
disorders in children.
– Examine time trends in the prevalence of atopic disorders in general practice.
– Determine the natural course of atopic disorders in general practice.
– Determine how atopic-related medication is used in daily practice.
– Determine whether GPs need to pay more attention to (atopic) comorbidity.
III. Is there a unique fourth group of atopic children that requires 
special attention?
In Chapter 2, the observed prevalence of having all three atopic disorders is 1.17% 
(95% CI: 1.17-1.17). This co-occurrence is substantially higher than could be 
expected by chance, based on the individual prevalence of each disorder (0.12%); 
the same observation emerged from Chapter 5. This supports the hypothesis that 
there could be a fourth distinct group of children with all three disorders.
In both Chapter 2 and 4, a wide variation was observed in the prevalence rates 
of atopic disorders. This variation has received considerable attention from other 
researchers (52-55). Possible causes of such variations include (amongst others): 
genetics (56, 57), use of paracetamol (58, 59), use of antibiotics (60, 61), diet 
(62), body mass index (63, 64), living in a rural area (36, 65), and air pollution (66, 
67). However, none of these proposed factors fully explained this wide variation. 
Remarkably, when looking at the prevalence rates of having all three disorders, this 
wide variation does not occur to the same extent. Furthermore, the limited degree of 
overlap (found in Chapter 2) between the three conditions (1.17%) was very similar 
to that reported by others (53, 68). Asher et al. (69) even demonstrated that this 
overlap has been relatively consistent over a period of seven years; for 6-7 year olds 
this overlap increased from 0.8% to 1.0%, and for the 13-14 year olds the overlap 
increased from 1.1% to 1.3%. This consistency in prevalence also suggests that a 
fourth group of children with atopic disorders might exist.
Finally, the existence of a fourth distinct group of atopic children is also supported 
by different observations emerging from the studies in this thesis. In Chapter 
6, some symptoms and diseases were significantly related to children having all 
three atopic disorders. For example, the risk for developing an ‘allergy’ that the GP 
considers relevant to register in the EHR can be considered high (OR: 17.8). Chapter 
7 describes that children with all three atopic disorders receive more atopic-related 
prescriptions (94%) from their GP compared to non-atopic children (10%), and 
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compared to children with only one atopic disorder (39-70%). Chapter 8 is also in 
agreement with these conclusions. Children having all three atopic disorders consult 
their GP significantly more often than children with only one atopic disorder (contact 
frequency: 4.3 consultations/year vs. 2.8-3.2 consultations/year).
All this evidence suggests that children with all three atopic disorders might have 
a different phenotype. However, since there is evidence for insufficient labelling 
of atopic disorders, this group might be even larger than observed in the present 
thesis. In addition to the three regularly described groups of children with eczema, 
asthma, or allergic rhinitis, there seems to be a fourth distinct group of children 
who have all three disorders. This group may show distinct characteristics regarding 
severity, causes, treatment and/or prognosis.
Implications for general practice
GPs should be aware that atopic children with all three atopic disorders might 
present a more severe phenotype (e.g. needing more medication, and requiring 
more frequent follow-up consultations); however, additional research is needed to 
determine the actual clinical relevance and its related impact.
Implications for future research
We suggest that future (epidemiological) research should focus on this (potentially) 
distinct fourth group of children with all three manifestations. Research could 
address the following items. Is this group distinctive due to the severity of the 
symptoms? Does this group have a different genotype? Does this group have a 
different aetiology? Does this group need a different pharmacological approach? 
Does this group have a different prognosis? Is this group influenced by various 
(environmental) factors? These questions need to be addressed to further unravel 
the complexities related to identifying and treating these children with all atopic 
disorders in a general practice setting.
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In this thesis the word ‘atopic’ refers to a predisposition toward developing a certain 
allergic hypersensitivity, which can result in the clinical diagnosis of atopic eczema 
(also called atopic dermatitis), asthma, or allergic rhinitis (also called allergic 
rhinoconjunctivitis, including hay fever). Food allergies are beyond the scope of this 
thesis.
Chapter 1 provides a short background of the research presented in this thesis. 
The atopic disorders examined in this thesis represent an important health 
problem in paediatric patients and create a serious burden on general practice 
resources as a result of frequent visits to the general practitioner (GP). Remarkably, 
epidemiological data from the general practice setting are scarce. Therefore, the first 
aim of this thesis was to obtain valid prevalence rates of atopic children in general 
practice. For this, two systematic literature searches were conducted to examine 
two epidemiological sources in more detail: one examining epidemiological data 
obtained from the open population using health surveys, and the other (albeit with 
limited availability) examining epidemiological data obtained from general practice 
databases. The knowledge obtained from these reviews is then used to acquire more 
reliable prevalence rates from the extensive and representative NIVEL-Primary Care 
Databases.
The second aim of this thesis was to examine different characteristics of atopic 
children in the same database, focussing on comorbidity, medication use, and 
healthcare utilisation. To our knowledge, no study has investigated the complete 
range of potential comorbidities in atopic children in a general practice setting, nor 
the complete range of potentially prescribed medication. Healthcare utilisation was 
also examined using the same database.
The first part of this thesis focused on obtaining valid prevalence rates of atopic 
children in general practice. Chapter 2 presents the results of a systematic review 
(including a meta regression analysis) determining worldwide prevalence rates 
for children with atopic eczema, asthma, allergic rhinitis, and of having all three 
disorders. Data obtained from ISAAC questionnaires (including the non-official 
ISAAC studies) were used and the interrelationship between these disorders was 
examined. Therefore, the Medline, Pubmed Publisher, EMBASE, Google Scholar and 
the Cochrane Central Register of Controlled Trials databases were systematically 
reviewed. To study the interrelationships, a new approach was applied. Risk ratios 
were calculated, describing the risk of having two different atopic disorders when 
the child is known with one disorder. Finally, 31 studies were included, covering a 
large number of surveyed children (n=1,430,329) in 102 countries. The calculated 
worldwide prevalence for atopic eczema, asthma and allergic rhinitis is 7.88% 
(95% CI: 7.88-7.89), 12.00% (95% CI: 11.99-12.00) and 12.66% (95% CI: 
12.65-12.67), respectively. The observed prevalence [1.17% (95% CI: 1.17-1.17)] 
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of having all three diseases is almost 10 times higher than could be expected by 
chance. For children with atopic eczema the calculated risk ratio of having the other 
two disorders is 4.24 (95% CI: 3.75-4.79), for children with asthma this is 5.41 
(95% CI: 4.76-6.16), and for children with allergic rhinitis this is 6.20 (95% CI: 
5.30-7.27).
The aim of the study presented in Chapter 3 was to develop and validate objective 
search filters, applicable in frequently-used online medical literature databases (i.e. 
PubMed, Ovid (MEDLINE/ Embase), Embase.com, Cochrane), to identify studies 
that are conducted in, or apply to, or refer to family medicine and general practice 
settings. To develop a search filter for general practice, a precise definition was 
obtained which allows to classify articles as ‘relevant’ or ‘irrelevant’ to general 
practice and allowed us to create a reference standard set of articles. Using 
specialised software, filter candidate terms and phrases were derived from this 
reference standard. Using these candidate terms and phrases, an optimal sensitive 
filter and an optimal specific filter were created and then validated on two external 
validation sets. The sensitive filter has a sensitivity of 96.8% with an adequate 
specificity of 74.9%. The specific filter has a specificity of 97.4% with an adequate 
sensitivity of 90.3%. Both filters can be applied in daily practice by GPs and 
researchers. The quality of these filters is good when compared with other search 
filters applied in different scientific fields. As a result of applying the sensitive search 
filter, in Chapter 4 only 37% of the initially identified articles needed to be reviewed.
The review in Chapter 4 compares self-reported prevalence rates in the open 
population (i.e. ISAAC studies) with clinician-diagnosed prevalence rates of the 
three atopic disorders in a general practice setting. The same online medical 
literature databases as used in Chapter 2 were systematically reviewed for articles 
providing data on the prevalence rates of atopic eczema, asthma and allergic rhinitis 
in a general practice setting. Also included were all ISAAC studies (i.e. the open 
population) that geographically matched a study selected from the ‘GP search’. 
A considerable difference was found between annual prevalence rates of atopic 
disorders retrieved in the open population setting versus the scarce available data in 
the general practice setting (e.g. in the Netherlands and the United Kingdom). The 
annual prevalence rate of atopic eczema in a general practice setting ranged from 
1.8%-9.5%, that of asthma ranged from 3.0%-6.5%, and that of allergic rhinitis 
ranged from 0.4%-4.1%. On average, the prevalence rates in the open population 
are considerably higher compared to those in general practice.
In Chapter 5, the knowledge obtained from these reviews was used to acquire 
more reliable prevalence rates from the extensive and representative NIVEL Primary 
Care Database. The effects of four different strategies on the prevalences of atopic 
disorders were examined: 1) the first strategy examined the diagnosis as recorded 
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in the electronic health records, whereas 2) the second strategy used additional 
requirements (i.e. the patient had at least two relevant consultations and at least 
two relevant prescriptions). Strategies 3) and 4) assumed the atopic disorders to be 
chronic based on strategy 1 and 2, respectively. For this study, all children aged 0-18 
years listed in this database in the period 2002-2014 (with sufficient data quality) 
were selected. Based on the results of Chapter 5, strategy 2, which at least corrects 
for the risk of overestimation due to misclassification and does not assume that a 
child will have the disorder for life, seems preferable and can be easily applied. This 
strategy will provide cases with a higher probability of a clinically relevant disorder 
and, therefore, yields a realistic estimation of the prevalence of atopic disorders 
derived from primary care data. Using this strategy, of the 478,076 included 
children, 28,946 (6.1%) had atopic eczema, 29,182 (6.1%) had asthma, and 28,064 
(5.9%) children had allergic rhinitis. Only 0.26% children had all three atopic 
disorders; this is a 12-fold higher prevalence than could be expected by chance 
based on the three individual prevalences of the atopic disorders.
In conclusion: the first part of this thesis provides evidence to support the 
hypothesis that there could be a fourth distinct group of atopic children that have all 
three disorders. Furthermore, the significant differences between the self-reported 
prevalence rates of atopic disorders in the open population compared with physician-
diagnosed prevalence rates of atopic disorders in general practice demonstrate that 
data obtained in the open population cannot simply be extrapolated to the general 
practice setting. This should be taken into account when considering a research topic 
or requirements for policy development. In turn, GPs should be aware of possible 
misclassification of allergic disorders in their practice, which could result in either 
overestimation or underestimation of prevalence rates. To retrieve valid prevalence 
rates, this potential misclassification of atopic disorders by a GP in the electronic 
health records of a patient, needs to be addressed. The strategy selecting cases with 
a higher probability of clinically relevant cases (Chapter 5), partly deals with the risk 
of overestimation by selecting cases that are, potentially, more clinically relevant. 
However, additional research is needed to solve the problem of identifying atopic 
disorders that are missed or misclassified.
In the second part of this thesis, different characteristics of atopic children in 
general practice are explored to gain a better understanding of general practice 
databases and of atopic children. This knowledge could support the development of 
effective methodologies that are needed to transform the huge amount of raw data 
obtained from databases into meaningful and valid information. Furthermore, this 
knowledge could help to identify atopic disorders that are missed or misclassified. We 
focused on comorbidity, medication use, and healthcare utilisation. For the analyses 
in Chapters 6-8, we used the recommended strategy from Chapter 5 to select atopic 
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cases with a higher probability of clinically relevant disorders. All children (aged 0-18 
years) listed in the NIVEL Primary Care Database with routinely collected healthcare 
data in 2014 were selected. An additional requirement was a minimum follow-up 
of three years for an individual child, to reduce the risk of registration bias. Atopic 
children were matched on age and gender with non-atopic controls within the same 
general practice.
In Chapter 6 a total of 404 different symptoms and diseases, and their possible 
association with atopic disorders, are examined. Logistic regression analyses were 
performed to examine the associations between the presence of atopic disorders and 
(non-)atopic symptoms and diseases by calculating odds ratios (OR). Having one of 
the atopic disorders significantly increased the risk of having other atopic-related 
symptoms, even if the child was not registered as having the related atopic disorder. 
Regarding non-atopic comorbidity, children with atopic eczema were at significantly 
increased risk for (infectious) skin diseases (OR: 1.2-3.4). Airway symptoms or 
(infectious) diseases (OR: 2.1-10.3) were observed significantly more frequently in 
children with asthma. Children with allergic rhinitis had a significantly distinctive risk 
of ear-nose-throat related symptoms and diseases (OR: 1.5-3.9). Neither age nor 
gender explained these increased risks.
In Chapter 7 a total of 93 different medication groups were investigated for their 
possible association with atopic disorders. Logistic regression analyses were also 
performed to study the differences in prescribed medication between both groups 
by calculating ORs. Disorder-specific prescriptions seem to reflect evidence-based 
medicine guidelines for atopic eczema, asthma and allergic rhinitis. However, these 
disorder-specific prescriptions were also prescribed for children who were not 
registered as having that specific disorder. For eczema-related medication, about 
3.7-8.4% of the children with non-eczematous atopic morbidity received these 
prescriptions compared to 1.4-3.5% of the non-atopic children. The same pattern 
was observed for anti-asthmatics (having non-asthmatic atopic morbidity: 0.8-6.2% 
vs. controls: 0.3-2.1%) and allergic rhinitis-related medication (having non-allergic 
rhinitis atopic morbidity: 4.7-12.5% vs. controls: 2.8-3.1%). Also, non-atopic related 
medication, such as laxatives and antibiotics, were more frequently prescribed for 
atopic children.
In Chapter 8 a study is presented that aimed to investigate healthcare utilisation in 
children with
atopic eczema, asthma, allergic rhinitis and having all three atopic disorders in 
general practice. Of the children with eczema (n=15,202), 80% visited the GP in 
2014 compared to 67% of controls. Also 80% of asthmatic children (n=7,754) 
visited the GP compared to 65% in controls and for children with allergic rhinitis 
(n=6,710) this was 82% and 66%, respectively. Of the children with all three 
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disorders 91% visited the GP (controls: 68%). On average a child with eczema visits 
the GP 2.8 times a year (controls: 1.9), for asthmatic children the contact frequency 
is 3.0 (controls: 1.9) and for allergic rhinitis 3.2 times a year (controls: 1.9). For 
having all three atopic disorders the contact frequency is 4.3 times a year (controls: 
2.0). Remarkably, non-atopic comorbidity is the most important reason for the 
increased healthcare utilisation in atopic children.
In conclusion: the second part of this thesis provides additional evidence to 
support the hypothesis that there could be a fourth distinct group of atopic children 
that have all three disorders. Furthermore, there is ample evidence to support a 
second hypothesis: GPs do not fully recognise other atopic disorders in children, 
irrespective of whether they are already diagnosed with one atopic disorder. This 
indicates that children with atopic disorders need better monitoring by their GP. The 
routinely used and standardised coded data from electronic health records (such as 
ICPC-coded comorbidity, and ATC-coded prescriptions) seems to be an important 
source to support identification of these undiagnosed atopic disorders.
In Chapter 9 the main results are discussed in a broader perspective, focusing on 
three main research questions, namely: i) How useful are general practice search 
filters in daily practice? ii) Are atopic children adequately identified by their GPs? and 
iii) Is there a unique fourth group of atopic children that requires special attention? 
Having discussed these topics, implications for clinical practice are addressed and 
recommendations are made for future research.
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In dit proefschrift verwijst het woord ‘atopie’ naar de aanleg om immunoglobulinen 
(antistoffen) van het type IgE aan te maken die specifiek gericht zijn tegen stoffen 
die in de omgeving kunnen voorkomen, zoals huisstofmijt en gras- of boompollen. 
Als ‘atopie’ klinisch manifest wordt, kan dit uiteindelijk resulteren in constitutioneel 
eczeem (ook wel atopische dermatitis genoemd), astma of allergische rhinitis (ook 
wel allergische rhinoconjunctivitis genoemd, inclusief hooikoorts). Voedselallergieën 
vallen buiten het bestek van dit proefschrift.
Hoofdstuk 1 beschrijft de achtergrond en de opbouw van dit proefschrift. Kort 
samengevat richt het onderzoek, zoals beschreven in dit proefschrift, zich op 
drie verschillende atopische aandoeningen bij kinderen, namelijk: constitutioneel 
eczeem, astma en allergische rhinitis. Deze atopische aandoeningen vormen onder 
kinderen een groot gezondheidsprobleem. Het is daarom des te opvallender dat 
er over deze aandoeningen slechts zeer beperkte cijfers beschikbaar zijn uit de 
huisartsenpraktijk. Het eerste doel van het onderzoek was dan ook het verkrijgen 
van valide prevalentiecijfers (hoe vaak komt een bepaalde ziekte voor) van deze 
drie atopische aandoeningen onder kinderen vanuit de huisartsenpraktijk. Als 
eerste werd daartoe de bestaande literatuur kritisch doorzocht middels twee 
systematic reviews, waarin twee ‘epidemiologische’ bronnen gedetailleerd werden 
bestudeerd. In de eerste review werd gekeken naar prevalentiecijfers die waren 
verkregen middels het afnemen van vragenlijsten op scholen (de zogenoemde 
prevalentie uit de ‘open populatie’). In de tweede review werd er gekeken naar 
prevalentiecijfers die zijn gebaseerd op huisartsendatabases (de zogenoemde 
prevalentie uit de ‘huisartsenpraktijk’). De kennis verkregen uit deze reviews kon 
vervolgens worden gebruikt om betrouwbaardere prevalentiecijfers te verkrijgen 
uit de ‘NIVEL Zorgregistraties eerste lijn’ (NIVEL-database). Deze database maakt 
gebruik van gegevens die routinematig in de zorg worden verzameld bij het leveren 
van zorg aan patiënten door zorgprofessionals. Hierbij kan gedacht worden aan 
gecodeerde diagnoses, gecodeerde recepten en gecodeerde financiële declaraties. 
In totaal doen 316 Nederlandse huisartsenpraktijken mee aan de onderzoeken die 
in dit proefschrift zijn beschreven. Deze database bevatte anonieme gegevens van 
478,076 verschillende kinderen.
Het tweede doel van het onderzoek was om verschillende karakteristieken van 
atopische kinderen binnen de Nederlandse huisartsenpraktijk te bestuderen, waarbij 
de nadruk is gelegd op gediagnostiseerde comorbiditeit, voorgeschreven medicatie 
en het gerelateerde zorggebruik. Zover onze kennis rijkt, heeft geen enkel ander 
onderzoek de complete reeks van ziektes en symptomen bestudeerd bij atopische 
kinderen binnen de huisartsenpraktijk, noch de complete reeks van voorgeschreven 
medicatie. Ook het zorggebruik kon meer gedetailleerd worden bestudeerd vanuit de 
‘NIVEL Zorgregistraties eerste lijn’.
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In het eerste deel van dit proefschrift ligt de focus dus op het verkrijgen 
van valide prevalentiecijfers van atopische aandoeningen bij kinderen binnen de 
huisartsenpraktijk. Hoofdstuk 2 laat de resultaten zien van een systematic review 
(inclusief een meta-regressieanalyse) waarin de wereldwijde prevalentiecijfers 
werden berekend van kinderen met constitutioneel eczeem, astma, allergische 
rhinitis en het hebben van al deze atopische aandoeningen in de ‘open populatie’. 
Om deze prevalentiecijfers te berekenen, maar ook om de onderlinge relaties 
tussen de drie atopische aandoeningen gedetailleerder te kunnen bestuderen, 
werd er gebruik gemaakt van data die waren verkregen van kinderen op school 
middels vragenlijsten. Deze vragenlijsten waren ontwikkeld in het kader van 
een grote internationale studie: ‘International Study of Asthma and Allergies in 
Childhood’ (ISAAC). Gepubliceerde data van zowel officiële als niet-officiële ISAAC-
onderzoeksgroepen konden worden gebruikt voor deze review. Om geen relevante 
wetenschappelijke publicaties te missen werden meerdere online databases 
systematisch doorzocht, te weten Medline, Pubmed Publisher, EMBASE, Google 
Scholar en Cochrane Central Register of Controlled Trials. Om de onderlinge relaties 
tussen de aangegeven aandoeningen te bestuderen, is er gebruik gemaakt van een 
nieuwe aanpak. Hierbij werd de risk ratio (RR) berekend. De RR geeft het risico aan 
op het hebben van de andere twee atopische aandoeningen, als het kind bekend is 
met één atopische aandoening. Bijvoorbeeld: als de RR voor astma vijf is, betekent 
dit dat een kind met astma een vijf keer zo hoog risico heeft op het hebben van 
constitutioneel eczeem en allergische rhinitis vergeleken met een kind zonder astma. 
Uiteindelijk werden 31 onderzoeken geïncludeerd in deze review, waarmee in totaal 
1.430.329 kinderen uit 102 verschillende landen konden worden geïncludeerd. De 
berekende wereldwijde prevalentie voor constitutioneel eczeem is 7,88% (95% CI: 
7,88-7,89), die voor astma is 12,00% (95% CI: 11,99-12,00) en die voor allergische 
rhinitis 12,66% (95% CI: 12,65-12,67). De waargenomen prevalentie [1,17% (95% 
CI: 1,17-1,17)] van het hebben van alle drie de atopische aandoeningen was bijna 
10 keer hoger dan wat verwacht had kunnen worden op basis van louter toeval. 
Voor kinderen met constitutioneel eczeem was de berekende risk ratio voor het 
hebben van de andere twee atopische aandoeningen 4,24 (95% CI: 3,75-4,79), 
voor kinderen met astma was dat 5,41 (95% CI: 4,76-6,16) en voor kinderen met 
allergische rhinitis 6,20 (95% CI: 5,30-7,27). Deze resultaten tonen aan dat de 
ziektes nauw met elkaar zijn verbonden.
In Hoofdstuk 3 is de ontwikkeling en validatie van een objectieve zoekfilter 
beschreven die gebruikt kan worden voor het verkrijgen van gegevens uit veel 
gebruikte online databases zoals PubMed, Ovid (MEDLINE/Embase), Embase.
com en Cochrane. Deze zoekfilter moet wetenschappelijke publicaties gaan 
identificeren die zijn uitgevoerd in, betrekking hebben op of verwijzen naar 
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‘huisartsgeneeskunde’. Om een dergelijk filter te ontwikkelen, moest er eerst een 
precieze definitie geformuleerd worden van ‘huisartsgeneeskunde’. Gebruikmakend 
van deze definitie konden vervolgens wetenschappelijke publicaties handmatig 
worden geclassificeerd als zijnde huisartsgeneeskundig relevant of niet. Hierdoor 
kon een ‘referentiestandaard’ worden gevormd. Uit deze referentiestandaard 
werden vervolgens middels specialistische software onderscheidende ‘woorden’ en 
‘zinnen’ verkregen. Deze mogelijk onderscheidende ‘woorden’ en ‘zinnen’ vormden 
vervolgens de basis voor de ontwikkeling van een zo’n optimaal mogelijke sensitieve 
en specifieke filter. De ontwikkelde filters werden vervolgens gevalideerd op twee 
externe validatiestandaarden. De sensitieve filter had uiteindelijk een sensitiviteit 
van 96,8% met een adequate specificiteit van 74,9%. De specifieke filter had een 
specificiteit van 97,4% met een adequate sensitiviteit van 90,3%. Beide filters 
kunnen zowel door huisartsen als wetenschappers worden gebruikt. De kwaliteit 
van de filters blijkt goed te zijn, vergeleken met andere zoekfilters die ontwikkeld 
zijn voor andere vakgebieden. Het toepassen van de sensitieve filter voor de 
systematische review in Hoofdstuk 4 levert een grote mate van efficiëntie op, slechts 
37% van de oorspronkelijk (zonder filter) gevonden wetenschappelijke publicaties 
hoeft nog maar bestudeerd te worden.
De review, zoals beschreven in Hoofdstuk 4, vergelijkt zelfgerapporteerde 
prevalentiecijfers van atopische aandoeningen uit de ‘open populatie’ (gebaseerd op 
ISAAC-studies) met de prevalentiecijfers die zijn gebaseerd op huisartsendatabases 
(diagnoses gesteld door huisartsen). Hiervoor zijn dezelfde online databases 
gebruikt als in Hoofdstuk 2 om relevante wetenschappelijke publicaties te vinden 
die prevalentiecijfers geven over constitutioneel eczeem, astma en allergische 
rhinitis in de huisartsgeneeskundige setting. Vervolgens werden ook alle relevante 
ISAAC-studies geïncludeerd voor zover deze geografisch gezien overeenkwamen met 
de geïncludeerde artikelen van de huisartsenzoekopdracht. Een aanzienlijk verschil 
werd gevonden tussen de jaarprevalenties van atopische aandoeningen bij kinderen 
in de ‘open populatie’ versus de ‘huisartsenpraktijk’. De jaarprevalentiecijfers in 
de huisartsenpraktijk en open populatie varieerde van 1,8-9,5% respectievelijk 
11,4-24,2% voor constitutioneel eczeem, 3,0-6,5% respectievelijk 12,3-34,2% voor 
astma en 0,4-4,1% respectievelijk 15,1-37,8% voor allergische rhinitis. Gemiddeld 
genomen zijn de prevalentiecijfers uit de ‘open populatie’ dus aanzienlijk hoger dan 
de prevalentiecijfers die worden gevonden in de ‘huisartsenpraktijk’.
De kennis die is verkregen middels de reviews is vervolgens toegepast in 
Hoofdstuk 5. Het doel daarbij was om valide prevalentiecijfers te verkrijgen uit de 
omvangrijke en representatieve NIVEL-database. De effecten van vier strategieën 
op prevalentiecijfers van atopische aandoeningen werden daarom bestudeerd: 1) de 
eerste strategie bestudeert de diagnoses zoals deze daadwerkelijk zijn geregistreerd 
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in de database van NIVEL, terwijl 2) de tweede strategie extra voorwaarden 
stelt (een patiëntje moest minstens twee keer de huisarts hebben bezocht en 
minstens twee keer een relevant recept hebben ontvangen). Strategieën 3) en 4) 
veronderstellen dat atopische aandoeningen ‘chronisch’ zouden zijn, gebaseerd op 
respectievelijk strategie 1 en 2. Voor dit onderzoek werden alle kinderen van 0 tot 18 
jaar die geregistreerd stonden in de NIVEL-database in de periode 2002-2014 (met 
voldoende datakwaliteit) geselecteerd. Gebaseerd op de resultaten van Hoofdstuk 5, 
geniet strategie 2 de voorkeur. Deze strategie corrigeert voor een deel het risico van 
overschatting, die het gevolg kan zijn van misclassificatie. Tevens gaat deze strategie 
er niet van uit dat deze atopische ziektes chronisch zijn. Deze strategie is eenvoudig 
toe te passen en zal kinderen selecteren met een hogere kans op een klinisch 
relevante ziekte. Op basis van deze strategie hadden, van de 478.076 geïncludeerde 
kinderen uit de NIVEL-database, 28.946 (6,1%) atopisch eczeem, 29.182 (6,1%) 
astma en 28.064 (5,9%) allergische rhinitis. Slechts 0,26% van de kinderen had alle 
drie de atopische aandoeningen. Dit is echter een twaalf keer hogere prevalentie dan 
kon worden verwacht op basis van het toeval.
Samenvattend: het eerste deel van dit proefschrift ondersteunt een 
nieuwe hypothese dat er een vierde onderscheidende groep atopische kinderen 
is die alle drie de aandoeningen heeft. Verder tonen de verschillen tussen de 
twee eerder genoemde epidemiologische bronnen aan dat cijfers verkregen uit 
de ‘open populatie’ niet zonder meer kunnen worden geëxtrapoleerd naar de 
‘huisartsenpraktijk’. Hiermee moet rekening worden gehouden bij het doen van 
wetenschappelijk onderzoek of het maken van beleid. Ook huisartsen zullen 
zich meer bewust moeten zijn van mogelijke misclassificatie van atopische 
aandoeningen in de dagelijkse praktijk. Deze misclassificatie kan zowel resulteren 
in een overschatting als in een onderschatting van de prevalentiecijfers betreffende 
atopische aandoeningen bij kinderen. Om toch valide prevalentiecijfers te verkrijgen 
uit de huisartsenpraktijk, moet deze potentiele misclassificatie van atopische 
aandoeningen door huisartsen in hun ‘huisartseninformatiesysteem’ (HIS) worden 
aangepakt. De strategie die atopische kinderen selecteert met een hogere kans 
op klinisch relevante aandoeningen (Hoofdstuk 5), pakt in ieder geval ten dele 
het risico aan op overschatting. Verder onderzoek zal nodig zijn om atopische 
aandoeningen te identificeren die zijn gemist of fout zijn geregistreerd in de 
huisartseninformatiesystemen.
In het tweede deel van dit proefschrift zijn verschillende karakteristieken 
van atopische kinderen in de huisartsenpraktijk bestudeerd om zo een beter 
begrip te krijgen van zowel atopische kinderen als van huisartsendatabases. Deze 
verworven kennis kan vervolgens gebruikt worden om in de toekomst methodes 
te helpen ontwikkelen die noodzakelijk zijn om de grote hoeveelheid ruwe data 
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uit huisartsendatabases om te zetten in betekenisvolle en valide data. Voorts 
kan deze verworven kennis mogelijk helpen bij het identificeren van atopische 
aandoeningen die zijn gemist of gemisclassificeerd. We zullen ons daarbij richten op 
door huisartsen gediagnosticeerde comorbiditeit, door huisartsen voorgeschreven 
medicatie en het gerelateerde zorggebruik. Voor de analyses in Hoofdstuk 6-8 
wordt de voorgestelde strategie uit Hoofdstuk 5 toegepast om zo atopische kinderen 
te selecteren die een grotere kans hebben op een klinisch relevante aandoening. 
Alle kinderen (0-18 jaar) die in de NIVEL-database staan geregistreerd en van 
wie routinematig geregistreerde data beschikbaar zijn over het jaar 2014, zijn 
geselecteerd. Een aanvullende eis was echter een minimale follow-up van 3 jaar 
(2012-2014) om zo het risico op registratiebias te verkleinen. Uiteindelijk zijn 
de atopische kinderen gematcht met niet-atopische kinderen binnen dezelfde 
huisartsenpraktijk, op basis van geslacht en leeftijd.
In Hoofdstuk 6 zijn de associaties bestudeerd tussen in totaal 404 verschillende 
symptoom- of ziektediagnoses (ICPC-codes) en de drie atopische aandoeningen. 
Logistische regressieanalyses werden uitgevoerd waarmee de odds ratio (OR) werd 
berekend. Deze odds ratio is een wetenschappelijke maat die aangeeft hoe sterk 
de relatie is tussen, in dit geval, een atopische aandoening en een (niet-)atopisch 
symptoom of een (niet-)atopische ziekte. Als een kind was gediagnostiseerd met één 
atopische aandoening dan bleek het risico op symptomen, die passen bij een andere 
atopische aandoening, significant te stijgen terwijl het betreffende kind niet met die 
andere atopische diagnose geregistreerd staat in het huisartsendossier. Bij niet-
atopische comorbiditeit blijken kinderen met constitutioneel eczeem een vergrote 
kans te hebben op (infectieuze) huidziektes (OR: 1,2-3,4). Luchtwegsymptomen en 
(infectieuze) luchtwegziektes komen juist significant vaker voor bij kinderen met 
astma (OR: 2,1-10,3). Kinderen met allergische rhinitis liepen een uitgesproken 
risico op KNO-gerelateerde symptomen en ziektes (OR: 1,5-3,9). Zowel geslacht als 
leeftijd verklaarde de verhoogde risico’s in deze studie niet.
In Hoofdstuk 7 zijn in totaal 93 verschillende medicatiegroepen (ATC2-codes) 
bestudeerd voor hun mogelijke associatie met atopische aandoeningen. Logistische 
regressieanalyses werden ook hier uitgevoerd om de relaties tussen medicijnen en 
atopische aandoeningen te bestuderen. Ziektespecifieke prescripties (bijvoorbeeld 
inhalatoren voor astma) lijken in overeenstemming te zijn met de betreffende NHG-
standaarden voor eczeem (M37), astma bij kinderen (M24) en rhinitis (M48). Het 
bleek echter dat deze ziektespecifieke prescripties ook voorgeschreven worden aan 
kinderen die niet waren gediagnostiseerd met die specifieke atopische aandoening. 
Voor eczeem gerelateerde medicatie gold dat 3,7-8,4% van de kinderen met astma 
of hooikoorts (maar zonder de diagnose eczeem), eczeem gerelateerde medicatie 
gebruikte tegenover 1,4-3,5% van de niet-atopische kinderen. Ditzelfde patroon is 
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gezien voor anti-astmamedicatie en hooikoorts gerelateerde medicatie. Kinderen met 
eczeem of allergische rhinitis (0,8-6,2%) kregen meer anti-astmamedicatie dan de 
controlegroep (0,3-2,1%). Voor hooikoorts gerelateerde medicatie gold dat 4,7-
12,5% van de kinderen met eczeem of astma deze medicatie gebruikte tegenover 
2,8-3,1% van de controlegroep. Ook niet-atopisch gerelateerde recepten, zoals 
laxantia en antibiotica, werden vaker aan atopische kinderen voorgeschreven. Zowel 
geslacht als leeftijd verklaarde de verhoogde risico’s in deze studie niet.
In Hoofdstuk 8 is het zorggebruik bestudeerd van kinderen die zijn gediagnostiseerd 
met constitutioneel eczeem, astma, allergische rhinitis en het hebben van alle drie 
de atopische aandoeningen. Van de kinderen met eczeem bezocht 80% de huisarts 
in 2014, in tegenstelling tot 67% van de patiënten in de controlegroep (gematchte 
kinderen zonder één van de atopische diagnoses). Ook 80% van de astmatische 
kinderen bezocht de huisarts in 2014, in tegenstelling tot 65% van de controlegroep 
en voor kinderen met allergische rhinitis lag het bezoekpercentage op 82% 
(controlegroep: 66%). Als een kind alle drie de atopische aandoeningen had, dan 
lagen de percentages nog hoger (91% versus 68%). Gemiddeld genomen bezoekt 
een kind met eczeem de huisarts 2,8 keer per jaar (controlegroep: 1,9). Voor 
astmatische kinderen is dit 3,0 keer per jaar (controlegroep: 1,9) en voor allergische 
rhinitis ligt de contactfrequentie op 3,2 keer per jaar (controlegroep: 1,9). Als een 
kind alle drie de aandoeningen had, dan was de contactfrequentie in 2014 4,3 keer 
per jaar (controlegroep: 2,0). Opmerkelijk genoeg zijn niet-atopische diagnoses de 
voornaamste reden voor dit toegenomen bezoek aan de huisarts.
Samenvattend: het tweede deel van dit proefschrift onderschrijft ook de 
hypothese dat er een unieke vierde groep atopische kinderen is die alle drie de 
aandoeningen heeft. Voorts is er voldoende bewijs om te stellen dat huisartsen 
niet al hun atopische kinderen goed in beeld hebben. Dit geeft dus aan dat 
er een noodzaak is om kinderen met atopische aandoeningen beter te laten 
volgen door hun huisarts. Verder lijken routinematig geregistreerde data in 
huisartseninformatiesystemen, zoals diagnoses en recepten, een rol te kunnen 
spelen om ongediagnostiseerde atopische kinderen te identificeren. Hiervoor is 
toekomstig nader onderzoek wel noodzakelijk.
In Hoofdstuk 9 worden de belangrijkste resultaten van dit proefschrift in een breder 
perspectief besproken, waarbij de nadruk ligt op de volgende drie onderzoeksvragen: 
i) Hoe nuttig zijn huisartsenfilters in de dagelijkse praktijk voor huisartsen en 
wetenschappers? ii) Zijn atopische kinderen adequaat in beeld bij de huisarts? en 
iii) Is er daadwerkelijk een unieke vierde groep van atopische kinderen die extra 
aandacht behoeft? In dit hoofdstuk worden tevens praktische handreikingen gedaan 
voor de dagelijkse praktijk van de huisarts en worden er voorstellen gedaan voor 
toekomstig wetenschappelijk onderzoek.
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Een proefschrift schrijf je niet alleen, daar heb je hulp bij nodig. Gelukkig heb ik die 
hulp in vele vormen mogen ontvangen en daar ben ik zeer dankbaar voor. Een aantal 
mensen wil ik uiteraard wel in het bijzonder noemen, aangezien hun rol voor de 
totstandkoming van dit proefschrift onmisbaar is geweest.
In de eerste plaats wil ik Patrick Bindels bedanken. Toen ik in 2011 nog aan je vroeg 
of het realistisch was om te promoveren en gelijktijdig een duo-praktijk te beginnen, 
zei je: “Dan zal je hard moeten werken, maar dan gaat het wel lukken.” Nou, daar 
heb je geen woord te veel of te weinig mee gezegd… Toch kijk ik terug op een goede 
en bovenal hele leerzame tijd. Jouw bijdrage was daarbij onmisbaar. Gedurende het 
gehele promotietraject was jij altijd een zeer stabiele factor en heb je mij die sturing 
gegeven die ik nodig had. Vooral de snelheid waarmee jij mijn manuscripten van 
goed en opbouwend commentaar retour zond, heb ik altijd enorm gewaardeerd. Ik 
ben zeer dankbaar dat jij mij als promotor hebt willen begeleiden en dat je tot het 
allerlaatst kritisch bent gebleven.
Heleen Moed was één van mijn initiële copromotoren. Gedurende de eerste twee 
jaar van dit traject was je een collega om op terug te kunnen vallen. Je was 
laagdrempelig te benaderen en hebt mij, gedurende de tijd dat je nog in het 
Erasmus MC werkte, vaak met praktische raad bijgestaan. Sinds de verhuizing 
naar het NA-gebouw heb ik eigenlijk mijn eerste copromotor, Arthur Bohnen, pas 
echt leren kennen. Jouw enorme methodologische kennis, scherpe inzichten en 
waardevolle aanvullingen op mijn manuscripten hebben mij enorm geholpen. Hoewel 
onze overleggen vaak met een korte vraag begonnen, eindigden ze steevast in 
‘dokterspraat’. Als laatste in dit rijtje natuurlijk mijn tweede copromotor Mark Nielen. 
Ik heb heel wat dagen in Utrecht versleten waarbij ik bezig was de NIVEL-database 
in mijn vingers te krijgen. De ene dag ging dat succesvoller dan de andere. In die 
periode heb je mij die sturing gegeven die ik nodig had om zelfstandig verder te 
komen. Daar heb ik enorm veel van geleerd. Daarnaast was jouw bijdrage in de 
laatste fase van dit promotietraject ook van grote waarde.
Naast Patrick, Heleen, Arthur en Mark wil ik ook nog vijf andere coauteurs bedanken 
voor hun bijdrage. In de eerste plaats Wichor Bramer voor zijn essentiële bijdrage 
aan de ontwikkeling van het huisartsenzoekfilter. Ook jouw specialistische hulp 
bij de zorgvuldige totstandkoming van de zoekstrategieën voor de systematische 
reviews waren voor mij onmisbaar en buitengewoon efficiënt. Ten tweede Floris 
van de Laar, jouw voorbereidend werk voor het huisartsenfilter zorgde voor een 
belangrijke bijdrage bij de snelle totstandkoming van ons huisartsenzoekfilter. Bij het 
schrijven van de ‘NIVEL-stukken’ was ook de bijdrage van Joke Korevaar van grote 
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toegevoegde waarde. Jouw frisse blik bracht de focus van de stukken terug als ik 10 
richtingen tegelijk opging. Elvira van Alphen heb ik als keuzestudent mede mogen 
begeleiden. Jouw inzet was enorm en heeft de ISAAC-review mogelijk gemaakt, 
samen met de hulp van Nadine Rasenberg. Als laatste wil ik Jorien Wartna bedanken. 
Door vanaf de zijlijn mee te mogen kijken bij jouw trial, heb ik zeer veel mogen 
leren over de vele uitdagingen die bij de uitvoering van een trial op het pad komen 
van een onderzoeker.
Graag wil ik ook de leden van de leescommissie: prof.dr. J.H. Raat, prof.dr. J. van 
der Lei en prof.dr. F.G. Schellevis bedanken voor het lezen en beoordelen van mijn 
proefschrift.
Ook Larraine Visser, Samana Jamsheed, Inge Spronk, Irina Stirbu-Wagner, Petra ten 
Veen, Rodrigo Davids, Karin Hek, Lucas van der Hoek, Magdalena Murawska, Nicole 
Erler, Hans van der Putten, Nannette Groenendal, Marlies Luiten en René Suurland 
hebben ieder op hun manier een bijdrage geleverd aan de totstandkoming van dit 
proefschrift. In het bijzonder dank aan Hendrik Bouw, mijn oude tekenleraar van 
de middelbare school, voor de prachtige en treffende illustraties in dit proefschrift. 
Ze zijn niet alleen verfraaiend voor het proefschrift, ze helpen ook daadwerkelijk 
de boodschap beter over te brengen. Ik kijk met zeer veel plezier terug op alle 
gesprekken die we hebben mogen voeren.
Werkplezier krijg je voor een heel groot deel door de collegae met wie je mag 
samenwerken en ik had geluk om in ‘het kippenhok’ te mogen zitten. Maar ook 
vele andere collegae van de afdeling huisartsgeneeskunde hebben een aanzienlijke 
bijdrage geleverd aan mijn werkplezier. Met een hoop medepromovendi heb ik leuke 
contacten opgebouwd en goede gesprekken mogen voeren. En ik neem mijn pet 
af voor het doorzettingsvermogen dat sommigen van jullie hebben laten zien in de 
afgelopen jaren, juist op momenten dat alles (wetenschappelijk) tegen lijkt te zitten. 
Dat doorzettingsvermogen gaat jullie nog heel ver brengen!
Mijn academische hart ligt ook bij het studentenonderwijs. Het is een fantastische 
club mensen waar ik mee samenwerk. Nurcan, Melanie, Lex, Gijs, Evelien, Anneke, 
Wendy, Carolien, Marleen, Sander en alle docenten die hier een bijdrage aan leveren, 
heel veel dank. Jullie geven me veel energie en ik kijk er naar uit om het onderwijs 
samen met jullie verder te mogen blijven verbeteren.
Ook mijn opleiders Marco en Guus wil ik hier noemen. Jullie hebben mij beiden 
enthousiast gemaakt voor het klinische deel van het huisartsgeneeskundige vak. 
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Marco (en natuurlijk ook alle andere collegae uit Nieuw-Beijerland), ik kijk met 
veel plezier terug op mijn tijd in de Hoeksche Waard. Ik heb erg veel van je mogen 
leren, vooral ten aanzien van het toepassen van medische kennis in de dagelijkse 
praktijk en het leren inschatten van risico’s. Guus, jouw plotselinge overlijden vorig 
jaar heeft een enorme indruk op mij en vele anderen gemaakt. Jouw uitbundige 
lach, jouw zorgzaamheid, jouw grote hart voor de patiënten, jouw collegialiteit, jouw 
uitgestoken hand, ik zal het nooit vergeten. We missen je nog iedere dag.
En dan mijn collegae van het Carnissehuis. Dank voor de fijne samenwerking 
ondanks de rumoerige tijd waar we als centrum in hebben gezeten. Mijn werk op 
de praktijk gaf mij toch vaak de energie die ik nodig had om door te gaan met mijn 
promotieonderzoek. In het bijzonder wil ik natuurlijk Martine bedanken. In 2012 zijn 
we samen gestart met onze huisartsenpraktijk en wat heb ik je leren waarderen! 
Jouw volhardendheid heeft onze praktijk heel veel opgeleverd. De ruimte die je mij 
op het einde hebt gegeven om mijn promotie af te ronden was cruciaal. Heel veel 
dank voor alles! Je bent meer dan een goede dokter!
Lieve Anneke en Henk-Jan. Sinds 2010 hebben we heel wat lief en leed gedeeld 
tijdens onze intervisie. Ik kijk altijd uit naar onze diners. Ik ben blij jullie als 
collegae, maar bovenal als vrienden te mogen hebben. Jullie hebben in de afgelopen 
jaren meerdere keren mijn grenzen goed weten te bewaken als dat nodig was.
Ook wil ik hier mijn paranimfen bedanken. Joost, jij bent mijn oudste academische 
vriend. Samen hebben wij in Utrecht de cursus ‘medische ethiek’ gevolgd, jij als 
aankomend theoloog en ik als aankomend arts. Ik ben blij met onze lange vriendschap 
en de vele goede gesprekken. Johan, als dispuutsgenoot heb ik je leren kennen tijdens 
mijn studententijd. Een tijd waarin je als mens gevormd wordt en waarin je hechte 
vriendschappen opbouwt voor de rest van je leven. Ik heb je in de loop van de jaren 
leren kennen als een zeer integer en betrokken persoon. Ik ben dankbaar om jou als 
trouwe vriend te mogen hebben.
Waar sta je zonder familie en goede vrienden. Nergens! Zonder nu mensen bij 
naam te noemen, wil ik een ieder van jullie uit de grond van mijn hart danken 
voor jullie interesse, betrokkenheid en mentale support. In de loop van je leven 
bouw je waardevolle vriendschappen op. Dat gebeurt al op de basisschool, maar 
ook tijdens de middelbare school, gesprekskringen van de kerk, reis naar Oxford, 
studie, studentenleven, beroepsopleiding, werk in de huisartsenpraktijk en dit 
promotieonderzoek. Het is van levensbelang om een groep mensen om je heen 
te hebben die je door dik en dun steunen en waar je op terug kunt vallen als het 
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nodig is. Soms voor een luisterend oor, soms voor een zeil- of motortochtje of een 
gezellig etentje.
Thomas, weet dat ik als broer en vriend ongelofelijk trots op je ben. Toen jij besloot 
te kiezen voor een ander carrièrepad heb ik je bewonderd. Het toont moed om zo’n 
keuze te maken en vergt een enorm doorzettingsvermogen om dat tot een succesvol 
einde te brengen. En dat is gelukt! Weet dat ik er altijd voor je ben.
Lieve pap en mam, wat ben ik gezegend met zulke lieve en betrokken ouders. Jullie 
zijn er altijd en onvoorwaardelijk voor me geweest en hebben mij gedurende mijn 
hele leven op een geweldige manier weten te stimuleren. Niet door te pushen, maar 
juist door een voorbeeld voor mij te zijn in de manier waarop jullie zelf in het leven 
staan. Jullie hebben mij daarbij altijd alle vrijheid gegeven, zodat ik zelf mijn eigen 
keuzes kon en mocht maken.
En tot slot lieve Chantal. Het valt niet in woorden uit te drukken wat jij voor mij 
betekent. Jouw doorzettingsvermogen: indrukwekkend. Jouw betrokkenheid: 
hartverwarmend. Jouw geduld (met mij): eindeloos. Jouw zorgzaamheid: onmisbaar. 
Jouw liefde: van levensbelang. Ik hoop van harte dat we net zo gelukkig blijven als 
we nu met elkaar zijn en ik kijk uit naar ieder moment dat ik samen met je mag zijn.
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Erasmus MC Department: General Practice
PhD period: January 2012 – december 2017
Promotor: Prof.dr. P.J.E. Bindels
Co-promotors: Dr. A.M. Bohnen and dr. M.M.J. Nielen
VOCATIONAL TRAINING
GP training, Dept. of General Practice, Erasmus MC, Rotterdam 2008-2011
PhD TRAINING
Research skills Year Workload
(ECTS)
Systematic literature search, Erasmus MC, Rotterdam 2012 0.3
Endnote, Erasmus MC, Rotterdam 2012 0.1
SPSS, VU, Amsterdam 2013 0.5
Biostatistics for clinicians, NIHES, Rotterdam 2013 1.0
Regression analysis for clinicians, NIHES, Rotterdam 2013 1.0
Scientific integrity, Erasmus MC, Rotterdam 2014 0.3
STATA, NIVEL, Utrecht 2015 0.5
CONFERENCES
Oral presentations
Dept. of General Practice, Rotterdam (1/yr.) 2012-2016 1.5
IPCRG 8th World Conference, Amsterdam 2016 1.0
CAHAG Conference, Utrecht 2017 1.0
Poster presentation
CAHAG Conference, Utrecht 2013 1.0
NHG-wetenschapsdag, LUMC, Leiden 2013 1.0
CAHAG Conference, Utrecht 2015 1.0
CAHAG Conference, Utrecht 2017 1.0
TEACHING ACTIVITIES
Teaching skills
BKO-training (incl. courses and workshops) 2014-2017 7.0
Teaching
Supervision of research projects by medical students (2x) 2013/2016 3.0
Clinical reasoning for bachelor and master students 2011-2017 11.0
Developing teaching materials and methods 2012-2017 7.0
Making exam questions 2012-2017 1.0
Supervision of medical interns 2011-2017 2.0
GP-training medical interns 2011-2012 4.0
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